Benzothia(di)azepine compounds and their use as bile acid modulators

Abstract

The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators with apical sodium-dependent bile acid transporter (ASBT) and / or hepatic bile acid transport (LBAT) inhibitory activity. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases.

Description

[Technical Field]

[0001] Cross-references to related applications This application claims priority to Indian Patent Application No. 202111024711, filed on 3 June 2021 (the disclosure of which is incorporated herein by reference in its entirety).

[0002] The present invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or hepatic bile acid transport (LBAT) inhibitory activity. The present invention also relates to pharmaceutical compositions comprising these compounds, as well as the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases. [Background technology]

[0003] Bile acids are physiological surfactants that play a crucial role in the intestinal absorption and transport of lipids, nutrients, and vitamins. They are also signaling molecules that activate nuclear receptors, as well as cellular signaling pathways that regulate lipid, glucose, and energy metabolism. Bile acids are steroid acids synthesized from cholesterol in the liver and stored in the gallbladder as mixed micelles. During digestion, the duodenum triggers the release of hormones that cause gallbladder contraction, thereby releasing bile acids into the small intestine, where they enable the absorption of fat-soluble vitamins and cholesterol. Upon reaching the ileum, bile acids are reabsorbed from the intestines and secreted into the portal blood, returning to the liver via the portal circulation. In this way, more than 90% of bile acids are recirculated and returned to the liver. These bile acids are then transported across the sinusoidal cell membrane of hepatocytes and resecreted into the bile across the canaliculi membrane. In this initial pass, 75-90% of the bile acids are taken up by hepatocytes, completing one enterohepatic circulation cycle. Some bile acids not removed by the liver enter the systemic circulation, where free bile acids are filtered by the renal glomeruli, efficiently recovered in the proximal tubules, and returned to the systemic circulation. Interestingly, the majority of bile acids secreted into the bile across the tubular membrane originate from the recirculation pool, with less than 10% resulting from new hepatic synthesis. A small amount of bile acids not reabsorbed in the ileum reach the colon. In the intestinal lumen, primary bile acids are converted to secondary bile acids, mainly by single or double dehydroxylation reactions of steroid nuclei, under the action of intestinal bacteria. Bile acids not absorbed in the intestinal tract are subsequently excreted in the feces.

[0004] Overall, an efficient transport system helps maintain a constant bile acid pool, thereby ensuring sufficiently high levels of conjugated bile acids in the intestines to promote lipid absorption and reduce the bacterial load in the small intestine. This system also protects the intestinal and hepatobiliary portions by minimizing the loss of bile acids to feces and urine and by eliminating potentially cytotoxic surfactants (as outlined by Kosters and Karpen (Xenobiotica 2008, Vol. 38, pp. 1043-1071); Chiang (J. Lipid Res. 2009, Vol. 50, pp. 1955-1966); and Dawson (Handb. Exp. Pharmacol. 2011, Vol. 201, pp. 169-203)).

[0005] The regulation of the bile acid pool size by converting cholesterol to bile acids in the liver has been found to play a crucial role in cholesterol homeostasis, and this corresponds to the main pathway for the excretion of cholesterol from the body. The liver plays an essential role in removing endogenous and xenobiotic compounds from the body. Normal hepatic bile secretion and enterohepatic circulation are necessary to excrete endogenous compounds such as cholesterol and bilirubin, and their metabolites, from the body, thereby maintaining lipid and bile acid homeostasis. (Kosters and Karpen, Xenobiotica 2008, Vol. 38, pp. 1043-1071).

[0006] The reabsorption of bile acids in the ileum can be inhibited by apical sodium-dependent bile acid transporter (ASBT) inhibitor compounds. Inhibition of bile acid reabsorption has been reported to be useful in the treatment of several diseases, including dyslipidemia, diabetes, obesity, constipation, cholestatic liver disease, non-alcoholic steatohepatitis, and other liver diseases. Several ASBT inhibitor compounds have been disclosed over the past several decades. For example, WO 93 / 16055, WO 94 / 18183, WO 94 / 18184, WO 96 / 05188, WO 96 / 08484, WO 96 / 16051, WO 97 / 33882, WO 98 / 03818, WO 98 / 07449, WO 98 / 40375, WO 99 / 35135, WO 99 / 64409, WO 99 / 64410, WO 00 / 47568, WO 00 / 61568, WO 00 / 38725, WO 00 / 38726, WO 00 / 38727, WO 00 / 38728, WO 00 / 38729, WO 01 / 66533, WO 01 / 68096, WO 02 / 32428, WO 02 / 50051, WO 03 / 020710, WO 03 / 022286, WO 03 / 022825, WO 03 / 022830, WO 03 / 061663, WO 03 / 091232, WO 03 / 106482, WO 2004 / 006899, WO 2004 / 076430, WO 2007 / 009655, WO 2007 / 009656, WO 2011 / 137135, WO 2019 / 234077, WO 2020 / 161216, WO See 2020 / 161217, WO 2021 / 110883, WO 2021 / 110884, WO 2021 / 110885, WO 2021 / 110886, WO 2021 / 110887, WO 2022 / 029101, DE 19825804, EP 864582, EP 489423, EP 549967, EP 573848, EP 624593, EP 624594, EP 624595, EP 624596, EP 0864582, EP 1173205, EP 1535913, and EP 3210977. [Prior art documents] [Patent Documents]

[0007] [Patent Document 1] WO 93 / 16055 [Patent Document 2] WO 94 / 18183 [Patent Document 3] WO 94 / 18184 [Patent Document 4] WO 96 / 05188 [Patent Document 5] WO 96 / 08484 [Patent Document 6] WO 96 / 16051 [Patent Document 7] WO 97 / 33882 [Patent Document 8] WO 98 / 03818 [Patent Document 9] WO 98 / 07449 [Patent Document 10] WO 98 / 40375 [Patent Document 11] WO 99 / 35135 [Patent Document 12] WO 99 / 64409 [Patent Document 13] WO 99 / 64410 [Patent Document 14] WO 00 / 47568 [Patent Document 15] WO 00 / 61568 [Patent Document 16] WO 00 / 38725 [Patent Document 17] WO 00 / 38726 [Patent Document 18] WO 00 / 38727 [Patent Document 19] WO 00 / 38728 [Patent Document 20] WO 00 / 38729 [Patent Document 21] WO 01 / 66533 [Patent Document 22] WO 01 / 68096 [Patent Document 23] WO 02 / 32428 [Patent Document 24] WO 02 / 50051 [Patent Document 25] WO 03 / 020710 [Patent Document 26] WO 03 / 022286 [Patent Document 27] WO 03 / 022825 [Patent Document 28] WO 03 / 022830 [Patent Document 29] WO 03 / 061663 [Patent Document 30] WO 03 / 091232 [Patent Document 31] WO 03 / 106482 [Patent Document 32] WO 2004 / 006899 [Patent Document 33] WO 2004 / 076430 [Patent Document 34] WO 2007 / 009655 [Patent Document 35] WO 2007 / 009656 [Patent Document 36] WO 2011 / 137135 [Patent Document 37] WO 2019 / 234077 [Patent Document 38] WO 2020 / 161216 [Patent Document 39] WO 2020 / 161217 [Patent Document 40] WO 2021 / 110883 [Patent Document 41] WO 2021 / 110884 [Patent Document 42] WO 2021 / 110885 [Patent Document 43] WO 2021 / 110886 [Patent Document 44] WO 2021 / 110887 [Patent Document 45] WO 2022 / 029101 [Patent Document 46] DE 19825804 [Patent Document 47] EP 864582 [Patent Document 48] EP 489423 [Patent Document 49] EP 549967 [Patent Document 50] EP 573848 [Patent Document 51] EP 624593 [Patent Document 52] EP 624594 [Patent Document 53] EP 624595 [Patent Document 54] EP 624596 [Patent Document 55] EP 0864582 [Patent Document 56] EP 1173205 [Patent Document 57] EP 1535913 [Patent Document 58] EP 3210977 [Patent Document 59] U.S. Patent Application Publication No. 2018 / 0140219 [Patent Document 60] U.S. Patent Application Publication No. 2016 / 146715 [Patent Document 61] U.S. Patent Application Publication No. 2005 / 0215882 [Patent Document 62] U.S. Patent No. 9,872,844 [Patent Document 63] WO 2017 / 138877 [Patent Document 64] WO 2017 / 138878 [Patent Document 65] WO 2019 / 032026 [Patent 66] WO 2019 / 032027 [Non-patent literature]

[0008] [Non-Patent Document 1] Kosters and Karpen (Xenobiotica 2008, Vol. 38, pp. 1043-1071) [Non-Patent Document 2] Chiang (J. Lipid Res. 2009, Vol. 50, pp. 1955-1966) [Non-Patent Document 3] Dawson (Handb. Exp. Pharmacol. 2011, Vol. 201, pp. 169-203) [Non-Patent Document 4] Dong et al., Mol. Pharm. 2013, Vol. 10, pp. 1008-1019. [Non-Patent Document 5] Vaz et al., Hepatology 2015, Vol. 61, pp. 260-267. [Non-Patent Document 6] Karpen and Dawson, Hepatology 2015, Vol. 61, pp. 24-27. [Non-Patent Document 7] Liu et al., Scientific Reports 2017, 7: 9214, pp. 1-7 [Non-Patent Document 8] Danese et al., PLoS One. 2017, Vol. 12(6): e0179200 [Non-Patent Document 9] Kooistra et al., "KLIFS: A structural kinase-ligand interaction database," Nucleic Acids Res. 2016, Vol. 44, No. D1, pp. D365-D371. [Non-Patent Document 10] Gunaydin, M. et al., Hepat Med. 2018, Vol. 10, pp. 95-104. [Non-Patent Document 11] Ferslew et al., Dig Dis Sci. 2015, Vol. 60, pp. 3318-3328. [Non-Patent Document 12] Chalasani et al., Hepatology 2018, Vol. 67(1), pp. 328-357. [Non-Patent Document 13] Kleiner et al., Hepatology. 2005, 41(6):1313~1321. [Non-Patent Document 14] Di Lascio et al., Ultrasound Med Biol. 2018, Vol. 44(8), pp. 1585-1596; [Non-Patent Document 15] Lv et al., J Clin Transl Hepatol. 2018, Vol. 6(2), pp. 217-221; [Non-Patent Document 16] Reeder et al., J Magn Reson Imaging. 2011, Vol. 34(4), spcone; [Non-Patent Document 17] de Ledinghen V et al., J Gastroenterol Hepatol. 2016, Vol. 31(4), pp. 848-855. [Non-Patent Document 18] Brunt et al., Am J Gastroenterol 1999, Vol. 94, pp. 2467-2474. [Non-Patent Document 19] Angulo et al., Hepatology 2007, Vol. 45(4), pp. 846-854. [Non-Patent Document 20] Ishak et al., J. Hepatol. 1995, Vol. 22, pp. 696-699. [Non-Patent Document 21] McPherson et al., Gut 2010, Vol. 59(9), pp. 1265-1269. [Non-Patent Document 22] Adams et al., Clin. Chem. 2005, Vol. 51(10), pp. 1867-1873. [Non-Patent Document 23] Lichtinghagen R et al., J Hepatol. August 2013; 59(2):236~42 [Non-Patent Document 24] Neuman et al., Can. J. Gastroenterol. Hepatol. 2014, Vol. 28(11), pp. 607-618. [Non-Patent Document 25] Perez MJ, Briz O. World J. Gastroenterol. 2009, No. 15(14), pp. 1677-1689 [Non-Patent Document 26] Sorrentino P et al., Dig. Dis. Sci. 2005, Vol. 50(6), pp. 1130-1135. [Non-Patent Document 27] Satapathy SK and Sanyal AJ. Semin. Liver Dis. 2015, Vol. 35(3), pp. 221-235. [Non-Patent Document 28] Greene's Protective Groups in Organic Synthesis, 4th edition, by PGM Wutz and TW Greene, John Wiley & Sons, Hoboken, 2006. [Overview of the project]

[0009] Despite several previously reported ASBT inhibitor compounds, there is a need for further bile acid-modulating compounds with optimized profiles in terms of potency, selectivity, and bioavailability. [Modes for carrying out the invention]

[0010] Certain 1,5-benzothiazepine and 1,2,5-benzothiasiazepine derivatives have been found to be potent inhibitors of apical sodium-dependent bile acid transporters (ASBTs) and / or hepatic bile acid transporters (LBATs), and may be useful in treating diseases in which inhibition of bile acid circulation is desirable.

[0011] In a first aspect, the present invention provides a compound of formula (I)

[0012]

Chemical formula

[0013] (wherein M is selected from -CH2- and -NR 1~4 -; R 1 is C 1~4 alkyl; R 2 is independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1~4 alkyl, C 1~4 haloalkyl, C 1~4 alkoxy, C 1~4 haloalkoxy, cyano, nitro, amino, N-(C 1~4 alkyl)amino, N,N-di(C 1~4 alkyl)amino, C 1~6 alkylcarbonylamino, C 3~6 cycloalkylcarbonylamino, N-(C 1~4 alkyl)aminocarbonyl, N,N-di(C 1~4 alkyl)aminocarbonyl, C 1~4 alkyloxycarbonylamino, C 3~6 cycloalkyloxycarbonylamino, C 1~4 alkylsulfonamide, and C 3~6 cycloalkylsulfonamide; n is an integer of 1, 2 or 3; R 3 is selected from the group consisting of hydrogen, halogen, cyano, C 1~4 alkyl, C 3~6 cycloalkyl, C 1~4 alkoxy, C 3~6 cycloalkyloxy, C 1~4 alkylthio, C 3~6 cycloalkylthio, amino, N-(C 1~4 alkyl)amino, and N,N-di(C 1~4 alkyl)amino; R4A and R 4B Each of these is independently hydrogen, halogen, hydroxyl, and C 1~4 Alkyl and C 1~4 Selected from the group consisting of alkoxys; or R 4A and R 4B These, together with the carbon atoms to which they are bonded, form a 3- to 5-membered saturated carbocyclic ring; R 4C and R 4D Each of them independently consists of hydrogen and C 1~4 Selected from the group consisting of alkyl groups; R 5 is hydrogen and C 1~4 (Selected from the group consisting of alkyl groups) or relating to the salt thereof that is permitted as a medicine.

[0014] In some embodiments, R 1 C 2~4 It is alkyl. In a preferred embodiment, R 1 is n-propyl. In another preferred embodiment, R 1 It is n-butyl.

[0015] In some embodiments, R 2 n is selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, and dimethylamino. In a preferred embodiment, n is 1, i.e., the phenyl ring has only one substituent R 2 It is replaced by R. In another preferred embodiment, R 2 It is in the para position.

[0016] In some embodiments, R 3 The group is selected from fluoro, chloro, bromo, methyl, cyclopropyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino, and dimethylamino.

[0017] In some embodiments, R 4A and R 4B Each of these is independently hydrogen, halogen, hydroxyl, and C 1~4Alkyl and C 1~4 Selected from the group consisting of alkoxys, or R 4A and R 4B These, together with the carbon atoms to which they are bonded, form a cyclopropyl ring. In some embodiments, R 4A and R 4B Each of these atoms is either independently fluoro, methyl, or methoxy, or together with the carbon atom to which they are bonded, they form a cyclopropyl ring.

[0018] In some embodiments, R 4C and R 4D Each is independently hydrogen or methyl. In some embodiments, R 4C and R 4D Each of them is hydrogen.

[0019] In some embodiments, R 5 R is hydrogen. In some embodiments, R 5 It is methyl.

[0020] In a preferred embodiment, the compound of formula (I) is the compound of formula (Ia):

[0021] [ka]

[0022] (In the formula, M is selected from the group consisting of -CH2-, -NH-, and -NCH3-; R 1 C 2~4 It is alkyl; R 2 These are independently hydrogen, halogen, hydroxyl, and C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, amino, N-(C) 1~4 Alkyl)amino, N,N-di(C 1~4 Selected from the group consisting of alkyl)amino; n is an integer, either 1 or 2; R 3 is halogen, C 1~4 Alkyl, C 3~6 Cycloalkyl, C 1~4 Alkoxy, C 1~4 Alkylthio, amino, N-(C 1~4 Alkyl)amino, and N,N-di(C 1~4 Selected from the group consisting of alkyl)amino; R 4A and R 4B Each of these is independently hydrogen, halogen, hydroxyl, and C 1~4 Alkyl and C 1~4 Selected from the group consisting of alkoxys, or R 4A and R 4B (These, together with the carbon atoms to which they are bonded, form a cyclopropyl ring.) Or the salt thereof that is permitted as a medicine.

[0023] In a preferred embodiment, the compound of formula (I) is the compound of formula (Ib):

[0024] [ka]

[0025] (In the formula, M is selected from the group consisting of -CH2-, -NH-, and -N(CH3)-; R 1 C 2~4 Alkyl, more preferably n-propyl or n-butyl; R 2 These are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, and dimethylamino; R 3 This is selected from the group consisting of fluoro, chloro, bromo, methyl, cyclopropyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino, and dimethylamino; R 4A and R 4Beach independently is hydrogen, fluoro, methyl, methoxy, or ethoxy, or together with the carbon atom to which they are attached forms a cyclopropyl ring) or a pharmaceutically acceptable salt thereof.

[0026] Preferred compounds of the present invention are compounds of formula (I-b) as defined above, wherein M, R 1 , R 2 , R 3 , R 4A , and R 4B are as shown in Table 1 below) or a pharmaceutically acceptable salt thereof:

[0027]

Table 1A

[0028]

Table 1B

[0029]

Table 1C

[0030] In certain embodiments, the compound of formula (I) is 3-((3-Butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid; (S)-3-((3-Butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid; (R)-3-((3-Butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (S)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (R)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (S)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (R)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid; (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid; (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (S)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (S)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (R)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (R)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; (S)-3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; (R)-3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-ethoxypropanoic acid; 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2-hydroxypropanoic acid; 3-((3-ethyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; 3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; 3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (S)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (R)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (S)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (R)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; and 3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoic acid; Alternatively, it is selected from the group consisting of salts thereof that are permitted as pharmaceuticals.

[0031] As used herein, the term "halo" refers to fluoro, chloro, bromo, and iodine.

[0032] When used herein, "C 1~6 The term "alkyl" refers to a linear or branched alkyl group having 1 to 6 carbon atoms, and "C 1~4 The term "alkyl" refers to a linear or branched alkyl group having 1 to 4 carbon atoms. 1~4 Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.

[0033] As used herein, "C" 1~4 The term "haloalkyl" refers to a straight-chain or branched C 1~4 alkyl group as defined herein, wherein one or more hydrogen atoms are replaced by halogen. Examples of C 1~4 haloalkyl include chloromethyl, fluoroethyl, and trifluoromethyl.

[0034] As used herein, "C" 1~4 The terms "alkoxy" and "alkylthio" refer to a straight-chain or branched C 1~4 alkyl group bonded through an oxygen or sulfur atom, respectively, to the remainder of the molecule. 1~4

[0035] As used herein, "C" 3~6 2]The term "cycloalkyl" refers to a monocyclic saturated hydrocarbon ring having 3 to 6 carbon atoms. Examples of C 3~6 cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0036] The term "aryl" refers to an aromatic monocyclic ring composed of 6 carbon atoms or an aromatic bicyclic ring system composed of 10 carbon atoms. Examples of aryl include phenyl, naphthyl, and azulenyl.

[0037] The term "amino" refers to the -NH2 group. As used herein, the terms "N-(C 1~4 alkyl)amino" and "N,N-di(C 1~4 alkyl)amino" refer to an amino group in which one or both hydrogen atoms are each replaced by a straight-chain or branched C 1~4 alkyl group. Examples of N-(C 1~4 alkyl)amino include methylamino, ethylamino, and tert-butylamino, and examples of N,N-di-(C 1~4 alkyl)amino include dimethylamino and diethylamino.

[0038] As used herein, "N-(aryl-C) 1~4 The term "alkyl-amino" refers to a hydrogen atom that is aryl-C. 1~4 This refers to an amino group replaced by an alkyl group. N-(aryl-C 1~4 Examples of alkyl)aminos include benzylamino and phenylethylamino. 1~6 The term "alkylcarbonylamino" refers to a hydrogen atom that is C 1~6 This refers to an amino group that has been replaced by an alkylcarbonyl group. 1~6 Examples of alkanoylaminos include acetylamino and tert-butylcarbonylamino. 1~4 The term "alkyloxycarbonylamino" refers to a hydrogen atom that is C 1~4 This refers to an amino group that has been replaced by an alkyloxycarbonyl group. 1~4 An example of an alkyloxycarbonylamino is tert-butoxycarbonylamino. 1~4 "Alkyl sulfonamide" and "C 3~6 The term "cycloalkylsulfonamide" refers to a hydrogen atom that is C 1~4 Alkylsulfonyl or C 3~6 This refers to amino groups that have been replaced by cycloalkylsulfonyl groups.

[0039] As used herein, the term “medically acceptable” means a compound, material, composition and / or dosage form that is suitable for human medicinal use, is generally safe and non-toxic, and is not biologically or otherwise undesirable.

[0040] As used herein, the term “about” means a value or parameter that includes (and is described) embodiments relating to that value or parameter itself. For example, a statement referring to “about 20” includes a statement of “20.” A numerical range includes the number defining the range. Generally speaking, the term “about” means the greater of the value that the variable represents, all values ​​within the experimental error of the value that the variable represents (e.g., within the 95% confidence interval of the mean), or within 10 percent of the value that the variable represents.

[0041] The 1,5-benzothiazepine and 1,2,5-benzothiasiazepine compounds of formula (I), or their pharmaceutically acceptable salts, are inhibitors of the apical sodium-dependent bile acid transporter, the hepatic bile acid transporter, or both the apical sodium-dependent bile acid transporter and the hepatic bile acid transporter (ASBT inhibitors, LBAT inhibitors, and dual ASBT / LBAT inhibitors, respectively). Therefore, they are useful for the treatment or prevention of conditions, disorders, and diseases in which inhibition of bile acid circulation is desirable, such as cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases, and liver diseases.

[0042] Cardiovascular diseases and disorders of fatty acid metabolism and glucose utilization include, but are not limited to, hypercholesterolemia; impaired fatty acid metabolism; type 1 and type 2 diabetes mellitus; complications of diabetes, e.g., cataracts, microvascular and macrovascular diseases, retinopathy, neuropathy, nephropathy, and delayed wound healing, tissue ischemia, diabetic foot lesions, arteriosclerosis, myocardial infarction, acute coronary syndrome, unstable angina, stable angina, stroke, peripheral artery occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders, and restenosis; diabetes-related diseases, e.g., insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, dyslipidemia, hyperlipidemia, e.g., hypertriglyceridemia, metabolic syndrome (X syndrome), atherosclerosis, and hypertension; and elevated high-density lipoprotein levels.

[0043] Gastrointestinal disorders and conditions include constipation (including chronic constipation, functional constipation, chronic idiopathic constipation (CIC), intermittent / sporadic constipation, constipation secondary to diabetes mellitus, constipation secondary to stroke, constipation secondary to chronic kidney disease, constipation secondary to multiple sclerosis, constipation secondary to Parkinson's disease, constipation secondary to systemic sclerosis, drug-induced constipation, constipation-predominant irritable bowel syndrome (IBS-C), mixed irritable bowel syndrome (IBS-M), pediatric functional constipation, and opioid-induced constipation); Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); inflammation of the ileum; and reflux disorders and their complications, such as Barrett's esophagus, bile reflux esophagitis, and bile reflux gastritis.

[0044] Liver disease, as defined herein, is any disease of the liver and related organs, including the pancreas, portal vein, hepatic parenchyma, intrahepatic biliary system, extrahepatic biliary system, and gallbladder. In some cases, liver disease is bile acid-dependent liver disease. Liver diseases and disorders include: hereditary metabolic disorders of the liver; congenital abnormalities of bile acid synthesis; congenital bile duct anomalies; biliary atresia; biliary atresia after Kasai procedure; biliary atresia after liver transplantation; neonatal hepatitis; neonatal cholestasis; hereditary cholestasis; cerebral tendon xanthomatous disease; secondary defects in BA synthesis; Zellweger syndrome; liver diseases associated with cystic fibrosis; α1 antitrypsin deficiency; Alagille syndrome (ALGS); Beiler syndrome; primary defects in bile acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC), e.g., PFIC-1, PFIC-2, PFIC-3, and unspecified PFIC, post-bile diversion PFIC, and post-liver transplant PFIC; benign recurrent intrahepatic cholestasis (BRIC), e.g., BRIC1 , BRIC2, and unspecified BRIC, post-bile diversion BRIC, and post-liver transplant BRIC; autoimmune hepatitis; primary biliary cirrhosis (PBC); hepatic fibrosis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); portal hypertension; cholestasis; cholestasis in Down syndrome; drug-induced cholestasis; intrahepatic cholestasis in pregnancy (jaundice during pregnancy); intrahepatic cholestasis; extrahepatic cholestasis; cholestasis associated with parenteral nutrition (PNAC); cholestasis associated with hypophospholipids; lymphedema-associated cholestasis syndrome 1 (LCS1); primary sclerosing cholangitis (PSC); cholangitis associated with immunoglobulin G4; primary biliary cholangitis; cholelithiasis (gallstones); biliary tract stones (biliary gallstones) Lithiasis; common bile duct stones; gallstone pancreatitis; caloric disease; malignant neoplasm of the bile duct; malignant neoplasm causing obstruction of the bile duct; bile duct stenosis; AIDS cholangiopathies; ischemic cholangiopathies; pruritus due to cholestasis or jaundice; pancreatitis; chronic autoimmune liver disease leading to progressive cholestasis; fatty liver degeneration; alcoholic hepatitis; acute fatty liver; fatty liver during pregnancy; drug-induced hepatitis; iron overload; congenital bile acid metabolism disorder type 1 (BAS disorder type 1); drug-induced liver injury (DILI); hepatic fibrosis; congenital hepatic fibrosis; cirrhosis; Langerhans cell histiocytosis (LCH); neonatal ichthyosis sclerosing cholangitis (NISCH); myeloid protoporphyria (EPP); idiopathic adult bile duct depletion (IAD); idiopathic neonatal hepatitis (INH);Non-symptomatic intrahepatic bile duct reduction disease (NS PILBD); autosomal recessive hereditary intrahepatic cholestasis (North American Indian childhood cirrhosis) (NAIC); hepatic sarcoidosis; amyloidosis; necrotizing enteritis; toxicity caused by serum bile acids, for example, arrhythmia (e.g., atrial fibrillation) in the situation of abnormal serum bile acid profile, cardiomyopathy associated with cirrhosis ("cholecardia"), and skeletal muscle wasting associated with cholestatic liver disease; polycystic liver disease; viral hepatitis (including hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E); hepatocellular carcinoma (hepatocellular tumor); cholangiocarcinoma; gastrointestinal cancer related to bile acids; and cholestasis caused by tumors and neoplasms of the liver, biliary tract, and pancreas are included, but not limited to these. The compound of formula (I) or a pharmaceutically acceptable salt thereof is also useful for enhancing corticosteroid therapy in liver diseases.;

[0045] Other diseases that can be treated or prevented by the compound of formula (I) or a pharmaceutically acceptable salt thereof include malabsorption syndromes (including abetalipoproteinemia, familial hypobetalipoproteinemia (FHBL), chylomicron retention disease (CRD), and sitosterolemia); vitamin excess and marble bone disease; hypertension; glomerular hyperfiltration; polycystic kidney disease (PKD), for example, autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD); and uremic pruritus. The compound is also useful for protecting against kidney injury associated with liver or metabolic diseases.

[0046] The transport of bile acids in the human body is by the action of members of the SLC10 family, which are solute transporter proteins, especially Na expressed on the sinusoidal cell membrane of hepatocytes +- taurocholic acid cotransporting polypeptide (NTCP, also known as liver bile acid transporter (LBAT); gene symbol SLC10A1), and apical sodium-dependent bile acid transporter (ASBT, also known as ileal bile acid transporter (IBAT), ISBT, ABAT, or NTCP2; gene symbol SLC10A2) expressed on the apical membranes of ileal enterocytes, proximal tubule cells, bile duct epithelium, large bile duct cells, and gallbladder epithelial cells. In the liver, bile acids are efficiently extracted from portal blood by the liver bile acid transporter (LBAT) and re-secreted across the canalicular membrane by the bile salt export pump (BSEP; gene symbol ABCB11). Reabsorption of bile acids in the ileum is handled by the apical sodium-dependent bile acid transporter (ASBT), generally called the ileal bile acid transporter (IBAT) in the ileum. Both LBAT and ASBT function as electrogenic sodium-solute cotransporters that move more than two Na + ions per molecule of solute.

[0047] Endogenous substances, including xenobiotics and bile acids, are taken up from portal blood by the liver and secreted into bile by distinct transport proteins with individualized substrate specificities. Glycine- and taurine-conjugated bile acids exist in anionic form and cannot cross membranes by diffusion, and thus are completely dependent on membrane transport proteins to enter and exit hepatocytes (Kosters and Karpen, Xenobiotica 2008, Vol. 38, pp. 1043-1071). ASBT and LBAT prefer glycine- and taurine-conjugated bile salts over their unconjugated counterparts and show higher affinity for dihydroxy bile salts than trihydroxy bile salts. The non-bile acid substrates of ASBT have not yet been identified, but LBAT has been found to transport various steroid sulfates, hormones, and xenobiotics as well.

[0048] LBAT is not as fully characterized as ASBT in terms of drug inhibition requirements. Dong et al. identified FDA-approved drugs that inhibit human LBAT and compared the inhibition requirements of LBAT and ASBT. A series of LBAT inhibition trials were conducted using FDA-approved drugs in conjunction with the development of iterative calculation models. From the screening trials, 27 drugs, including irbesartan (Ki=11.9 μM) and ezetimibe (Ki=25.0 μM), were identified as novel LBAT inhibitors. Common features in the pharmacophore indicated that two hydrophobic substances and one hydrogen-bonding receptor are important for LBAT inhibition. Of the 72 drugs screened in vitro, a total of 31 drugs inhibited LBAT, while 51 drugs (i.e., more than half) inhibited ASBT. Therefore, although there is some overlap in inhibitors, ASBT is unexpectedly more tolerant of drug inhibition than LBAT, which may be related to the fact that LBAT has fewer pharmacophore characteristics (Dong et al., Mol. Pharm. 2013, Vol. 10, pp. 1008-1019).

[0049] Vaz et al. described the identification of LBAT deficiency as a novel congenital anomaly with a relatively mild clinical phenotype. Identifying LBAT deficiency confirms that this transporter is the primary transporter of conjugated bile salts into the liver, but also demonstrates that auxiliary transporters can sustain enterohepatic circulation even without it (Vaz et al., Hepatology 2015, Vol. 61, pp. 260-267). These findings support the hypothesis that LBAT inhibition is a safe mechanism of action, because hepatocytes still have the potential to take up the necessary amount of bile acids.

[0050] Liu et al. describe the identification of a novel type of hypercholanacinemia associated with homozygosity of the p.Ser267Phe mutation in SLC10A1(LBAT). The allele frequency of this mutation in the SLC10A1 gene differs across ethnic groups, with the highest incidence occurring in southern China (8% and 12% in the Han and Dai ethnic groups, respectively) and Vietnam (11%). This "hidden" hypercholanacinemia was thought to affect 0.64% of the southern Han ethnic group in China, 1.44% of the Dai ethnic group, and 1.21% of the ethnic group in Vietnam. Increased conjugated and unconjugated serum BA levels were also observed in homozygous individuals. Liu et al. suggest that this finding is most likely due to reduced BA transport from the portal circulation to hepatocytes. This supports the hypothesis (Karpen and Dawson, Hepatology 2015, Vol. 61, pp. 24-27) that the physiological function of enterohepatic circulation is not only the recirculation of bile acids but also the removal of bile acids from the circulation to achieve homeostasis. Alternatively, in homozygous carriers, the liver may be synthesizing increased levels of bile acids to compensate for the reduced enterohepatic recirculation. Since LBAT also transports unconjugated bile acids, the increase in unconjugated bile acids in this study was not surprising (Liu et al., Scientific Reports 2017, 7: 9214, pp. 1-7).

[0051] LBAT has been found to be downregulated in several forms of cholestatic liver injury and cholestasis, while ASBT has been found to be downregulated in various gastrointestinal disorders such as Crohn's disease, primary bile acid malabsorption, inflammatory bowel disease, and ileal inflammation, but upregulated in cholestasis. LBAT also functions as a cellular receptor for viral entry by hepatitis B virus (HBV) and hepatitis D virus (HDV), which in turn is a major cause of liver disease and hepatocellular carcinoma.

[0052] ASBT inhibition has been investigated for its ability to reduce plasma cholesterol levels, improve insulin resistance, and alleviate the hepatic bile acid burden in cholestatic liver disease. In addition, ASBT inhibition has been found to restore insulin levels and normal blood glucose levels, thereby establishing it as a promising treatment for type 2 diabetes mellitus. ASBT inhibitors are also used to treat functional constipation.

[0053] Since ASBT is primarily expressed in the ileum (often called IBAT in the ileum), ASBT inhibitors do not need to be systemically absorbable. On the other hand, ASBT is also expressed in the proximal tubular cells of the kidney. Therefore, systemically absorbable ASBT inhibitors may also inhibit the reuptake of bile acids in the kidney. This is thought to increase bile acid levels in the urine and increase the removal of bile acids from the body through urine. Therefore, systemically absorbable ASBT inhibitors that affect not only the ileum but also the kidney are expected to lead to a greater reduction in bile acid levels than non-systemically absorbable ASBT inhibitors that affect only the ileum.

[0054] Compounds with high ASBT inhibitory activity are particularly suitable for the treatment of liver diseases that cause cholestasis, such as progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, biliary atresia, and non-alcoholic steatohepatitis (NASH).

[0055] Biliary atresia is a rare childhood liver disorder characterized by partial or complete obstruction (or even absence) of the bile ducts. This obstruction or absence leads to cholestasis, resulting in the accumulation of bile acids that damage the liver. In some embodiments, the accumulation of bile acids occurs in the extrahepatic biliary system. In some embodiments, the accumulation of bile acids occurs in the intrahepatic biliary system. The current standard treatment is the Kasai procedure, a surgical procedure that removes the obstructed bile duct and connects a portion of the small intestine directly to the liver. Currently, there are no approved drug therapies for this disorder.

[0056] A method for treating biliary atresia in subjects requiring treatment is provided herein, the method comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the subject is administered the compound of formula (I) or a pharmaceutically acceptable salt thereof after undergoing the Kasai procedure. In some embodiments, the subject is administered the compound of formula (I) or a pharmaceutically acceptable salt thereof before undergoing the Kasai procedure. In some embodiments, treatment of biliary atresia reduces the serum bile acid levels in the subject. In some embodiments, the serum bile acid levels are determined, for example, by an ELISA enzyme assay or a total bile acid assay such as that described in Danese et al., PLoS One. 2017, Vol. 12(6): e0179200 (which is incorporated herein by reference in its entirety). In some embodiments, serum bile acid levels can be reduced by, for example, 10% to 40%, 20% to 50%, 30% to 60%, 40% to 70%, 50% to 80%, or more than 90% of the serum bile acid levels prior to administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, treatment of biliary atresia includes treatment of pruritus.

[0057] PFIC is a rare genetic disorder that is estimated to affect 1 in 50,000 to 100,000 live births worldwide and causes a progressive, life-threatening liver disease.

[0058] One symptom of PFIC is itching, which often significantly reduces the quality of life. In some cases, PFIC progresses to cirrhosis and liver failure. Current treatments include partial extracholestasis fistula (PEFD) and liver transplantation, but these options carry not only substantial risks of postoperative complications but also potential psychological and social problems.

[0059] Three alternative gene deletions have been identified that correlate with three distinct PFIC subtypes, known as type 1, type 2, and type 3. PFIC type 1, sometimes called "Bailer's disease," is caused by impaired bile secretion resulting from a mutation in the ATP8B1 gene, which codes for a protein that helps maintain a proper balance of lipids known as phospholipids in the cell membranes of the bile ducts. This imbalance of phospholipids is associated with cholestasis and elevated bile acids in the liver. Individuals with PFIC type 1 typically develop cholestasis at one month of age and, without surgical treatment, progress to cirrhosis and end-stage liver disease before the age of 10. PFIC type 2, sometimes called "Bailer syndrome," is caused by impaired bile salt secretion resulting from a mutation in the ABCB11 gene, which codes for a protein known as a bile salt efflux pump that moves bile acids out of the liver. Individuals with PFIC type 2 often develop liver failure within the first few years of life and are at high risk of developing certain types of liver cancer, known as hepatocellular carcinoma. PFIC type 3 typically presents in the first few years of childhood with progressive cholestasis and is caused by mutations in the ABCB4 gene, which encodes a transporter that moves phospholipids across cell membranes.

[0060] In addition, mutations in the TJP2, NR1H4, or Myo5b genes have been suggested as causes of PFIC. Furthermore, some individuals with PFIC do not have mutations in any of the ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or Myo5b genes. In these cases, the cause of the condition is unknown.

[0061] Exemplary mutations in the ATP8B1 gene or the resulting protein are numbered based on the human wild-type ATP8B1 protein (e.g., SEQ ID NO: 1) or the gene (e.g., SEQ ID NO: 2) and listed in Tables 2 and 3. Exemplary mutations in the ABCB11 gene or the resulting protein are numbered based on the human wild-type ABCB11 protein (e.g., SEQ ID NO: 3) or the gene (e.g., SEQ ID NO: 4) and listed in Tables 4 and 5.

[0062] As will be understood by those skilled in the art, the amino acid positions in the reference protein sequence corresponding to the specific amino acid positions in SEQ ID NO: 1 or 3 can be determined by aligning the reference protein sequence with SEQ ID NO: 1 or 3 (for example, using a software program such as ClustalW2). Changes to these residues (referred to herein as "mutations") can include single or multiple amino acid substitutions, insertions, and deletions within or adjacent to the sequence. As will be understood by those skilled in the art, the nucleotide positions in the reference gene sequence corresponding to the specific nucleotide positions in SEQ ID NO: 2 or 4 can be determined by aligning the reference gene sequence with SEQ ID NO: 2 or 4 (for example, using a software program such as ClustalW2). Changes to these residues (referred to herein as "mutations") can include single or multiple nucleotide substitutions, insertions, and deletions within or adjacent to the sequence. See also Kooistra et al., "KLIFS: A structural kinase-ligand interaction database", Nucleic Acids Res. 2016, Vol. 44, No. D1, pp. D365-D371 (which is hereby incorporated by reference in its entirety).

[0063] Canonical protein sequence of ATP8B1 (SEQ ID NO: 1) - Uniprot ID O43520

[0064]

Chemical formula

[0065] Canonical DNA sequence of ATP8B1 (SEQ ID NO: 2)

[0066]

Chemical formula

[0067]

Chemical formula

[0068]

change

[0069] Table 2A

[0070] Table 2B

[0071] Table 2C

[0072]

Table 2D

[0073] Table 2E

[0074] Table 2F

[0075]

Table 2G

[0076] Table 2H

[0077] Table 2I

[0078] Table 3A

[0079] Table 3B

[0080]

Table 3C

[0081]

Table 3D

[0082] References for Table 2 and Table 3 1 Folmer et al., Hepatology. 2009, vol. 50(5), p. 1597-1605. 2 Hsu et al., Hepatol Res. 2009, vol. 39(6), p. 625-631. 3 Alvarez et al., Hum Mol Genet. 2004, vol. 13(20), p. 2451-2460. 4 Davit-Spraul et al., Hepatology 2010, vol. 51(5), p. 1645-1655. 5 Vitale et al., J Gastroenterol. 2018, vol. 53(8), p. 945-958. 6 Klomp et al., Hepatology 2004, vol. 40(1), p. 27-38. 7Zarenezhad et al., Hepatitis Monthly: 2017, vol. 17(2); e43500. 8 Dixon et al., Scientific Reports 2017, vol. 7, 11823. 9 Painter et al., Eur J Hum Genet. 2005, vol. 13(4), p. 435-439. 10 Deng et al., World J Gastroenterol. 2012, vol. 18(44), p. 6504-6509. 11 Giovannoni et al., PLoS One. 2015, vol. 10(12): e0145021. 12 Li et al., Hepatology International 2017, vol. 11, No. 1, Supp. Supplement 1, pp. S180. Abstract Number: OP284. 13 Togawa et al., Journal of Pediatric Gastroenterology and Nutrition 2018, vol. 67, Supp. Supplement 1, pp. S363. Abstract Number: 615. 14 Miloh et al., Gastroenterology 2006, vol. 130, No. 4, Suppl. 2, pp. A759-A760. Meeting Info.: Digestive Disease Week Meeting / 107th Annual Meeting of the American-Gastroenterological-Association. Los Angeles, CA, USA. May 19. 15Droege et al., Journal of Gastroenterology 2015, vol. 53, no. 12. Abstract Number: A3-27. Meeting info: 32nd Annual Meeting of the German Working Community for the Study of the Liver. Dusseldorf, Germany. 22 Jan 2016-23 Jan 2016 16 Mizuochi et al., Clin Chim Acta. 2012, Vol. 413(15-16), p. 1301-1304. 17 Liu et al., Hepatology International 2009, vol. 3, no. 1, p. 184-185. Abstract Number: PE405. Meeting Info: 19th Conference of the Asian Pacific Association for the Study of the Liver. Hong Kong, China. 13 Feb 2009-16 Feb 2009 18 McKay et al., Version 2. F1000Res. 2013; 2: 32. DOI: 10.12688 / f1000research.2-32.v2 19 Hasegawa et al., Orphanet J Rare Dis. 2014, Vol. 9:89. 20 Stone et al., J Biol Chem. 2012, Vol. 287(49), p. 41139-51. 21 Kang et al., J Pathol Transl Med. 2019 May 16. doi: 10.4132 / jptm.2019.05.03. [Epub ahead of print] 22Sharma et al., BMC Gastroenterol. 2018, vol. 18(1), p. 107. 23 Uegaki et al., Intern Med. 2008, vol. 47(7), p. 599-602. 24 Goldschmidt et al., Hepatol Res. 2016, vol. 46(4), p. 306-311. 25 Liu et al., J Pediatr Gastroenterol Nutr. 2010, vol. 50(2), p. 179-183. 26 Jung et al., J Pediatr Gastroenterol Nutr. 2007, vol. 44(4), p. 453-458. 27 Bounford. University of Birmingham. Dissertation Abstracts International, (2016) Vol. 75, No. 1C. Order No.: AAI10588329. ProQuest Dissertations & Theses. 28 Stolz et al., Aliment Pharmacol Ther. 2019, vol. 49(9), p. 1195-1204. 29 Ivashkin et al., Hepatology International 2016, vol. 10, No. 1, Supp. SUPPL. 1, pp. S461. Abstract Number: LBO-38. Meeting Info: 25th Annual Conference of the Asian Pacific Association for the Study of the Liver, APASL 2016. Tokyo, Japan. 20 Feb 2016-24 Feb 2016 30 Blackmore et al., J Clin Exp Hepatol. 2013, vol. 3(2), p. 159-161. 31 Matte et al., J Pediatr Gastroenterol Nutr. 2010, vol. 51(4), p. 488-493. 32 Squires et al., J Pediatr Gastroenterol Nutr. 2017, vol. 64(3), p. 425-430. 33 Hayshi et al., EBioMedicine. 2018, vol. 27, p. 187-199. 34 Nagasaka et al., J Pediatr Gastroenterol Nutr. 2007, vol. 45(1), p. 96-105. 35 Wang et al., PLoS One. 2016; vol. 11(4): e0153114. 36 Narchi et al., Saudi J Gastroenterol. 2017, vol. 23(5), p. 303-305. 37 Alashkar et al., Blood 2015, vol. 126, No. 23. Meeting Info.: 57th Annual Meeting of the American-Society-of-Hematology. Orlando, FL, USA. December 05 -08, 2015. Amer Soc Hematol. 38Ferreira et al., Pediatric Transplantation 2013, vol. 17, Supp. SUPPL. 1, pp. 99. Abstract Number: 239. Meeting Info: IPTA 7th Congress on Pediatric Transplantation. Warsaw, Poland. 13 Jul 2013-16 Jul 2013. 39 Pauli-Magnus et al., J Hepatol. 2005, vol. 43(2), p. 342-357. 40 Jericho et al., Journal of Pediatric Gastroenterology and Nutrition 2015, vol. 60(3), p. 368-374. 41 van der Word et al., PLoS One. 2013, vol. 8(11): e80553. 42 Copeland et al., J Gastroenterol Hepatol. 2013, vol. 28(3), p. 560-564. 43 Droege et al., J Hepatol. 2017, vol. 67(6), p. 1253-1264. 44 Chen et al., Journal of Pediatrics 2002, vol. 140(1), p. 119-124. 45 Jirsa et al., Hepatol Res. 2004, vol. 30(1), p. 1-3. 46 van der Word et al., Hepatology 2015, vol. 61(4), p. 1382-1391.

[0083] In some embodiments, the mutation in ATP8B1 is selected from L127P, G308V, T456M, D554N, F529del, I661T, E665X, R930X, R952X, R1014X, and G1040R.

[0084] Canonical protein sequence of ABCB11 (SEQ ID NO: 3) - Uniprot ID O95342

[0085] [ka]

[0086] Canonical DNA sequence of ABCB11 (SEQ ID NO: 4)

[0087] [ka]

[0088] [ka]

[0089] [Table 4A]

[0090] [Table 4B]

[0091] [Table 4C]

[0092] [Table 4D]

[0093] [Table 4E]

[0094] [Table 4F]

[0095]

Table 4G

[0096] Table 4H

[0097] Table 4I

[0098]

Table 4J

[0099]

Table 4K

[0100]

Table 4L

[0101]

Table 4M

[0102]

Table 4N

[0103] Table 5A

[0104] Table 5B

[0105]

Table 5C

[0106] Table 5D

[0107]

Table 5E

[0108] Table 5F

[0109]

Table 5G

[0110] Table 5H

[0111] References for Table 4 and Table 5 1 Noe et al., J Hepatol. 2005, vol. 43(3), p. 536-543. 2 Lam et al., Am J Physiol Cell Physiol. 2007, vol. 293(5), p. C1709-16. 3 Stindt et al., Liver Int. 2013, vol. 33(10), p. 1527-1735. 4Gao et al., Shandong Yiyao 2012, vol. 52(10), p. 14-16. 5 Strautnieks et al., Gastroenterology. 2008, vol. 134(4), p. 1203-1214. 6 Kagawa et al., Am J Physiol Gastrointest Liver Physiol. 2008, vol. 294(1), p. G58-67. 7 Byrne et al., Hepatology. 2009, vol. 49(2), p. 553-567. 8 Chen et al., J Pediatr. 2008, vol. 153(6), p. 825-832. 9 Davit-Spraul et al., Hepatology 2010, vol. 51(5), p. 1645-1655. 10 Droege et al., Sci Rep. 2016, vol. 6: 24827. 11 Lang et al., Pharmacogenet Genomics. 2007, vol. 17(1), p. 47-60. 12 Ellinger et al., World J Gastroenterol. 2017, vol. 23(29), p. :5295-5303. 13 Vitale et al., J Gastroenterol. 2018, vol. 53(8), p. 945-958. 14 Knisely et al., Hepatology. 2006, vol. 44(2), p. 478-86. 15Ellis et al., Hepatology. 2018, vol. 67(4), p. 1531-1545. 16 Lam et al., J Hepatol. 2006, vol. 44(1), p. 240-242. 17 Varma et al., Hepatology 2015, vol. 62(1), p. 198-206. 18 Treepongkaruna et al., World J Gastroenterol. 2009, vol. 15(34), p. 4339-4342. 19 Zarenezhad et al., Hepatitis Monthly: 2017, vol. 17(2); e43500. 20 Hayashi et al., Hepatol Res. 2016, vol. 46(2), p. 192-200. 21 Guorui et al., Linchuang Erke Zazhi 2013, vol. 31(10), 905-909. 22 van Mil et al., Gastroenterology. 2004, vol. 127(2), p. 379-384. 23 Anzivino et al., Dig Liver Dis. 2013, vol. 45(3), p. 226-232. 24 Park et al., World J Gastroenterol. 2016, vol. 22(20), p. 4901-4907. 25 Imagawa et al., J Hum Genet. 2018, vol. 63(5), p. 569-577. 26Giovannoni et al., PLoS One. 2015, vol. 10(12): e0145021. 27 Hu et al., Mol Med Rep. 2014, vol. 10(3), p. 1264-1274. 28 Lang et al,. Drug Metab Dispos. 2006, vol. 34(9), p. 1582-1599. 29 Masahata et al., Transplant Proc. 2016, vol. 48(9), p. 3156-3162. 30 Holz et al., Hepatol Commun. 2018, vol. 2(2), p. 152-154. 31 Li et al., Hepatology International 2017, vol. 11, No. 1, Supp. Supplement 1, pp. S180. Abstract Number: OP284. 32 Francalanci et al., Laboratory Investigation 2011, vol. 91, Supp. SUPPL. 1, pp. 360A. Abstract Number: 1526. 33 Francalanci et al., Digestive and Liver Disease 2010, vol. 42, Supp. SUPPL. 1, pp. S16. Abstract Number: T.N.5. 34 Shah et al., J Pediatr Genet. 2017, vol. 6(2), p. 126-127. 35 Gao et al., Hepatitis Monthly 2017, vol. 17(10), e55087 / 1-e55087 / 6. 36 Evason et al., Am J Surg Pathol. 2011, vol. 35(5), p. 687-696. 37 Davit-Spraul et al., Mol Genet Metab. 2014, vol. 113(3), p. 225-229. 38 Maggiore et al., J Hepatol. 2010, vol. 53(5), p. 981-6. 39 McKay et al., Version 2. F1000Res. 2013; 2: 32. DOI: 10.12688 / f1000research.2-32.v2 40 Liu et al., Pediatr Int. 2013, vol. 55(2), p. 138-144. 41 Waisbourd-Zinman et al., Ann Hepatol. 2017, vol. 16(3), p. 465-468. 42 Griffin, et al., Canadian Journal of Gastroenterology and Hepatology 2016, vol. 2016. Abstract Number: A200. Meeting Info: 2016 Canadian Digestive Diseases Week, CDDW 2016. Montreal, QC, United States. 26 Feb 2016-29 Feb 2016 43 Qiu et al., Hepatology 2017, vol. 65(5), p. 1655-1669. 44 Imagawa et al., Sci Rep. 2017, 7:41806. 45Kang et al., J Pathol Transl Med. 2019 May 16. doi: 10.4132 / jptm.2019.05.03. [Epub ahead of print] 46 Takahashi et al., Eur J Gastroenterol Hepatol. 2007, vol. 19(11), p. 942-6. 47 Shimizu et al., Am J Transplant. 2011, vol. 11(2), p. 394-398. 48 Krawczyk et al., Ann Hepatol. 2012, vol. 11(5), p. 710-744. 49 Sharma et al., BMC Gastroenterol. 2018, vol. 18(1), p. 107. 50 Sattler et al., Journal of Hepatology 2017, vol. 66, No. 1, Suppl. S, pp. S177. Meeting Info.: International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. Amsterdam, NETHERLANDS. April 19 -23, 2017. European Assoc Study Liver. 51 Jung et al., J Pediatr Gastroenterol Nutr. 2007, vol. 44(4), p. 453-458. 52Sciveres. Digestive and Liver Disease 2010, vol. 42, Supp. SUPPL. 5, pp. S329. Abstract Number: CO18. Meeting Info: 17th National Congress SIGENP. Pescara, Italy. 07 Oct 2010-09 Oct 2010 53 Sohn et al., Pediatr Gastroenterol Hepatol Nutr. 2019, vol. 22(2), p. 201-206. 54 Ho et al., Pharmacogenet Genomics. 2010, vol. 20(1), p. 45-57. 55 Wang et al., Hepatol Res. 2018, vol. 48(7), p. 574-584. 56 Shaprio et al., J Hum Genet. 2010, vol. 55(5), p. 308-313. 57 Bounford. University of Birmingham. Dissertation Abstracts International, (2016) Vol. 75, No. 1C. Order No.: AAI10588329. ProQuest Dissertations & Theses. 58 Stolz et al., Aliment Pharmacol Ther. 2019, vol. 49(9), p. 1195-1204. 59 Jankowska et al., J Pediatr Gastroenterol Nutr. 2014, vol. 58(1), p. 92-95. 60Kim. Journal of Pediatric Gastroenterology and Nutrition 2016, vol. 62, Supp. SUPPL. 1, pp. 620. Abstract Number: H-P-045. Meeting Info: 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, ESPGHAN 2016. Athens, Greece. 25 May 2016-28 May 2016. 61 Pauli-Magnus et al., Hepatology 2003, vol. 38, No. 4 Suppl. 1, pp. 518A. print. Meeting Info.: 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA. October 24-28, 2003. American Association for the Study of Liver Diseases. 62 Li et al., Hepatology International 2017, vol. 11, No. 1, Supp. Supplement 1, pp. S362. Abstract Number: PP0347. Meeting Info: 26th Annual Conference of the Asian Pacific Association for the Study of the Liver, APASL 2017. Shanghai, China. 15 Feb 2017-19 Feb 2017. 63Rumbo et al., Transplantation 2018, vol. 102, No. 7, Supp. Supplement 1, pp. S848. Abstract Number: P.752. Meeting Info: 27th International Congress of The Transplantation Society, TTS 2018. Madrid, Spain. 30 Jun 2018-05 Jul 2018. 64 Lee et al., Pediatr Gastroenterol Hepatol Nutr. 2017, vol. 20(2), p. 114-123. 65 Sherrif et al., Liver international: official journal of the International Association for the Study of the Liver 2013, vol. 33, No. 8, pp. 1266-1270. 66 Blackmore et al., J Clin Exp Hepatol. 2013, vol. 3(2), p. 159-161. 67 Matte et al., J Pediatr Gastroenterol Nutr. 2010, vol. 51(4), p. 488-493. 68 Lin et al., Zhongguo Dang Dai Er Ke Za Zhi. 2018, vol. 20(9), p. 758-764. 69Harmanci et al., Experimental and Clinical Transplantation 2015, vol. 13, Supp. SUPPL. 2, pp. 76. Abstract Number: P62. Meeting Info: 1st Congress of the Turkic World Transplantation Society. Astana, Kazakhstan. 20 May 2015-22 May 2015. 70 Herbst et al., Mol Cell Probes. 2015, vol. 29(5), p. 291-298. 71 Moghadamrad et al., Hepatology. 2013, vol. 57(6), p. 2539-2541. 72 Holz et al., Zeitschrift für Gastroenterologie 2016, vol. 54, No. 8. Abstract Number: KV275. Meeting Info: Viszeralmedizin 2016, 71st Annual Meeting of the German Society for Gastroenterology, Digestive and Metabolic Diseases with Endoscopy Section - 10th Autumn Meeting of the German Society for General and Visceral Surgery. Hamburg, Germany. 21 Sep 2016-24 Sep 2016. 73 Wang et al., PLoS One. 2016; vol. 11(4): e0153114. 74Hao et al., International Journal of Clinical and Experimental Pathology 2017, vol. 10(3), p. 3480-3487. 75 Arnell et al., J Pediatr Gastroenterol Nutr. 2010, vol. 51(4), p. 494-499. 76 Sharma et al., Indian Journal of Gastroenterology 2017, vol. 36, No. 1, Supp. Supplement 1, pp. A99. Abstract Number: M-20. Meeting Info: 58th Annual Conference of the Indian Society of Gastroenterology, ISGCON 2017. Bhubaneswar, India. 14 Dec 2017-17 Dec 2017. 77 Beausejour et al., Can J Gastroenterol. 2011, vol. 25(6), p. 311-314. 78 Imagawa et al., Journal of Pediatric Gastroenterology and Nutrition 2016, vol. 63, Supp. Supplement 2, pp. S51. Abstract Number: 166. Meeting Info: World Congress of Pediatric Gastroenterology, Hepatology and Nutrition 2016. Montreal, QC, Canada. 05 Oct 2016-08 Oct 2016. 79Peng et al., Zhonghua er ke za zhi (Chinese journal of pediatrics) 2018, vol. 56, No. 6, pp. 440-444. 80 Tibesar et al., Case Rep Pediatr. 2014, vol. 2014: 185923. 81 Ng et al., Journal of Pediatric Gastroenterology and Nutrition 2018, vol. 66, Supp. Supplement 2, pp. 860. Abstract Number: H-P-127. Meeting Info: 51st Annual Meeting European Society for Paediatric Gastroenterology, Hepatology and Nutrition, ESPGHAN 2018. Geneva, Switzerland. 09 May 2018-12 May 2018. 82 Wong et al., Clin Chem. 2008, vol. 54(7), p. 1141-1148. 83 Pauli-Magnus et al., J Hepatol. 2005, vol. 43(2), p. 342-357. 84 Jericho et al., Journal of Pediatric Gastroenterology and Nutrition. 60, vol. 3, p. 368-374. 85Scheimann et al., Gastroenterology 2007, vol. 132, No. 4, Suppl. 2, pp. A452. Meeting Info.: Digestive Disease Week Meeting / 108th Annual Meeting of the American-Gastroenterological-Association. Washington, DC, USA. May 19 -24, 2007. Amer Gastroenterol Assoc; Amer Assoc Study Liver Dis; Amer Soc Gastrointestinal Endoscopy; Soc Surg Alimentary Tract. 86 Jaquotot-Haerranz et al., Rev Esp Enferm Dig. 2013, vol. 105(1), p. 52-54. 87 Khosla et al., American Journal of Gastroenterology 2015, vol. 110, No. Suppl. 1, pp. S397. Meeting Info.: 80th Annual Scientific Meeting of the American-College-of-Gastroenterology. Honolulu, HI, USA. October 16 -21, 2015. 88 Droege et al., J Hepatol. 2017, vol. 67(6), p. 1253-1264. 89 Liu et al., Liver International 2010, vol. 30(6), p. 809-815. 90 Chen et al., Journal of Pediatrics 2002, vol. 140(1), p. 119-124. 91US Patent No. 9,295,677

[0112] In some embodiments, the mutations in ABCB11 are selected from A167T, G238V, V284L, E297G, R470Q, R470X, D482G, R487H, A570T, N591S, A865V, G982R, R1153C, and R1268Q.

[0113] A method is provided for treating PFIC (e.g., PFIC-1 and PFIC-2) in a subject, the method comprising: performing an assay on a sample obtained from the subject to determine whether the subject has a PFIC-related mutation (e.g., ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or Myo5b mutation); and administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to the subject determined to have a PFIC-related mutation (e.g., specifically or selectively). In some embodiments, the mutation is an ATP8B1 or ABCB11 mutation, for example, one of those shown in Tables 1-4. In some embodiments, the mutation in ATP8B1 is selected from L127P, G308V, T456M, D554N, F529del, I661T, E665X, R930X, R952X, R1014X, and G1040R. In some embodiments, the mutations in ABCB11 are selected from A167T, G238V, V284L, E297G, R470Q, R470X, D482G, R487H, A570T, N591S, A865V, G982R, R1153C, and R1268Q.

[0114] Methods are also provided for treating PFIC (e.g., PFIC-1 and PFIC-2) in subjects requiring treatment for PFIC, the methods comprising (a) detecting a PFIC-related mutation (e.g., ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or Myo5b mutation) in the subject; and (b) administering to the subject a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the method for treating PFIC may comprise administering a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject having a PFIC-related mutation (e.g., ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or Myo5b mutation). In some embodiments, the mutation is the ATP8B1 or ABCB11 mutation, for example, one of the mutations shown in any of Tables 1-4. In some embodiments, the mutation in ATP8B1 is selected from L127P, G308V, T456M, D554N, F529del, I661T, E665X, R930X, R952X, R1014X, and G1040R. In some embodiments, the mutation in ABCB11 is selected from A167T, G238V, V284L, E297G, R470Q, R470X, D482G, R487H, A570T, N591S, A865V, G982R, R1153C, and R1268Q.

[0115] In some embodiments, a subject is determined to have a PFIC-related mutation in the subject or a biopsy specimen from the subject through the use of tests known to those skilled in the art, including next-generation sequencing (NGS). In some embodiments, a subject is determined to have a PFIC-related mutation by using a regulatory agency-approved test or assay, such as an FDA-approved test, or by performing any of the non-limiting examples of assays described herein, for the purpose of identifying a PFIC-related mutation in the subject or a biopsy specimen from the subject. Further methods for diagnosing PFIC are described in Gunaydin, M. et al., Hepat Med. 2018, Vol. 10, pp. 95-104 (the entire text of which is incorporated herein by reference).

[0116] In some embodiments, treatment of PFIC (e.g., PFIC-1 or PFIC-2) reduces serum bile acid levels in the subject. In some embodiments, serum bile acid levels are determined, for example, by an ELISA enzyme assay or by an assay for measuring total bile acid, such as that described in Danese et al., PLoS One. 2017, Vol. 12(6): e0179200 (which is incorporated herein by reference in its entirety). In some embodiments, serum bile acid levels can be reduced by, for example, 10% to 40%, 20% to 50%, 30% to 60%, 40% to 70%, 50% to 80%, or more than 90% of the serum bile acid levels prior to administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, treatment of PFIC includes treatment of pruritus.

[0117] Since LBAT is expressed in hepatocytes, LBAT and dual ASBT / LBAT inhibitors must have at least some bioavailability and free fractions in the blood. Because LBAT inhibitor compounds only need to persist from the intestines to the liver, relatively low systemic exposure to such compounds is sufficient, thereby minimizing the potential risk of any side effects in other parts of the body. Inhibition of LBAT and ASBT is expected to have at least an additive effect on reducing bile acid concentrations in the liver. Dual ASBT / LBAT inhibitors may also be able to reduce bile acid levels without inducing diarrhea, as is sometimes observed with ASBT inhibitors.

[0118] Compounds with high LBAT inhibitory efficacy and sufficient bioavailability are expected to be particularly suitable for the treatment of hepatitis. Compounds with dual ASBT / LBAT inhibitory efficacy and sufficient bioavailability are expected to be particularly suitable for the treatment of non-alcoholic steatohepatitis (NASH).

[0119] NASH is a common and serious chronic liver disease similar to alcoholic liver disease, but occurs in people who drink little to no alcohol. In patients with NASH, intrahepatic fat accumulation, known as non-alcoholic fatty liver disease (NAFLD) or steatosis, and other factors such as high LDL cholesterol and insulin resistance, can induce chronic inflammation in the liver, leading to progressive scarring of the tissue known as fibrosis, cirrhosis, and ultimately liver failure and death. Patients with NASH have been found to have significantly higher total serum bile acid concentrations than healthy subjects at fasting and all postprandial time points (2.2–2.4-fold increase in NASH at fasting time, and 1.7–2.2-fold increase in NASH at all postprandial time points). These are driven by increases in taurine- and glycine-conjugated primary and secondary bile acids. Patients with NASH exhibited significant variability in their fasting and postprandial bile acid profiles. These results suggest that patients with NASH are more exposed to bile acids, including more hydrophobic and cytotoxic secondary species, both in a fasted and postprandial state. Increased exposure to bile acids may be involved in liver injury and the development of NAFLD and NASH (Ferslew et al., Dig Dis Sci. 2015, Vol. 60, pp. 3318-3328). Therefore, ASBT and / or LBAT inhibition are likely to be beneficial in the treatment of NASH.

[0120] NAFLD is characterized by hepatic steatosis without secondary causes of hepatic steatosis, including excessive alcohol consumption, other known liver diseases, or long-term use of steatogenic drug therapies (Chalasani et al., Hepatology 2018, Vol. 67(1), pp. 328-357). NAFLD can be classified into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). According to Chalasani et al., NAFL is defined as the presence of ≥5% hepatic steatosis with no evidence of hepatocyte damage in the form of ballooning hepatocytes. NASH is defined as the presence of ≥5% hepatic steatosis and inflammation with hepatocyte damage (e.g., ballooning hepatocytes), with or without hepatic fibrosis. NASH is generally associated with hepatic inflammation and hepatic fibrosis, which may progress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma. While liver fibrosis is not always present in NASH, if it is, the severity of the fibrosis may be associated with long-term outcomes.

[0121] Numerous methods exist for assessing and evaluating the severity of a disease, including determining whether a subject has NAFLD and, if so, distinguishing whether it is NAFL or NASH. In some embodiments, the severity of NAFLD can be assessed using NAS. In some embodiments, the treatment of NAFLD can be assessed using NAS. In some embodiments, NAS can be determined as described in Kleiner et al., Hepatology. 2005, 41(6):1313-1321 (which is incorporated herein by reference in its entirety). See, for example, Table 6 for a simplified NAS scheme from Kleiner.

[0122] [Table 6]

[0123] In some embodiments, the NAS is determined non-invasively, for example, as described in U.S. Patent Application Publication No. 2018 / 0140219 (which is incorporated herein by reference in its entirety). In some embodiments, the NAS is determined for a sample from a subject prior to administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the NAS is determined during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, a lower NAS score during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration, indicates treatment of NAFLD (e.g., NASH). For example, a decrease of 1, 2, 3, 4, 5, 6, or 7 in the NAS indicates treatment of NAFLD (e.g., NASH). In some embodiments, the NAS after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 7 or less. In some embodiments, the NAS during the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the NAS during the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 7 or less. In some embodiments, the NAS during the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the NAS after the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 7 or less. In some embodiments, the NAS after the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof is 5 or less, 4 or less, 3 or less, or 2 or less.

[0124] Further methods for evaluating or assessing NASH in a subject include determining hepatic steatosis (e.g., fat accumulation in the liver); hepatic inflammation; and determining one or more biomarkers (e.g., serum markers and panels) indicating one or more of liver damage, hepatic inflammation, hepatic fibrosis, and / or cirrhosis. Further examples of physiological indicators of NASH include liver morphology, stiffness, and size or mass of the subject's liver. In some embodiments, NASH in a subject is demonstrated by the detection of biomarkers indicating hepatic fat accumulation and liver damage. For example, elevated serum ferritin and low titers of serum autoantibodies may be common features of NASH.

[0125] In some embodiments, methods for evaluating NASH include magnetic resonance imaging (by either spectroscopy or proton density lipid measurement (MRI-PDFF)) for quantifying fatty degeneration, transient elastography (FIBROSCAN®) for diagnosing substantial hepatic fibrosis and / or cirrhosis, hepatic venous pressure gradient (HPVG), liver stiffness measurement using MRE, and evaluation of histological features of liver biopsies. In some embodiments, magnetic resonance imaging is used to detect one or more of steatohepatitis (NASH-MRI), hepatic fibrosis (Fibro-MRI), and fatty degeneration. See, for example, U.S. Patent Application Publications 2016 / 146715 and 2005 / 0215882 (each of which is incorporated herein by reference in its entirety).

[0126] In some embodiments, as a treatment for NASH, the following can be observed in subjects after administration of one or more doses of a compound of formula (I) or a pharmaceutically acceptable salt thereof: reduction of one or more symptoms associated with NASH; reduction of the amount of hepatic steatosis; reduction of NAS; reduction of hepatic inflammation; reduction of levels of biomarkers indicating one or more of hepatic impairment, inflammation, hepatic fibrosis, and / or cirrhosis; and reduction of fibrosis and / or cirrhosis, absence of further progression of fibrosis and / or cirrhosis, or delay of progression of fibrosis and / or cirrhosis.

[0127] In some embodiments, treatment of NASH involves a reduction in one or more symptoms associated with NASH in the subject. Exemplary symptoms may include one or more of the following: hepatomegaly, fatigue, right upper abdominal pain, abdominal distension, enlargement of blood vessels just below the skin surface, mammary gland enlargement in males, splenomegaly, palmar erythema, jaundice, and itching. In some embodiments, the subject is asymptomatic. In some embodiments, the subject's total weight does not increase. In some embodiments, the subject's total weight decreases. In some embodiments, the subject's body mass index (BMI) does not increase. In some embodiments, the subject's BMI decreases. In some embodiments, the subject's waist-to-hip ratio (WTH) does not increase. In some embodiments, the subject's waist-to-hip ratio (WTH) decreases.

[0128] In some embodiments, the treatment of NASH can be evaluated by measuring hepatic steatosis. In some embodiments, the treatment of NASH includes the reduction of hepatic steatosis after administration of a compound of formula (I) as described herein or a pharmaceutically acceptable salt thereof. In some embodiments, hepatic steatosis is determined by one or more methods selected from the group consisting of ultrasound, computed tomography (CT), magnetic resonance imaging, magnetic resonance spectroscopy (MRS), magnetic resonance elastography (MRE), transient elastography (TE) (e.g., FIBROSCAN®), and measurement of liver size or mass, or by liver biopsy (e.g., Di Lascio et al., Ultrasound Med Biol. 2018, Vol. 44(8), pp. 1585-1596; Lv et al., J Clin Transl Hepatol. 2018, Vol. 6(2), pp. 217-221; Reeder et al., J Magn Reson Imaging. 2011, Vol. 34(4), spcone; and de Ledinghen V et al., J Gastroenterol Hepatol. See Vol. 31(4), pp. 848–855, 2016 (each of these is incorporated herein by reference in its entirety). Subjects diagnosed with NASH may have hepatic steatosis of more than about 5%, e.g., more than about 5% to about 25%, about 25% to about 45%, about 45% to about 65%, or more than about 65%. In some embodiments, subjects with hepatic steatosis of more than about 5% to about 33% have stage 1 hepatic steatosis, subjects with hepatic steatosis of about 33% to about 66% have stage 2 hepatic steatosis, and subjects with hepatic steatosis of more than about 66% have stage 3 hepatic steatosis.

[0129] In some embodiments, the amount of hepatic steatosis is determined before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the amount of hepatic steatosis is determined during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, a reduction in the amount of hepatic steatosis during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration, indicates treatment of NASH. For example, a reduction of about 1% to about 50%, about 25% to about 75%, or about 50% to about 100% in the amount of hepatic steatosis indicates treatment of NASH. In some embodiments, a reduction of approximately 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the amount of hepatic steatosis indicates treatment of NASH.

[0130] In some embodiments, the presence of hepatic inflammation is determined by one or more methods selected from the group consisting of biomarkers indicating hepatic inflammation and liver biopsy samples from the subject. In some embodiments, the severity of hepatic inflammation is determined from liver biopsy samples from the subject. For example, hepatic inflammation in liver biopsy specimens can be assessed as described in Kleiner et al., Hepatology 2005, Vol. 41(6), pp. 1313-1321, and Brunt et al., Am J Gastroenterol 1999, Vol. 94, pp. 2467-2474 (each of these is incorporated herein by reference in whole). In some embodiments, the severity of hepatic inflammation is determined before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the severity of hepatic inflammation is determined during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, a reduction in the severity of hepatic inflammation during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, indicates treatment of NASH. For example, a reduction in the severity of hepatic inflammation of about 1% to about 50%, about 25% to about 75%, or about 50% to about 100% indicates treatment of NASH. In some embodiments, a reduction in the severity of hepatic inflammation of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment of NASH.

[0131] In some embodiments, treatment of NASH includes treatment of fibrosis and / or cirrhosis, e.g., reduction of the severity of fibrosis, prevention of further progression of fibrosis and / or cirrhosis, or delay of the progression of fibrosis and / or cirrhosis. In some embodiments, the presence of fibrosis and / or cirrhosis is determined by one or more methods selected from the group consisting of transient elastography (e.g., FIBROSCAN®), non-invasive markers of hepatic fibrosis, and histological features of liver biopsy. In some embodiments, the severity of fibrosis (e.g., stage) is determined by one or more methods selected from the group consisting of transient elastography (e.g., FIBROSCAN®), fibrosis-scoring systems, biomarkers of hepatic fibrosis (e.g., non-invasive biomarkers), and hepatic venous pressure gradient (HVPG). Non-limiting examples of fibrosis scoring systems include the NAFLD fibrosis scoring system (see, for example, Angulo et al., Hepatology 2007, Vol. 45(4), pp. 846-854), the fibrosis scoring system of Brunt et al., Am. J. Gastroenterol. 1999, Vol. 94, pp. 2467-2474, the fibrosis scoring system of Kleiner et al., Hepatology 2005, Vol. 41(6), pp. 1313-1321, and the ISHAK fibrosis scoring system (see Ishak et al., J. Hepatol. 1995, Vol. 22, pp. 696-699) (the contents of each of these are incorporated herein by reference in their entirety).

[0132] In some embodiments, the severity of fibrosis is determined before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the severity of fibrosis is determined during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, a reduction in the severity of fibrosis during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration, indicates treatment of NASH. In some embodiments, a reduction in the severity of fibrosis, absence of further progression of fibrosis and / or cirrhosis, or a delay in the progression of fibrosis and / or cirrhosis indicates treatment of NASH. In some embodiments, the severity of fibrosis is determined using a scoring system, such as one of the fibrosis scoring systems described herein, for example, the score may indicate the stage of fibrosis, e.g., stage 0 (no fibrosis), stage 1, stage 2, stage 3, and stage 4 (cirrhosis) (see, for example, Kleiner et al.). In some embodiments, a decrease in the stage of fibrosis is a decrease in the severity of fibrosis. For example, a decrease in stage 1, 2, 3, or 4 is a decrease in the severity of fibrosis. In some embodiments, a decrease in stage, for example, from stage 4 to stage 3, stage 4 to stage 2, stage 4 to stage 1, stage 4 to stage 0, stage 3 to stage 2, stage 3 to stage 1, stage 3 to stage 0, stage 2 to stage 1, stage 2 to stage 0, or stage 1 to stage 0, indicates treatment of NASH. In some embodiments, the stage of fibrosis decreases after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, from stage 4 to stage 3, stage 4 to stage 2, stage 4 to stage 1, stage 4 to stage 0, stage 3 to stage 2, stage 3 to stage 1, stage 3 to stage 0, stage 2 to stage 1, stage 2 to stage 0, or stage 1 to stage 0. In some embodiments.The stage of fibrosis decreases during the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, from stage 4 to stage 3, stage 4 to stage 2, stage 4 to stage 1, stage 4 to stage 0, stage 3 to stage 2, stage 3 to stage 1, stage 3 to stage 0, stage 2 to stage 1, stage 2 to stage 0, or stage 1 to stage 0. In some embodiments, the stage of fibrosis decreases after the administration period of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, from stage 4 to stage 3, stage 4 to stage 2, stage 4 to stage 1, stage 4 to stage 0, stage 3 to stage 2, stage 3 to stage 1, stage 3 to stage 0, stage 2 to stage 1, stage 2 to stage 0, or stage 1 to stage 0.

[0133] In some embodiments, the presence of NASH is determined by one or more biomarkers indicating one or more of liver damage, inflammation, hepatic fibrosis, and / or cirrhosis, or by a scoring system thereof. In some embodiments, the severity of NASH is determined by one or more biomarkers indicating one or more of liver damage, inflammation, hepatic fibrosis, and / or cirrhosis, or by a scoring system thereof. The level of the biomarker can be determined, for example, by measuring, quantifying, and monitoring the expression levels of the gene or mRNA encoding the biomarker and / or the peptide or protein of the biomarker.Biomarkers indicating one or more liver disorders, inflammation, hepatic fibrosis, and / or cirrhosis, and / or scoring systems thereof, as non-limiting examples include: aspartate aminotransferase (AST)-to-platelet ratio index (APRI); aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) ratio (AAR); and FIB-4 scores based on APRI, alanine aminotransferase (ALT) levels, and age of the subject (e.g., McPherson et al., Gut See Vol. 59(9), pp. 1265-1269, 2010 (this is incorporated herein in its entirety by reference); hyaluronic acid; pro-inflammatory cytokines; a panel of biomarkers consisting of α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, and γ-glutamyltranspeptidase (GGT) combined with the age and sex of subjects to generate a measure of fibrotic and necrotizing inflammatory activity in the liver (e.g., FIBROTEST®, FIBROSURE®); a panel of biomarkers consisting of bilirubin, γ-glutamyltransferase, hyaluronic acid, and α2-macroglobulin combined with the age and sex of subjects (e.g., HEPASCORE®); e.g., Adams et al., Clin. Chem. See Vol. 51(10), pp. 1867-1873, 2005; and a panel of biomarkers consisting of tissue metalloproteinase inhibitor 1, hyaluronic acid, and α2-macroglobulin (e.g., FIBROSPECT®); and a panel of biomarkers consisting of tissue metalloproteinase inhibitor 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) (e.g., Enhanced Liver Fibrosis (ELF) score, e.g., Lichtinghagen R et al., J Hepatol. August 2013; 59(2): 236-42 (which is incorporated herein by reference in its entirety)).In some embodiments, the presence of fibrosis is determined by combining a panel of biomarkers consisting of α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, and γ-glutamyltranspeptidase (GGT) (e.g., FIBROTEST®, FIBROSURE®) with the age and sex of the subject to generate a FIB-4 score, a measure of fibrosis and necrotizing inflammatory activity in the liver; or by combining a panel of biomarkers consisting of bilirubin, γ-glutamyltransferase, hyaluronic acid, and α2-macroglobulin with the age and sex of the subject (e.g., HEPASCORE®; e.g., Adams et al., Clin. Chem.). The level is determined by one or more of the following: (see Vol. 51(10), pp. 1867-1873, 2005), and a panel of biomarkers consisting of tissue metalloproteinase inhibitor 1, hyaluronic acid, and α2-macroglobulin (e.g., FIBROSPECT®); and a panel of biomarkers consisting of tissue metalloproteinase inhibitor 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) (e.g., Enhanced Liver Fibrosis (ELF) score). In some embodiments, the level of aspartate aminotransferase (AST) does not increase. In some embodiments, the level of aspartate aminotransferase (AST) decreases. In some embodiments, the level of alanine aminotransferase (ALT) does not increase. In some embodiments, the level of alanine aminotransferase (ALT) decreases. In some embodiments, the "level" of the enzyme refers to the concentration of the enzyme, e.g., the concentration in the blood. For example, the level of AST or ALT can be expressed as units / L.

[0134] In some embodiments, the severity of fibrosis is measured by a panel of biomarkers consisting of α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, and γ-glutamyltranspeptidase (GGT) combined with the age and sex of the subject to generate a FIB-4 score, a measure of fibrotic and necrotizing inflammatory activity in the liver (e.g., FIBROTEST®, FIBROSURE®), or a panel of biomarkers consisting of bilirubin, γ-glutamyltransferase, hyaluronic acid, and α2-macroglobulin combined with the age and sex of the subject (e.g., HEPASCORE®; e.g., Adams et al., Clin. Chem.). See Vol. 51(10), pp. 1867–1873, 2005 (this is incorporated herein by reference in its entirety), and a panel of biomarkers consisting of tissue metalloproteinase inhibitor 1, hyaluronic acid, and α2-macroglobulin (e.g., FIBROSPECT®); and one or more of a panel of biomarkers consisting of tissue metalloproteinase inhibitor 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP), and hyaluronic acid (HA) (e.g., Enhanced Liver Fibrosis (ELF) score).

[0135] In some embodiments, hepatic inflammation is determined by the level of hepatic inflammation biomarkers, such as the level of pro-inflammatory cytokines. Non-limiting examples of biomarkers indicating hepatic inflammation include interleukin-(IL)6, interleukin-(IL)1β, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, monocyte chemotactic protein (MCP)-1, C-reactive protein (CRP), PAI-1, and collagen isoforms, such as Col1a1, Col1a2, and Col4a1 (see, for example, Neuman et al., Can. J. Gastroenterol. Hepatol. 2014, Vol. 28(11), pp. 607-618, and U.S. Patent No. 9,872,844 (each of which is incorporated herein by reference in whole)). Hepatic inflammation can also be assessed by changes in macrophage infiltration, for example, by measuring changes in CD68 expression levels. In some embodiments, hepatic inflammation can be determined by measuring or monitoring serum or circulating levels of one or more of the following: interleukin-(IL)6, interleukin-(IL)1β, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, monocyte chemotactic protein (MCP)-1, and C-reactive protein (CRP).

[0136] In some embodiments, the levels of one or more biomarkers indicating one or more liver damage, inflammation, hepatic fibrosis, and / or cirrhosis are determined for a sample from a subject before administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the levels of one or more biomarkers indicating one or more liver damage, inflammation, hepatic fibrosis, and / or cirrhosis are determined during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, a decrease in the levels of one or more biomarkers indicating one or more liver damage, inflammation, hepatic fibrosis, and / or cirrhosis during or after administration of the compound of formula (I) or a pharmaceutically acceptable salt thereof, compared to before administration, indicates treatment of NASH. For example, a reduction of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% in the level of one or more biomarkers indicating one or more of liver damage, inflammation, liver fibrosis, and / or cirrhosis indicates treatment of NASH. In some embodiments, the reduction in the levels of one or more biomarkers indicating one or more of liver damage, inflammation, liver fibrosis, and / or cirrhosis after administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%.In some embodiments, the reduction in the levels of one or more biomarkers indicating one or more of liver damage, inflammation, liver fibrosis, and / or cirrhosis during the period of administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%. In some embodiments, the reduction in the levels of one or more biomarkers indicating one or more of liver damage, inflammation, liver fibrosis, and / or cirrhosis after a period of administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%.

[0137] In some embodiments, treatment of NASH reduces serum bile acid levels in the subject. In some embodiments, serum bile acid levels are determined, for example, by an ELISA enzyme assay or a total bile acid assay, such as that described in Danese et al., PLoS One. 2017, Vol. 12(6): e0179200 (which is incorporated herein by reference in its entirety). In some embodiments, serum bile acid levels can be reduced by, for example, 10% to 40%, 20% to 50%, 30% to 60%, 40% to 70%, 50% to 80%, or more than 90% of the serum bile acid levels prior to administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, NASH is NASH with concomitant cholestasis, in which the release of bile containing bile acids from the liver is blocked. Bile acids can cause damage to liver cells (see, for example, Perez MJ, Briz O. World J. Gastroenterol. 2009, Vol. 15(14), pp. 1677-1689), which may lead to or increase fibrosis (e.g., cirrhosis) and increase the risk of hepatocellular carcinoma (see, for example, Sorrentino P et al., Dig. Dis. Sci. 2005, Vol. 50(6), pp. 1130-1135, and Satapathy SK and Sanyal AJ. Semin. Liver Dis. 2015, Vol. 35(3), pp. 221-235 (each of these is incorporated herein by reference in its entirety)). In some embodiments, treatment of NASH includes treatment of pruritus. In some embodiments, treatment of NASH with associated cholestasis includes treatment of pruritus. In some embodiments, subjects with NASH accompanied by cholestasis also experience itching.

[0138] Table 7 shows exemplary biomarkers for NASH.

[0139] [Table 7]

[0140] References related to Table 7 1 McPherson et al., Gut. 2010, vol. 59(9), p. 1265-1269. 2 Adams, et al. Clin Chem. 2005, vol. 51(10), p. 1867-1873. 3 Lichtinghagen, et al. J Hepatol. 2013, vol. 59(2), p. 236-242. 4 Neuman, et al. Can J Gastroenterol Hepatol. 2014, vol. 28(11), p. 607-618. 5 US Patent No. 9,872,844

[0141] Some compounds of formula (I) or pharmaceutically acceptable salts thereof may exhibit a greater free fraction in plasma. In some embodiments, the free fraction is greater than about 0.2%, e.g., greater than about 0.4%, e.g., greater than about 0.6%, e.g., greater than about 0.8%, e.g., greater than about 1.0%, e.g., greater than about 1.25%, e.g., greater than about 1.5%, e.g., greater than about 1.75%, e.g., greater than about 2.0%, e.g., greater than about 2.5%, e.g., greater than about 3%, e.g., greater than about 4%, e.g., greater than about 5%, e.g., greater than about 7.5%, e.g., greater than about 10%, or e.g., greater than about 20%.

[0142] Some compounds of formula (I) or pharmaceutically acceptable salts thereof may be excreted in urine. In some embodiments, the fraction of the compound excreted in urine is greater than about 0.2%, for example greater than about 0.4%, for example greater than about 0.6%, for example greater than about 0.8%, for example greater than about 1.0%, for example greater than about 2%, for example greater than about 3%, for example greater than about 5%, for example greater than about 7.5%, for example greater than about 10%, for example greater than about 15%, for example greater than about 20%, for example greater than about 30%, or for example greater than about 50%.

[0143] After absorption from the intestines, several compounds of formula (I) or pharmaceutically acceptable salts thereof may circulate via enterohepatic circulation. In some embodiments, the fraction of the compound circulating via enterohepatic circulation is greater than about 0.1%, e.g., greater than about 0.2%, e.g., greater than about 0.3%, e.g., greater than about 0.5%, e.g., greater than about 1.0%, e.g., greater than about 1.5%, e.g., greater than about 2%, e.g., greater than about 3%, e.g., greater than about 5%, e.g., greater than about 7%, e.g., greater than about 10%, e.g., greater than about 15%, e.g., greater than about 20%, e.g., greater than about 30%, or e.g., greater than about 50%.

[0144] Several compounds of formula (I) or pharmaceutically acceptable salts thereof may cause renal excretion of bile salts. In some embodiments, the fraction of circulating bile acids excreted by the renal pathway is greater than about 1%, e.g., greater than about 2%, e.g., greater than about 5%, e.g., greater than about 7%, e.g., greater than about 10%, e.g., greater than about 15%, e.g., greater than about 20%, or e.g., greater than about 25%.

[0145] Several compounds of formula (I) or pharmaceutically acceptable salts thereof may exhibit improved or optimal permeability. Permeability can be measured in Caco2 cells, and the value is expressed in cm / s as a Papp (apparent permeability) value. In some embodiments, the permeability is at least about 0.1 × 10⁻⁶ -6 More than cm / s, for example, about 0.2 × 10⁻⁶ -6 More than cm / s, for example, about 0.4 × 10⁻⁶ -6 More than cm / s, for example, about 0.7 × 10⁻⁶ -6 More than cm / s, for example, about 1.0 × 10 -6 More than cm / s, for example, about 2 × 10⁻⁶ -6 More than cm / s, for example, about 3 × 10⁻⁶ -6 More than cm / s, for example, about 5 × 10⁻⁶ -6 More than cm / s, for example, about 7 × 10⁻⁶ -6 More than cm / s, for example, about 10 × 10 -6 More than cm / s, for example, about 15 × 10⁻⁶ -6 It is over cm / s.

[0146] Several compounds of formula (I) or pharmaceutically acceptable salts thereof may exhibit improved or optimal bioavailability. In some embodiments, the oral bioavailability is greater than about 5%, e.g., greater than about 7%, e.g., greater than about 10%, e.g., greater than about 15%, e.g., greater than about 20%, e.g., greater than about 30%, e.g., greater than about 40%, e.g., greater than about 50%, e.g., greater than about 60%, e.g., greater than about 70%, or e.g., greater than about 80%. In other embodiments, the oral bioavailability is between about 10% and about 90%, e.g., between about 20% and about 80%, e.g., between about 30% and about 70%, or e.g., between about 40% and about 60%.

[0147] Several compounds of formula (I) or pharmaceutically acceptable salts thereof may serve as substrates for the associated transporters in the kidney.

[0148] Several compounds of formula (I) or pharmaceutically acceptable salts thereof may produce concentrations of bile acids in the intestines, liver, and serum that do not cause adverse gastrointestinal effects.

[0149] Several compounds of formula (I) or pharmaceutically acceptable salts thereof can reduce the concentration of bile acids in the liver without causing gastrointestinal disorders such as diarrhea.

[0150] As used herein, the terms “treatment,” “to treat,” and “to treat” mean the reduction, alleviation, delay of onset, or inhibition of progression of a disease or disorder, or one or more of its symptoms, as described herein. In some embodiments, treatment may be administered after the onset of one or more symptoms. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual before the onset of symptoms (e.g., taking into account a medical history of the symptoms and / or genetic or other susceptibility factors). Treatment may be continued after the symptoms have resolved, for example, to prevent or delay their recurrence.

[0151] Suitable pharmaceutically acceptable salts of the compounds of the present invention include, for example, salts with base addition salts of the compounds of the present invention that are sufficiently acidic, such as alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), ammonium salts, or salts with organic bases that yield physiologically acceptable cations, such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine, or tris-(2-hydroxyethyl)amine.

[0152] Some compounds of formula (I) or pharmaceutically acceptable salts thereof may have chiral centers and / or geometric isomers (E- and Z-isomers). It should be understood that the present invention encompasses all such optical isomers, diastereoisomers, and geometric isomers that possess ASBT and / or LBAT inhibitory activity. The present invention also encompasses all tautomers of compounds of formula (I) or pharmaceutically acceptable salts thereof that possess ASBT and / or LBAT inhibitory activity. Certain compounds of formula (I) or pharmaceutically acceptable salts thereof may exist not only in non-solvated forms but also in solvated forms, such as hydrated forms. It should be understood that the present invention encompasses all such solvated forms that possess ASBT and / or LBAT inhibitory activity.

[0153] In another aspect, the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. Examples of excipients include fillers, binders, disintegrants, flow promoters, and lubricants. Generally, pharmaceutical compositions can be prepared in conventional ways using conventional excipients.

[0154] Suitable fillers include, but are not limited to, dicalcium phosphate dihydrate, calcium sulfate, lactose (such as lactose monohydrate), sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, dry starch, hydrolyzed starch, and pregelatinized starch.

[0155] Examples of suitable binders include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (sucrose, glucose, dextrose, lactose, and sorbitol, etc.), polyethylene glycol, waxes, natural and synthetic rubbers (acalycium gum and tragacanth gum, etc.), sodium alginate, cellulose derivatives (hydroxypropyl methylcellulose (or hypromellose), hydroxypropylcellulose, and ethylcellulose, etc.), and synthetic polymers (acrylic acid-methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid / polymethacrylic acid copolymers, and polyvinylpyrrolidone (povidone), etc.).

[0156] Examples of suitable disintegrants include, but are not limited to, dried starch, modified starch (partially pregelatinized starch, sodium starch glycolate, and sodium carboxymethyl starch, etc.), alginic acid, cellulose derivatives (sodium carboxymethylcellulose, hydroxypropylcellulose, and low-substituted hydroxypropylcellulose (L-HPC), etc.), and crosslinked polymers (carmellose, croscarmellose sodium, carmellose calcium, and crosslinked PVP (crospovidone), etc.).

[0157] Examples of suitable flow promoters and lubricants include, but are not limited to, talc, magnesium stearate, calcium stearate, stearic acid, glyceryl behenate, colloidal silica, aqueous silicon dioxide, synthetic magnesium silicate, finely atomized silicon dioxide, starch, sodium lauryl sulfate, boric acid, magnesium oxide, waxes (such as carnauba wax), hydrogenated oils, polyethylene glycol, sodium benzoate, polyethylene glycol, and mineral oils.

[0158] The pharmaceutical composition may conventionally be coated with one or more coating layers. Enteric coating layers of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or coating layers for delayed release or targeted release, are also intended. The coating layers may contain one or more coating agents and may optionally contain plasticizers and / or pigments (or colorants).

[0159] Examples of suitable coating agents include, but are not limited to, cellulosic polymers (ethylcellulose, hydroxypropyl methylcellulose (or hypromellose), hydroxypropylcellulose, cellulose phthalate acetate, cellulose succinate acetate, hydroxypropyl methylcellulose succinate acetate, and hydroxypropyl methylcellulose phthalate, etc.), vinyl polymers (polyvinyl alcohol, etc.), and polymers based on acrylic acid and its derivatives (polymers of acrylic acid and methacrylic acid, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid / polymethacrylic acid copolymers, etc.).

[0160] Suitable plasticizers include, but are not limited to, triethyl citrate, glyceryl triacetate, tributyl citrate, diethyl phthalate, tributyl acetyl citrate, dibutyl phthalate, dibutyl sebacate, and polyethylene glycol.

[0161] Suitable pigments include, but are not limited to, titanium dioxide, iron oxides (such as yellow, brown, red, or black iron oxides), and barium sulfate.

[0162] The pharmaceutical composition may be in a form suitable for oral administration, injection (including intravenous, subcutaneous, intramuscular, and intravascular injection), or local administration for rectal administration. In a preferred embodiment, the pharmaceutical composition is in a form suitable for oral administration, such as a tablet or capsule.

[0163] The dosage required for therapeutic or prophylactic treatment will depend on the route of administration, the severity of the disease, the patient's age and weight, and other factors that are typically considered by the attending physician when determining the appropriate regimen and dosage level for a particular patient.

[0164] The amount of compound to be administered will vary depending on the patient being treated, and may range from approximately 1 μg / kg body weight to approximately 50 mg / kg body weight per day. A unit dosage form, such as a tablet or capsule, will typically contain approximately 1 to approximately 250 mg of the active ingredient, for example, approximately 1 to approximately 100 mg, or for example, approximately 1 to approximately 50 mg, or for example, approximately 1 to approximately 20 mg, for example, approximately 2.5 mg, or approximately 5 mg, or approximately 10 mg, or approximately 15 mg of the active ingredient. The daily dose can be administered as a single dose or divided into one, two, three, or more unit doses. The daily dose of orally administered bile acid modulator is preferably within approximately 0.1 to approximately 250 mg, more preferably within approximately 1 to approximately 100 mg, for example, within approximately 1 to approximately 5 mg, for example, within approximately 1 to approximately 10 mg, for example, within approximately 1 to approximately 15 mg, or for example, within approximately 1 to approximately 20 mg.

[0165] In another aspect, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as a pharmaceutical. The present invention also relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as a pharmaceutical.

[0166] In another aspect, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of any of the diseases described herein. The present invention also relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prevention of any of the diseases described herein. The present invention also relates to a method for treating or preventing any of the diseases described herein in a subject such as a human, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need of such treatment or prevention.

[0167] Combination therapy In one aspect of the present invention, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with at least one other therapeutically active agent, for example, one, two, three, or more other therapeutically active agents. The compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one other therapeutically active agent may be administered simultaneously, sequentially, or separately. Suitable therapeutically active agents for combination with the compound of formula (I) include, but are not limited to, known active agents useful for treating any of the above-mentioned conditions, disorders, and diseases.

[0168] In one embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with another ASBT inhibitor. Suitable ASBT inhibitors include WO 93 / 16055, WO 94 / 18183, WO 94 / 18184, WO 96 / 05188, WO 96 / 08484, WO 96 / 16051, WO 97 / 33882, WO 98 / 03818, WO 98 / 07449, WO 98 / 40375, WO 99 / 35135, WO 99 / 64409, WO 99 / 64410, WO 00 / 47568, WO 00 / 61568, WO 00 / 38725, WO 00 / 38726, WO 00 / 38727, WO 00 / 38728, WO 00 / 38729, WO 01 / 66533, WO 01 / 68096, WO 02 / 32428, WO 02 / 50051, WO 03 / 020710, WO 03 / 022286, WO 03 / 022825, WO 03 / 022830, WO 03 / 061663, WO 03 / 091232, WO 03 / 106482, WO 2004 / 006899, WO 2004 / 076430, WO 2007 / 009655, WO 2007 / 009656, WO 2011 / 137135, WO 2019 / 234077, WO 2020 / 161216, WO 2020 / 161217, WO 2021 / 110883, WO 2021 / 110884, WO 2021 / 110885, WO 2021 / 110886, WO 2021 / 110887, WO 2022 / 029101, DE 19825804, EP 864582, EP 489423, EP 549967, EP 573848, EP 624593, EP 624594, EP 624595, EP 624596, EP 0864582, EP 1173205, EP 1535913, and EP All of these are disclosed in 3210977 (all of which are incorporated herein by reference in their entirety).Specific examples of suitable ASBT inhibitors include 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine (elobixibat) and 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odebixibat).

[0169] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a bile acid binder (also called a bile acid scavenger or resin), such as choleceveram, cholestyramine, or colestipol. In a preferred embodiment of such a combination, the bile acid binder is formulated for colonic release. Examples of such formulations are disclosed, for example, in WO 2017 / 138877, WO 2017 / 138878, WO 2019 / 032026, and WO 2019 / 032027 (all of which are incorporated herein by reference in their entirety).

[0170] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a DPP-IV inhibitor, such as gliptin, such as sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, omaligliptin, evogliptin, gosogliptin, and dutogliptin, or a pharmaceutically acceptable salt thereof.

[0171] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an HMG CoA reductase inhibitor, such as fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, pitavastatin, cerivastatin, mevastatin, rosuvastatin, beruvastatin, or dalvastatin, or a pharmaceutically acceptable salt thereof.

[0172] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a cholesterol absorption inhibitor, such as ezetimibe or a pharmaceutically acceptable salt thereof.

[0173] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a PPARα agonist, such as a fibrate, such as clofibrate, bezafibrate, cyprofibrate, clinofibrate, clofibride, fenofibrate, gemfibrozil, ronifibrate, and simfribrate, or a pharmaceutically acceptable salt thereof.

[0174] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a PPARγ agonist, for example, thiazolidinediones, for example, pioglitazone, rosiglitazone, and robeglitazone, or a pharmaceutically acceptable salt thereof.

[0175] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a dual PPARα / γ agonist, such as glitazar, such as saroglitazal, alleglitazal, mulaglitazal, or tesaglitazal, or a pharmaceutically acceptable salt thereof.

[0176] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a dual PPARα / δ agonist, such as ellafibranol.

[0177] In yet another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a pan-PPAR agonist (i.e., a PPAR agonist having activity across all subtypes: α, γ, and δ), such as IVA337.

[0178] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a farnesoid X receptor (FXR) modulator, e.g., an FXR agonist, e.g., cafestol, chenodeoxycholic acid, 6α-ethylchenodeoxycholic acid (oveticholic acid; INT-747), fexalamine, tropifexol, cilofexor, and MET409.

[0179] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a TGR5 receptor modulator, e.g., a TGR5 agonist, e.g., 6α-ethyl-23(S)-methylcholic acid (INT-777).

[0180] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a dual FXR / TGR5 agonist, such as INT-767.

[0181] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with ursodeoxycholic acid (UDCA). In yet another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with norursodeoxycholic acid (norUDCA).

[0182] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an FGF19 modulator, such as NGM282.

[0183] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an FGF21 agonist, such as BMS-986036.

[0184] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an integrin inhibitor, such as PLN-74809 and PLN-1474.

[0185] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a CCR2 / CCR5 inhibitor, such as senicliviroc.

[0186] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a caspase protease inhibitor, such as emricasan.

[0187] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a galectin-3 inhibitor, such as GR-MD-02.

[0188] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a stearoyl-CoA unsaturated enzyme (SCD) inhibitor, such as alamcol (arachidylamidecoranic acid).

[0189] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an apoptosis signal-regulated kinase 1 (ASK1) inhibitor, such as ceroncertib.

[0190] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a LOXL2 inhibitor, such as simtuzumab.

[0191] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an ACC inhibitor, such as GS-0976.

[0192] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a thyroid hormone receptor β-agonist, such as MGL3196.

[0193] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a GLP-1 agonist, such as liraglutide.

[0194] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a glucagon-like peptide and a glucagon receptor dual agonist, such as SAR425899.

[0195] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a mitochondrial pyruvate transporter inhibitor, such as MSDC-0602K.

[0196] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an antioxidant, such as vitamin E.

[0197] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an SGLT1 inhibitor, an SGLT2 inhibitor, or a dual inhibitor of SGLT1 and SGLT2. Examples of such compounds include dapagliflozin, sotagliflozin, canagliflozin, empagliflozin, LIK066, and SGL5213.

[0198] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor, such as DGAT2RX and PF-06865571.

[0199] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a fatty acid synthase (FASN) inhibitor, such as TVB-2640.

[0200] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an AMP-activated protein kinase (AMPK) activator, such as PXL-770.

[0201] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a glucocorticoid receptor antagonist (GR), a mineralocorticoid receptor antagonist (MR), or a dual GR / MR antagonist. Examples of such compounds are MT-3995 and CORT-118335.

[0202] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a cannabinoid receptor 1 (CB1) antagonist, such as IM102.

[0203] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with Klotho-β (KLB) and a fibroblast growth factor receptor (FGFR) activator, such as MK-3655 (formerly known as NGM-313).

[0204] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a chemokine (cc motif) ligand 24 (CCL24) inhibitor, such as CM101.

[0205] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an A3 antagonist, such as PBF-1650.

[0206] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a P2x7 receptor antagonist, such as SGM 1019.

[0207] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a P2Y13 receptor agonist, such as CER-209.

[0208] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a sulfated oxysterol, such as Dur-928.

[0209] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a leukotriene D4 (LTD4) receptor antagonist, such as MN-001.

[0210] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a type 1 natural killer T cell (NKT1) inhibitor, such as GRI-0621.

[0211] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an anti-lipopolysaccharide (LPS) compound, such as IMM-124E.

[0212] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a VAP1 inhibitor, such as BI1467335.

[0213] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an A3 adenosine receptor agonist, such as CF-102.

[0214] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a SIRT-1 activator, such as NS-20.

[0215] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a nicotinic acid receptor 1 agonist, such as ARI-3037MO.

[0216] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a TLR4 antagonist, such as JKB-121.

[0217] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a ketohexokinase inhibitor, such as PF-06835919.

[0218] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an adiponectin receptor agonist, such as ADP-335.

[0219] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with an autotaxin inhibitor, such as PAT-505 and PF8380.

[0220] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a chemokine (cc motif) receptor 3 (CCR3) antagonist, such as vertilimumab.

[0221] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a chloride ion channel stimulant, such as cobiprostone and lubiprostone.

[0222] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a heat shock protein 47 (HSP47) inhibitor, such as ND-L02-s0201.

[0223] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with sterol regulatory region-binding protein (SREBP) transcription factor inhibitors, such as CAT-2003 and MDV-4463.

[0224] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a biguanidine, such as metformin.

[0225] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with insulin.

[0226] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a glycogen phosphorylase inhibitor and / or a glucose-6-phosphatase inhibitor.

[0227] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a sulfonylurea, such as glipizide, glibenclamide, and glimepiride.

[0228] In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with meglitinides, such as repaglinide, nateglinide, and ormiglitinide.

[0229] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a glucosidase inhibitor, such as acarbose or miglitol.

[0230] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a squalene synthase inhibitor, such as TAK-475.

[0231] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with a PTPB1 inhibitor, such as trozusquemin, ertiprotafib, JTT-551, and claramine.

[0232] Preparation of compounds The compounds of the present invention can be prepared as free acids or pharmaceutically acceptable salts thereof by the processes described below. Throughout the following description of such processes, it will be understood that, where appropriate, suitable protecting groups will be added and subsequently removed from various reactants and intermediates in a manner readily understood by those skilled in the art of organic synthesis. Conventional procedures for using such protecting groups, and examples of suitable protecting groups, are described, for example, in Greene's Protective Groups in Organic Synthesis, 4th edition, by PGM Wutz and TW Greene, John Wiley & Sons, Hoboken, 2006.

[0233] General method All solvents used were analytical grade. Commercially available anhydrous solvents were conventionally used in the reactions. Starting materials were either available from commercial suppliers or prepared according to literature procedures. 3-Butyl-8-hydroxy-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide and 3-ethyl-8-hydroxy-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide can be prepared as described in WO 2021 / 110883 (intermediates 7 and 18, respectively). Room temperature refers to 20–25°C. The composition of the solvent mixture is given as a volume percentage or volume ratio.

[0234] LCMS: Instrument name: Agilent 1290 infinity II. Method A: Mobile phase: A: 0.1% HCOOH:ACN (95:5) in water, B: ACN; flow rate: 1.5 mL / min; column: ZORBAX XDB C-18 (50 x 4.6 mm), 3.5 μm. Method B: Mobile phase: A: 10 mM NH4HCO3 in water, B: ACN; Flow rate: 1.2 mL / min; Column: XBridge C8 (50 × 4.6 mm), 3.5 μm. Method C: Mobile phase: A: 0.1% HCOOH in water: ACN (95:5), B: ACN; Flow rate: 1.5 mL / min; Color: ATLANTIS dC18 (50 × 4.6 mm), 5 μm. Method D: Mobile phase: A: 10 mM NH4OAc in water, B: ACN; Flow rate: 1.2 mL / min; Color: Zorbax Extend C18 (50 × 4.6 mm), 5 μm. Method E: Mobile phase: A: 0.1% TFA in water: ACN (95:5), B: 0.1% TFA in ACN; Flow rate: 1.5 mL / min; Color: XBridge C8 (50 × 4.6 mm), 3.5 μm. Method F: Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 0.8 mL / min; Color: ZORBAX ECLIPSE PLUS C18 (50×2.1 mm), 1.8 μm. Method G: Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 0.8 mL / min; Color: Acquity UPLC BEH C18 (2.1 × 50 mm), 1.7 μm. Method H: Mobile phase: A: 10 mM NH4OAc, B: 100% ACN; Flow rate: 0.8 mL / min; Color: Acquity UPLC BEH C18 (2.1 × 50) mm; 1.7 μm. Method I: Mobile phase: A: 0.1% HCOOH in water: ACN (95:5), B: ACN; Flow rate: 0.8 mL / min; Color: ZORBAX ECLIPSE PLUS C18 (2.1×50) mm, 1.8 μm. Method J: Mobile phase: A: 0.1% TFA in water, B: ACN; Flow rate: 1.0 mL / min; Color: Zorbax Extend C18 (50×4.6 mm), 5 μM. Method K: Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 1.5 mL / min; Color: XBridge C8 (50 × 4.6 mm), 3.5 μM.

[0235] UPLC: Machine Name: Waters Acquity I Class Method A: Mobile phase: A: 0.1% HCOOH in water, B: 0.1% HCOOH in ACN; flow rate: 0.8 mL / min; column: Acquity UPLC HSS T3 (2.1 × 50) mm; 1.8 μm. Device name: Shimadzu Nexera X2 LC / 2020 MSD Method B: Mobile phase: A: 0.1% HCOOH in water, B: ACN; flow rate: 0.8 mL / min; column: Acquity UPLC BEH C18 (2.1 × 50) mm; 1.7 μm.

[0236] HPLC: Instrument name: Agilent 1260 Infinity II series instrument (use the percentage in UV detection (max plot) as follows). Method A: Mobile phase: A: 10 mM NH4HCO3 in water, B: ACN; Flow rate: 1.0 mL / min; Column: XBridge C8 (50 × 4.6 mm, 3.5 μm). Method B: Mobile phase: A: 0.1% TFA in water, B: 0.1% TFA in ACN; Flow rate: 2.0 mL / min; Column: XBridge C8 (50 × 4.6 mm, 3.5 μm). Method C: Mobile phase: A: MilliQ 10mM NH4OAc in water, B: ACN; Flow rate: 1.0 ml / min; Column: Phenomenex Gemini C18 (150 × 4.6 mm, 3.0 μm). Method D: Mobile phase: A: 0.1% TFA in water, B: ACN; Flow rate: 1.0 mL / min; Column: ATLANTIS dC18 (250 × 4.6 mm, 5.0 μm). Method E: Mobile phase: A: 0.1% TFA in water; B: ACN, flow rate: 2.0 mL / min; Column: X-Bridge C8 (50 × 4.6 mm, 3.5 μm).

[0237] Chiral SFC: Equipment name: PIC SFC 10 (for analysis) The ratio of CO2 to the cosolvent is within the range of 60:40 to 80:20. Method A: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: YMC Amylose-SA (250 × 4.6 mm, 5 μm). Method B: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: Chiralpak AD-H (250 × 4.6 mm, 5 μm). Method C: Mobile phase: 20 mM ammonia in methanol; flow rate: 3 mL / min; column: YMC Cellulose-SC (250 × 4.6 mm, 5 μm). Method D: Mobile phase: methanol; flow rate: 3 mL / min; column: Lux A1 (250 × 4.6 mm, 5 μm). Method E: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 5 mL / min; column: Lux C4. Method F: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 3 mL / min; column: YMC Cellulose-SC. Method G: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 3 mL / min; column: Lux A1. Method H: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: Lux A1 (250 × 4.6 mm, 5 μm). Method I: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 3 mL / min; column: Chiral CCS (250 × 4.6 mm, 5 μm). Method J: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 5 mL / min; column: YMC Cellulose-SC AD-H (250 × 4.6 mm, 5 μm). Method K: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 4 mL / min; column: (R,R)-Whelk-01 (250 × 4.6 mm, 5 μm). Method L: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: Chiralcel OX-H (250 × 4.6 mm, 5 μm). Method M: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 5 mL / min; column: YMC Cellulose-SC (250 × 4.6 mm, 5 μm). Method N: Mobile phase: methanol, flow rate: 5 mL / min; column: Chiralcel OX-H (250 × 4.6 mm, 5 μm). Method O: Mobile phase: 0.1% isopropylamine in IPA:methanol (1:1), flow rate: 3 mL / min; Column: Chiralpak AS-H (250 × 4.6 mm, 5 μm). Method P: Mobile phase: 0.5% isopropylamine in methanol, flow rate: 3 mL / min; Column: Chiralpak AS-H (250 × 4.6 mm, 5 μm). Method Q: Mobile phase: IPA, flow rate: 3 mL / min; Column: Lux A1 (250 x 4.6 mm, 5 μm). Method R: Mobile phase: 0.1% isopropylamine in IPA:methanol (1:1), flow rate: 3 mL / min; Column: Lux A1 (250 × 4.6 mm, 5 μm). Method S: Mobile phase: 0.5% isopropylamine in methanol, flow rate: 3 mL / min; Column: Chiralpak OX-H (250 × 4.6 mm, 5 μm). Method T: Mobile phase: 0.5% isopropylamine in IPA, flow rate: 4 mL / min; Column: YMC Cellulose-SB (250 × 4.6 mm, 5 μm). Method U: Mobile phase: 0.5% isopropylamine in IPA, flow rate: 3 mL / min; Column: Chiralpak AS-H (250 × 4.6 mm, 5 μm).

[0238] Preparative HPLC: Instrument name: Agilent 1290 Infinity II Method A: Mobile phase: A: 0.1% TFA in water; mobile phase; B: 0.1% TFA in ACN; flow rate: 2.0 mL / min; column: X-Bridge C8 (50 × 4.6 mm, 3.5 μM). Method B: Mobile phase: A: 10mM NH4OAc in water; B: ACN; flow rate: 35mL / min; column: X select C18 (30 x 150mm, 5μm). Method C: Mobile phase: A: 10 mM NH4HCO3 in water; B: ACN; Flow rate: 1.0 mL / min; Column: XBridge C8 (50 × 4.6 mm, 3.5 μm). Method D: Mobile phase: A: 0.1% HCOOH in water; B: ACN; flow rate: 1.0 mL / min; column: X-select C18 (30 × 150 mm, 5 μm).

[0239] Chiral Partition SFC: Device names: PIC SFC 100 and PSC SFC 400 The ratio of CO2 to the cosolvent is within the range of 60:40 to 80:20. Method A: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: YMC Amylose-SA (250 × 30 mm, 5 μm). Method B: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: Chiralpak AD-H (250 × 30 mm, 5 μm). Method C: Mobile phase: 20 mM ammonia in methanol; flow rate: 3 mL / min; column: YMC Cellulose-SC (250 × 30 mm, 5 μm). Method D: Mobile phase: methanol; flow rate: 3 mL / min; column: Chiral CCS (250 × 30 mm, 5 μm). Method E: Mobile phase: methanol; flow rate: 3 mL / min; column: Lux A1 (250 × 30 mm, 5 μm). Method F: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: Lux A1 (250 × 30 mm, 5 μm). Method G: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 3 mL / min; column: Chiral CCS (250 × 30 mm, 5 μm). Method H: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 4 mL / min; column: (R,R)-Whelk-01 (250 × 30 mm, 5 μm). Method I: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 5 mL / min; column: YMC Cellulose-SC (250 × 30 mm, 5 μm). Method J: Mobile phase: 0.5% isopropylamine in IPA; flow rate: 3 mL / min; column: Chiralcel OX-H (250 × 30 mm, 5 μm). Method K: Mobile phase: 0.5% isopropylamine in methanol; flow rate: 5 mL / min; column: YMC Cellulose-SC (250 × 30 mm, 5 μm). Method L: Mobile phase: methanol; Flow rate: 5 mL / min; Column: Chiralcel OX-H (250 × 30 mm, 5 μm).

[0240] Abbreviation ACN Acetonitrile BOC tert-butoxycarbonyl DBAD azodicarboxylate di-tert-butyl DCM Dichloromethane DMF Dimethylformamide HPLC (High-Performance Liquid Chromatography) IPA Isopropyl Alcohol LCMS (Liquid Chromatography Mass Spectrometry) NMP N-methyl-2-pyrrolidone PE (Petroleum Ether) SFC Supercritical Fluid Chromatography TFA (Trifluoroacetic Acid) THF (Tetrahydrofuran) TLC (Thin-Layer Chromatography) UPLC Ultra-High-Speed ​​Liquid Chromatography

[0241] The present invention will now be described by the following embodiments, but these are not intended to limit the invention in any way. All cited and referenced documents are incorporated by reference. [Examples]

[0242] Intermediate 1 2-((tert-butoxycarbonyl)amino)hexanoic acid

[0243] [ka]

[0244] To a solution of 2-aminohexanoic acid (25 g, 0.19 mol) in water (250 mL) and THF (250 mL), NaHCO3 (48 g, 0.57 mol) and anhydrous Boc (52.2 mL, 0.23 mol) were added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was cooled, quenched, and acidified with 1.5 N HCl. The reaction mixture was extracted with ¼ (2 × 150 mL). The combined organic layer was washed with ice-cold water (150 mL) and brine (150 mL), dried over anhydrous Na₂SO₄, and concentrated to obtain the title compound. Yield: 45.5 g (crude, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 5.10-4.98 (m, 1H), 4.33-4.30 (m, 1H), 1.95-1.81 (m, 1H), 1.75-1.55 (m, 1H), 1.46 (s, 10H), 1.45-1.31 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H). LCMS: (Method E) 132.2 (M + -Boc+H), Rt. 2.36 minutes, 99.98% (max).

[0245] Intermediate 2 tert-butyl(1-oxo-1-(phenylamino)hexane-2-yl)carbamate

[0246] [ka]

[0247] To a stirred solution of 2-((tert-butoxycarbonyl)amino)hexanoic acid (intermediate 1; 45.5 g, 0.196 mol) in DMF (150 mL), triethylamine (54.83 mL, 0.39 mol) was added, and the reaction mixture was cooled to 0°C. A solution of 1-propanephosphonic anhydride (50% in HCl; 75.1 g, 0.23 mol) and aniline (18 g, 0.196 mol) were added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with ice-cold water (50 mL) and diluted with HCl (200 mL). The aqueous layer was washed with ice-cold water (200 mL) and brine (200 mL), then dried over anhydrous Na₂SO₄ and filtered. The organic portion was concentrated under vacuum to obtain the title compound. Yield: 82% (49.7 g, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H), 7.60 (d, J = 7.6 Hz, 2H), 7.30 (t, J = 8.0 Hz, 2H), 7.06-6.99 (m, 2H), 4.07-4.02 (m, 1H), 1.63-1.56 (m, 2H), 1.46-1.28 (m, 13H), 0.86 (t, J = 6.8 Hz, 3H). LCMS: (Method E) 207.0 (M + -Boc+H), Rt. 2.69 minutes, 91.20% (max).

[0248] Intermediate 3 2-amino-N-phenylhexaneamide

[0249] [ka]

[0250] To a solution of tert-butyl(1-oxo-1-(phenylamino)hexane-2-yl)carbamate (intermediate 2; 49.7 g, 0.162 mol) in 1,4-dioxane (500 mL) at 0°C, a solution of HCl in 1,4-dioxane (4 M, 199 mL) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was concentrated under vacuum, and the resulting residue was quenched with saturated NaHCO3 solution. The aqueous layer was extracted with SiO2 (2 × 200 mL). The combined organic layers were washed with brine (200 mL) and dried over anhydrous Na2SO4. The organic portion was filtered, and concentrated under vacuum to obtain the title compound. Yield: 95% (32 g, colorless gum). 1 H NMR (400 MHz, DMSO-d6): δ 10.20-9.66 (m, 1H), 7.64 (dd, J = 4.8, 2.4 Hz, 2H), 7.32-7.27 (m, 2H), 7.06-7.02 (m, 1H), 3.29-3.26 (m, 1H), 1.67-1.61 (m, 1H), 1.46-1.27 (m, 5H), 0.89-0.85 (m, 3H). LCMS: (Method B) 207.2 (M + +H), Rt. 2.03 minutes, 84.36% (max).

[0251] Intermediate 4 N1-Phenylhexane-1,2-diamine

[0252] [ka]

[0253] To a solution of 2-amino-N-phenylhexaneamide (intermediate 3; 32 g, 0.15 mol) in 320 mL of THF at 0°C, boranedimethyl sulfide (2 M solution in THF, 117 mL, 0.23 mol) was added, and the reaction mixture was heated at 75°C for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was cooled to 0°C, quenched with methanol (150 mL), and then heated at 60°C for 2 hours. The reaction mixture was cooled to room temperature and concentrated under vacuum. The resulting residue was partitioned between water (50 mL) and ethyl acetate (50 mL). The aqueous layer was extracted with ethyl acetate (2 × 250 mL). The combined organic layers were washed with water (250 mL) and brine (250 mL). The organic portion was dried over anhydrous sodium 2SO4, filtered, and concentrated under vacuum. The obtained crude substance was purified by Isolera column chromatography (eluent: 10% SiO2 / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 93% (28 g, yellow oily substance). LCMS: (Method B) 193.3(M + +H), Rt.1.98 min, 76.9% (max).

[0254] Intermediate 5 2,4-Dibromo-5-methoxy-N-(1-(phenylamino)hexane-2-yl)benzenesulfonamide

[0255] [ka]

[0256] To a solution of 2,4-dibromo-5-methoxybenzenesulfonyl chloride (3.2 g, 8.79 mmol) in 50 mL of THF at 0°C, N1-phenylhexane-1,2-diamine (intermediate 4; 1.3 g, 6.76 mmol) and triethylamine (2.8 mL, 20.3 mmol) were added, and the reaction mixture was stirred at room temperature for 4 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was concentrated under vacuum, and the resulting residue was dissolved in HCl (60 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 18% HCl / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 97% (3.5 g, brown gum-like substance). LCMS: (Method E) 521.0 (M + +H), Rt.3.14 minutes, 93.57% (maximum).

[0257] Intermediate 6 7-Bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0258] [ka]

[0259] To a solution of 2,4-dibromo-5-methoxy-N-(1-(phenylamino)hexane-2-yl)benzenesulfonamide (intermediate 5; 3.5 g, 6.72 mmol) in DMF (30 mL), K2CO3 (1.73 g, 12.5 mmol) and copper powder (0.42 g, 6.72 mmol) were added. The reaction mixture was degassed under an N2 atmosphere for 5 minutes, and then heated at 115°C for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice-cold water (25 mL), and the aqueous layer was extracted with a 1:1 mixture of siRNA and PE (2 × 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 25% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 51% (1.5 g, brown gum). LCMS: (Method A) 439.0(M + +H), Rt.2.83 min, 82.06% (max).

[0260] Intermediate 7 7-Bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0261] [ka]

[0262] To a stirred solution of 7-bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 6; 4.5 g, 10.24 mmol) in N-methyl-2-pyrrolidone (20 mL), Cs2CO3 (6.7 g, 20.5 mmol) was added, followed by iodomethane (3.2 mL, 51.2 mmol). The reaction mixture was stirred at room temperature for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was quenched with water (25 mL), and the aqueous layer was extracted with a mixture of siRNA and PE (30%, 2 × 75 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The resulting crude product was sent directly to the next step without further purification. Yield: 4.5 g (crude, light brown solid). LCMS: (Method E) 452.8(M + +H), Rt.3.19 minutes, 95.26% (maximum).

[0263] Intermediate 8 3-Butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0264] [ka]

[0265] To a solution of 7-bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 7; 4.5 g, 9.92 mmol) in DMF (50 mL), sodium thiomethoxide (3.5 g, 49.6 mmol) was added, and the reaction mixture was heated at 80 °C for 16 hours. After the reaction (monitored by ULC) was complete, the reaction mixture was quenched with ice-cold water (25 mL), and the aqueous layer was extracted with ethyl acetate (4 × 50 mL). The combined organic layers were washed with water (2 × 100 mL) and brine (100 mL) and dried over anhydrous sodium 2SO4. The organic portion was concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 26% ethyl acetate PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 77% (3.1g, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 10.73 (s, 1H), 7.29 (s, 1H), 7.12-7.16 (m, 2H), 6.99 (s, 1H), 6.67 (t, J = 7.2 Hz, 1H), 6.54 (d, J = 8.0 Hz, 2H), 4.06-3.89 (m, 2H), 3.21-3.09 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.68-1.55 (m, 1H), 1.54-1.42 (m, 1H), 1.41-1.25 (m, 4H), 0.93-0.90 (m, 3H).LCMS: (Method A) 406.9 (M + +H), Rt. 2.65 minutes, 92.05% (max.).

[0266] Intermediate 9 (S)-3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide and (R)-3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0267] [ka]

[0268] Two enantiomers of racemic 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 8; 10.0 g, 24.59 mmol) were separated using an SFC instrument (Method E). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponds to enantiomer 1, and the second eluted fraction corresponds to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 42% (4.3g, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 10.69 (s, 1H), 7.28 (s, 1H), 7.13 (t, J = 10.8 Hz, 2H), 6.99 (s, 1H), 6.66 (t, J = 9.6 Hz, 1H), 6.53 (d, J = 10.8 Hz, 2H), 4.00-3.89 (m, 2H), 3.19-3.14 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.68-1.55 (m, 1H), 1.55-1.45 (m, 1H), 1.40-1.25 (m, 4H), 0.95-0.85 (m, 3H). LCMS: (Method A) 407.1 (M + +H), Rt. 2.56 min, 98.41% (maximum). HPLC: (Method E) Rt. 5.43 min, 98.58% (maximum). Chiral SFC: (Method D) Rt. 1.83 min, 100% (maximum). Enantiomer 2: Yield: 34% (4.2g, off-white solid). 1H NMR (400 MHz, DMSO-d6): δ 10.58 (s, 1H), 7.27 (s, 1H), 7.13 (t, J = 10.0 Hz, 2H), 6.98 (s, 1H), 6.66 (t, J = 10.0 Hz, 1H), 6.53 (d, J = 10.8 Hz, 2H), 4.10-3.80 (m, 2H), 3.25-3.05 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.68-1.45 (m, 2H), 1.45-1.25 (m, 4H), 0.98-0.85 (m, 3H). LCMS: (Method A) 407.2 (M + +H), Rt. 2.56 min, 98.25% (maximum). HPLC: (Method E) Rt. 5.43 min, 97.49% (maximum). Chiral SFC: (Method D) Rt. 3.06 min, 99.76% (maximum).

[0269] Intermediate 10 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate

[0270] [ka]

[0271] To a stirred solution of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 8; 0.2 g, 0.49 mmol) in 5 mL of THF at 0°C, methyl 3-hydroxy-2,2-dimethylpropanoate (0.07 g, 0.49 mmol) and triphenylphosphine (0.19 g, 0.73 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.22 g, 0.98 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous sodium 2 SO4. The organic portion was filtered and concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 20-22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 60% (0.15 g, white solid). LCMS: (Method K) 521.1(M + +H), Rt.3.23 min, 75.58% (max).

[0272] Intermediate 11 Methyl(S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate and Methyl(R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate

[0273] [ka]

[0274] To a stirred solution of enantiomer 1 of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 9; 0.1 g, 0.24 mmol) in 5 mL of THF at 0°C, methyl 3-hydroxy-2,2-dimethylpropanoate (0.04 g, 0.24 mmol) and triphenylphosphine (0.09 g, 0.36 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.11 g, 0.48 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 20% siRNA / PE; silica gel: 230-400 mesh) to obtain enantiomer 1 of the title compound. Starting with 0.3 g of enantiomer 2 of intermediate 9, the same procedure was followed to obtain enantiomer 2 of the title compound. After the reaction was complete, the reaction mixture was concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 8% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 80% (80 mg, white solid). LC-MS: (Method K) 521.0 (M + +H), Rt.3.24 minutes, 91.11% (maximum). Enantiomer 2: Yield: 99% (0.4g, yellow solid). LCMS: (Method K) 521.0 (M + +H), Rt.3.26 min, 95.22% (max).

[0275] Intermediate 12 Ethyl 1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0276] [ka]

[0277] To a stirred solution of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 8; 0.1 g, 0.25 mmol) in THF (5 mL) at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.04 g, 0.25 mmol) and triphenylphosphine (0.09 g, 0.37 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.09 g, 0.37 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 30% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 46% (0.12 g, white solid). LCMS: (Method K) 533.3(M + +H), Rt.3.10 minutes, 39.60%.

[0278] Intermediate 13 Ethyl(S)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate and Ethyl(R)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0279] [ka]

[0280] Starting with 0.1 g of enantiomer 1 of intermediate 9, and following the same procedure as described above for intermediate 12, enantiomer 1 of the title compound was obtained. Following the same procedure, but starting with 0.1 g of enantiomer 2 of intermediate 9, enantiomer 2 of the title compound was obtained. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 72% (0.12 g, white solid). LC-MS: (Method K) 533.0 (M + +H), Rt.3.29 min, 78.91% (max). Enantiomer 2: Yield: 66% (0.13 g, white solid). LC-MS: (Method K) 533.0 (M + +H), Rt.3.29 minutes, 66.72% (maximum).

[0281] Intermediate 14 3-Butyl-7-(ethylthio)-8-hydroxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0282] [ka]

[0283] To a solution of 7-bromo-3-butyl-8-methoxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 7; 0.3 g, 0.66 mmol) in N-methyl-2-pyrrolidone (5 mL), sodium ethanethiolate (0.27 g, 3.31 mmol) was added, and the reaction mixture was stirred at 100 °C for 12 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was quenched with ice-cold water (25 mL), and the aqueous layer was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with ice-cold water (50 mL) and brine (50 mL), and dried over anhydrous sodium 2SO4. The organic portion was concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 30% ethyl acetate / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 69% (0.2g, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.63 (s, 1H), 7.42 (s, 1H), 7.23-7.21 (m, 2H), 6.83 (t, J = 7.6 Hz, 1H), 6.68-6.64 (m, 3H), 4.05-4.01 (m, 2H), 3.23-3.21 (m, 1H), 2.80 (q, J = 7.2 Hz, 2H), 2.60 (s, 3H), 1.57-1.31 (m, 6H), 1.27 (t, J = 7.20 Hz, 3H), 0.96 (t, J = 7.20 Hz, 3H). LCMS: (Method E) 421.0 (M + +H), Rt. 3.04 minutes, 95.23% (max).

[0284] Intermediate 15 Methyl 3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate

[0285] [ka]

[0286] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 14; 0.15 g, 0.36 mmol) in THF (5 mL) at 0°C, methyl 3-hydroxy-2,2-dimethylpropanoate (0.05 g, 0.36 mmol) and triphenylphosphine (0.14 g, 0.54 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.12 g, 0.54 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na₂SO₄, then filtered, and concentrated under vacuum. The obtained crude substance was purified by Isolera column chromatography (eluent: 22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 32% (0.16 g, white solid). LCMS: (Method A) 535.2(M + +H), Rt.3.08 min, 38.01% (max).

[0287] Intermediate 16 Ethyl 1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0288] [ka]

[0289] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-2-methyl-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 14; 0.15 g, 0.36 mmol) in 10 mL of THF at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.05 g, 0.36 mmol) and triphenylphosphine (0.14 g, 0.54 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.12 g, 0.54 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 81% (0.16 g, white solid). LCMS: (Method A) 547.2(M + +H), Rt.3.06 minutes, 98.17% (max).

[0290] Intermediate 17 3-Butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3-dihydro-1,5-benzothiazepine-4(5H)-one

[0291] [ka]

[0292] To a stirred solution of 3-butyl-7-chloro-8-methoxy-2,3-dihydro-1,5-benzothiazepine-4(5H)-one (6 g, 20.01 mmol) in 1-bromo-4-fluorobenzene (88 g, 500 mmol), copper(I) iodide (0.38 g, 2.00 mmol) and K2CO3 (5.53 g, 40.0 mmol) were added, and the solution was purged with nitrogen for 20 minutes to degass. Then, tris[2-(2-methoxyethoxy)ethyl]amine (1.30 g, 4.00 mmol) was added under a nitrogen atmosphere, and the resulting reaction mixture was heated at 135 °C for 40 hours. After the completion of the reaction (monitored by UPLC), the reaction mixture was filtered through Celite, and the Celite pad was washed with ELISA (100 mL). The filtrate was concentrated under vacuum, and the resulting crude substance was purified by Isolera column chromatography (eluent: 15-20% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 64% (5.5 g, off-white solid). LCMS: (Method E) 394.0(M + +H), Rt.3.19 min, 91.57%.

[0293] Intermediate 18 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine

[0294] [ka]

[0295] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3-dihydro-1,5-benzothiazepine-4(5H)-one (intermediate 17; 5.5 g, 13.96 mmol) in 60 mL of THF at 0°C, boranedimethyl sulfide (140 mL, 140 mmol) was added dropwise, and the reaction mixture was refluxed at 75°C for 40 hours. After the completion of the reaction (monitored by ULC), the reaction mixture was cooled to 0°C and quenched with methanol (100 mL). The resulting solution was heated at 65°C for 2 hours, then cooled to room temperature and concentrated under vacuum. The crude substance was purified by Isolera column chromatography (eluent: 15-20% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 77% (4.5 g, colorless liquid). LCMS: (Method A) 380.0(M + ) Rt.3.61 minutes, 90.76% (max).

[0296] Intermediate 19 3-Butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide

[0297] [ka]

[0298] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine (intermediate 18; 4.5 g, 11.84 mmol) in THF (45 mL) and water (10 mL), Oxone (36.4 g, 59.2 mmol) was added, and the reaction mixture was stirred at room temperature for 24 hours. After the reaction was completed (monitored by TLC), the reaction mixture was filtered through a Buchner funnel, and the filtrate was extracted with siRNA (2 × 200 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum. The crude product was purified by Isolera column chromatography (eluent: 10-13% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 84% (4.1 g, colorless solid). LCMS: (Method A) 412.1(M + +H), Rt.2.83 minutes, 96.78% (maximum).

[0299] Intermediate 20 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide

[0300] [ka]

[0301] To a stirred solution of 3-butyl-7-chloro-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (intermediate 19; 1 g, 2.42 mmol) in DMF (12 mL), sodium thiomethoxide (0.85 g, 12.14 mol) was added at room temperature, and the resulting mixture was stirred overnight at 100 °C. After the reaction (monitored by TLC) was complete, the reaction mixture was quenched with water (20 mL), and the aqueous layer was extracted with siRNA (2 × 20 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 30-35% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 30% (0.300 g, off-white solid). 1 H NMR (400 MHz, CDCl3): δ 7.66 (s, 1H), 7.27 (s, 1H), 6.94-6.94 (m, 2H), 6.62-6.64 (m, 2H), 4.14-4.16 (m, 1H), 3.41-3.42 (m, 1H), 2.96-2.96 (m, 1H), 2.50 (s, 1H), 2.40 (s, 3H), 1.37-1.37 (m, 4H), 1.29-1.30 (m, 4H), 0.95 (t, J = 7.20 Hz, 3H). LCMS: (Method A) 408.2 (M +_ H), Rt. 2.54 minutes, 98.39% (max).

[0302] Intermediate 21 Methyl 3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2,2-dimethylpropanoate

[0303] [ka]

[0304] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (intermediate 20; 0.1 g, 0.25 mmol) in THF (5 mL) at 0°C, methyl 3-hydroxy-2,2-dimethylpropanoate (0.03 g, 0.25 mmol) and triphenylphosphine (0.09 g, 0.37 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.08 g, 0.37 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with brine (5 mL) and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude substance was purified by Isolera column chromatography (eluent: 22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 73% (0.12 g, white solid). LCMS: (Method A) 524.1(M + +H), Rt.3.33 minutes, 77.91% (maximum).

[0305] Intermediate 22 Ethyl 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0306] [ka]

[0307] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (intermediate 20; 0.1 g, 0.25 mmol) in THF (5 mL) at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.04 g, 0.25 mmol) and triphenylphosphine (0.09 g, 0.37 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.08 g, 0.37 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 20-22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 82% (0.11 g, white solid). LCMS: (Method A) 536.2(M + +H), Rt.3.35 minutes, 97.37% (max).

[0308] Intermediate 23 tert-butyl(1-((4-fluorophenyl)amino)-1-oxohexan-2-yl)carbamate

[0309] [ka]

[0310] Triethylamine (112 mL, 804 mmol) was added dropwise to a stirred solution of 2-((tert-butoxycarbonyl)amino)hexanoic acid (93.0 g, 402 mmol) in DMF (930 mL) at 0°C. Then, 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosfinan 2,4,6-trioxide (307 g, 483 mmol) was added, and the reaction mixture was stirred at 0°C for 10 minutes. Next, 4-fluoroaniline (44.7 g, 402 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with ice-cold water (500 mL), and the solid product was precipitated. The obtained solid was filtered, washed with water (2 × 100 mL), and dried under vacuum to obtain the title compound. The obtained crude product was sent directly to the next step without further purification. Yield: 69% (90g, pale yellow solid). LCMS:(Method K)225.2(M + +H-Boc), Rt.2.66 min, 99.41% (max).

[0311] Intermediate 24 2-amino-N-(4-fluorophenyl)hexaneamide

[0312] [ka]

[0313] To a stirred solution of tert-butyl(1-((4-fluorophenyl)amino)-1-oxohexane-2-yl)carbamate (intermediate 23; 90 g, 277 mmol) in 1,4-dioxane (900 mL), HCl in dioxane (4 M in 1,4-dioxane, 360 mL, 1280 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was concentrated under vacuum, and the resulting residue was basicized with 10% NaHCO3 solution (400 mL). The aqueous layer was extracted with ELISA (2 × 500 mL), and the combined organic layers were washed with water (2 × 100 mL) and dried over anhydrous Na2SO4. The organic portion was concentrated under vacuum, and the resulting crude product was sent directly to the next step without further purification. Yield: 91% (60 g, light brown liquid). LCMS:(Method K)225.1(M + +H), Rt.1.97 min, 94.23% (maximum).

[0314] Intermediate 25 N1-(4-fluorophenyl)hexane-1,2-diamine

[0315] [ka]

[0316] To a stirred solution of 2-amino-N-(4-fluorophenyl)hexanamide (intermediate 24; 60 g, 268 mmol) in THF (300 mL), boranedimethyl sulfide (1 M in THF, 401 mL, 401 mmol) was added at 0°C, and the reaction mixture was heated at 75°C for 24 hours. After the reaction was completed (monitored by TLC), the reaction mixture was quenched with methanol (200 mL) at 0°C, and the reaction mixture was heated at 75°C for 2 hours. The reaction mixture was concentrated under vacuum, and the resulting residue was dissolved in DCM (500 mL). The organic layer was washed with water (2 × 200 mL), dried over anhydrous Na₂SO₄, and then concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 5-20% MeOH in DCM; silica gel: 230-400 mesh) to obtain the title compound. Yield: 87% (53 g, brown liquid). LCMS: (Method K) 211.2(M + +H), Rt.1.97 min, 92.44% (maximum).

[0317] Intermediate 26 2,4-Dibromo-N-(1-((4-Fluorophenyl)amino)Hexane-2-yl)-5-Methoxybenzenesulfonamide

[0318] [ka]

[0319] To a stirred solution of N1-(4-fluorophenyl)hexane-1,2-diamine (intermediate 25; 20 g, 95 mmol) in THF (200 mL), 2,4-dibromo-5-methoxybenzenesulfonyl chloride (41.6 g, 114 mmol) and triethylamine (39.8 mL, 285 mmol) were added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed (monitored by TLC), the reaction mixture was diluted with siRNA (400 mL). The organic layer was washed with water (2 × 100 mL) and dried over anhydrous Na₂SO₄. The organic portion was concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 15% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 86% (45.5 g, brown solid). 1 H NMR (400 MHz, DMSO-d6): δ 8.02-7.90 (m, 2H), 7.55 (s, 1H), 6.82 (m, 2H), 6.31-6.26 (m, 2H), 5.45-5.30 (m, 1H), 3.90 (s, 3H), 3.30-3.15 (m, 1H), 3.05-2.82 (m, 2H), 1.60-1.40 (m, 1H), 1.40-1.30 (m, 1H), 1.30-1.20 (m, 1H), 1.15-0.98 (m, 3H), 0.73 (t, J = 8.80 Hz, 3H). LCMS: (Method A) 538.9 (M + +H), Rt. 3.04 minutes, 85.57% (max).

[0320] Intermediate 27 7-Bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0321] [ka]

[0322] To a stirred solution of 2,4-dibromo-N-(1-((4-fluorophenyl)amino)hexane-2-yl)-5-methoxybenzenesulfonamide (intermediate 26; 45 g, 84 mmol) in DMF (450 mL), potassium carbonate (23.11 g, 167 mmol) and copper iodide (1.59 g, 8.36 mmol) were added at room temperature. The reaction mixture was degassed under nitrogen for 15 minutes. Then, tris[2-(2-methoxyethoxy)ethyl]amine (5.41 g, 16.72 mmol) was added at room temperature, and the reaction mixture was heated at 130 °C for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was filtered through a Celite pad, and the Celite pad was washed with ELISA (50 mL). The filtrate was concentrated under vacuum. The resulting residue was diluted with ELISA (400 mL), and the organic layer was washed with water (2 × 100 mL). The organic portion was dried over anhydrous Na2SO4, and the resulting crude product was purified by Isolera column chromatography (eluent: 12% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 55% (22.0 g, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.57 (s, 1H), 7.50-7.42 (d, J = 6.6 Hz, 2H), 7.02 (t, J = 9.0 Hz, 2H), 6.70-6.50 (m, 2H), 4.38-4.22 (m, 1H), 3.95 (s, 3H), 3.33 (m, 1H), 2.95-2.80 (m, 1H), 1.65-1.15 (m, 6H), 0.89 (t, J = 9.2 Hz, 3H). LCMS: (Method A) 455.0 (M + -H), Rt. 2.71 minutes, 95.55% (max).

[0323] Intermediate 28 7-Bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0324] [ka]

[0325] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 27; 5.8 g, 12.68 mmol) in N-methyl-2-pyrrolidone (24 mL), Cs2CO3 (8.26 g, 25.4 mmol) was added at 0°C, and the reaction mixture was stirred for 15 minutes. Then, methyl iodide (1.58 mL, 25.4 mmol) was added dropwise at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with ELISA (100 mL), and the organic layer was washed with water (50 mL). The organic portion was dried over anhydrous Na2SO4 and concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 15% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 75% (5.1 g, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.47 (s, 1H), 7.41 (s, 1H), 6.98-6.94 (m, 2H), 6.72-6.69 (m, 2H), 3.99-3.92 (m, 5H), 3.40-3.22 (m, 1H), 2.63 (s, 3H), 1.68-1.60 (m, 1H), 1.50-1.35 (m, 5H), 0.95 (t, J = 7.2 Hz, 3H). LCMS: (Method A) 471.0 (M + +H), Rt. 2.89 minutes, 88.26% (max).

[0326] Intermediate 29 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-2-methyl-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0327] [ka]

[0328] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 28; 2.0 g, 4.24 mmol) in DMF (20 mL), sodium thiomethoxide (1.48 g, 21.21 mmol) was added at room temperature, and the reaction mixture was stirred at 100 °C for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was cooled to room temperature and quenched with water (20 mL). The aqueous layer was extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous sodium 2SO4. The organic portion was concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 15-20% ethyl acetate / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 81% (1.6g, pale yellow solid). 1 H NMR (400 MHz, DMSO-d6): δ 10.72 (s, 1H), 7.27 (s, 1H), 6.97 (t, J = 11.2 Hz, 3H), 6.55-6.50 (m, 2H), 3.98-3.86 (m, 2H), 3.30-3.05 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.70-1.45 (m, 2H), 1.40-1.25 (m, 4H), 1.00-0.80 (m, 3H). LCMS: (Method A) 425.2 (M + +H), Rt. 2.56 minutes, 90.64% (max).

[0329] Intermediate 30 Ethyl 1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0330] [ka]

[0331] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-2-methyl-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 29; 0.06 g, 0.14 mmol) in THF (3 mL) at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.02 g, 0.14 mmol) and triphenylphosphine (0.056 g, 0.212 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.05 g, 0.21 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 22-25% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 69% (70 mg, off-white solid). LCMS: (Method A) 551.2(M + +H), Rt.2.96 min, 77.38% (max).

[0332] Intermediate 31 Methyl 3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate

[0333] [ka]

[0334] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-2-methyl-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 29; 0.05 g, 0.12 mmol) in THF (3 mL) at 0°C, methyl 3-hydroxy-2,2-dimethylpropanoate (0.02 g, 0.12 mmol) and triphenylphosphine (0.05 g, 0.18 mmol) were added, and the reaction mixture was stirred for 30 minutes. Then, DBAD (0.04 g, 0.18 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 12 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude substance was purified by Isolera column chromatography (eluent: 30% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 57% (60 mg, brown solid). LCMS: (Method A) 538.8(M + ), Rt.3.03 minutes, 60.90% (max).

[0335] Intermediate 32 2-((tert-butoxycarbonyl)amino)hexanoic acid

[0336] [ka]

[0337] To a solution of 2-aminohexanoic acid (25 g, 0.19 mol) in water (250 mL) and THF (250 mL), NaHCO3 (48 g, 0.57 mol) and anhydrous Boc (52.2 mL, 0.23 mol) were added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was cooled, quenched, and acidified with 1.5 N HCl. The reaction mixture was extracted with ¼ (2 × 150 mL). The combined organic layer was washed with ice-cold water (150 mL) and brine (150 mL), dried over anhydrous Na₂SO₄, and concentrated to obtain the title compound. Yield: 45.5 g (crude, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 5.10-4.98 (m, 1H), 4.33-4.30 (m, 1H), 1.95-1.81 (m, 1H), 1.75-1.55 (m, 1H), 1.46 (s, 10H), 1.45-1.31 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H). LCMS: (Method E) 132.2 (M + -Boc+H), Rt. 2.36 minutes, 99.98% (max).

[0338] Intermediate 33 tert-butyl(1-oxo-1-(phenylamino)hexane-2-yl)carbamate

[0339] [ka]

[0340] To a stirred solution of 2-((tert-butoxycarbonyl)amino)hexanoic acid (intermediate 32; 45.5 g, 0.196 mol) in DMF (150 mL), triethylamine (54.83 mL, 0.39 mol) was added, and the reaction mixture was cooled to 0°C. A solution of 1-propanephosphonic anhydride (50% in HCl; 75.1 g, 0.23 mol) and aniline (18 g, 0.196 mol) were added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with ice-cold water (50 mL) and diluted with HCl (200 mL). The aqueous layer was washed with ice-cold water (200 mL) and brine (200 mL), then dried over anhydrous Na₂SO₄ and filtered. The organic portion was concentrated under vacuum to obtain the title compound. Yield: 82% (49.7 g, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 9.93 (s, 1H), 7.60 (d, J = 7.6 Hz, 2H), 7.30 (t, J = 8.0 Hz, 2H), 7.06-6.99 (m, 2H), 4.07-4.02 (m, 1H), 1.63-1.56 (m, 2H), 1.46-1.28 (m, 13H), 0.86 (t, J = 6.8 Hz, 3H). LCMS: (Method E) 207.0 (M + -Boc+H), Rt. 2.69 minutes, 91.20% (max).

[0341] Intermediate 34 2-amino-N-phenylhexaneamide

[0342] [ka]

[0343] To a solution of tert-butyl(1-oxo-1-(phenylamino)hexane-2-yl)carbamate (intermediate 33; 49.7 g, 0.162 mol) in 1,4-dioxane (500 mL) at 0°C, a solution of HCl in 1,4-dioxane (4 M, 199 mL) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was concentrated under vacuum, and the resulting residue was quenched with saturated NaHCO3 solution. The aqueous layer was extracted with SiO2 (2 × 200 mL). The combined organic layers were washed with brine (200 mL) and dried over anhydrous Na2SO4. The organic portion was filtered, and concentrated under vacuum to obtain the title compound. Yield: 95% (32 g, colorless gum). 1 H NMR (400 MHz, DMSO-d6): δ 10.20-9.66 (m, 1H), 7.64 (dd, J = 4.8, 2.4 Hz, 2H), 7.32-7.27 (m, 2H), 7.06-7.02 (m, 1H), 3.29-3.26 (m, 1H), 1.67-1.61 (m, 1H), 1.46-1.27 (m, 5H), 0.89-0.85 (m, 3H). LCMS: (Method B) 207.2 (M + +H), Rt. 2.03 minutes, 84.36% (max).

[0344] Intermediate 35 N1-Phenylhexane-1,2-diamine

[0345] [ka]

[0346] To a solution of 2-amino-N-phenylhexaneamide (intermediate 34; 32 g, 0.15 mol) in 320 mL of THF at 0°C, boranedimethyl sulfide (2 M solution in THF, 117 mL, 0.23 mol) was added, and the reaction mixture was heated at 75°C for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was cooled to 0°C, quenched with methanol (150 mL), and then heated at 60°C for 2 hours. The reaction mixture was cooled to room temperature and concentrated under vacuum. The resulting residue was partitioned between water (50 mL) and ethyl acetate (50 mL). The aqueous layer was extracted with ethyl acetate (2 × 250 mL). The combined organic layers were washed with water (250 mL) and brine (250 mL). The organic portion was dried over anhydrous sodium 2SO4, filtered, and concentrated under vacuum. The obtained crude substance was purified by Isolera column chromatography (eluent: 10% SiO2 / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 93% (28 g, yellow oily substance). LCMS: (Method B) 193.3(M + +H), Rt.1.98 min, 76.9% (max).

[0347] Intermediate 36 2,4-Dibromo-5-methoxy-N-(1-(phenylamino)hexane-2-yl)benzenesulfonamide

[0348] [ka]

[0349] To a solution of 2,4-dibromo-5-methoxybenzenesulfonyl chloride (3.2 g, 8.79 mmol) in 50 mL of THF at 0°C, N1-phenylhexane-1,2-diamine (intermediate 35; 1.3 g, 6.76 mmol) and triethylamine (2.8 mL, 20.3 mmol) were added, and the reaction mixture was stirred at room temperature for 4 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was concentrated under vacuum, and the resulting residue was dissolved in HCl (60 mL). The organic layer was washed with water (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 18% HCl / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 97% (3.5 g, brown gum-like substance). LCMS: (Method E) 521.0 (M + +H), Rt.3.14 minutes, 93.57% (maximum).

[0350] Intermediate 37 7-Bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0351] [ka]

[0352] To a solution of 2,4-dibromo-5-methoxy-N-(1-(phenylamino)hexane-2-yl)benzenesulfonamide (intermediate 36; 3.5 g, 6.72 mmol) in DMF (30 mL), K2CO3 (1.73 g, 12.5 mmol) and copper powder (0.42 g, 6.72 mmol) were added. The reaction mixture was degassed under an N2 atmosphere for 5 minutes, and then heated at 115°C for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with ice-cold water (25 mL), and the aqueous layer was extracted with a 1:1 mixture of siRNA and PE (2 × 50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 25% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 51% (1.5 g, brown gum). LCMS: (Method A) 439.0(M + +H), Rt.2.83 min, 82.06% (max).

[0353] Intermediate 38 7-Bromo-3-butyl-8-methoxy-2-(4-methoxybenzyl)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0354] [ka]

[0355] To a stirred solution of 7-bromo-3-butyl-8-methoxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 37; 2g, 4.55 mmol) in NMP (15 mL), Cs2CO3 (1.78 g, 5.46 mmol) was added at 0°C, and the reaction mixture was stirred for 15 minutes. Then, 1-(bromomethyl)-4-methoxybenzene (1.37 g, 6.83 mmol) was added dropwise at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with ELISA (50 mL), and the organic layer was washed with water (2 × 10 mL). The organic portion was dried over anhydrous Na2SO4 and concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 20-22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 46% (2.1 g, white solid). LCMS: (Method K) 559.1(M + ), Rt.2.99 minutes, 56.12% (max).

[0356] Intermediate 39 3-Butyl-7-(ethylthio)-8-hydroxy-2-(4-methoxybenzyl)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0357] [ka]

[0358] To a stirred solution of 7-bromo-3-butyl-8-methoxy-2-(4-methoxybenzyl)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 38; 1.0 g, 1.79 mmol) in NMP (10 mL), sodium ethanethiolate (0.75 g, 8.94 mmol) was added at room temperature, and the reaction mixture was heated at 100 °C for 12 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was cooled to room temperature and quenched with water (20 mL). The aqueous layer was extracted with siRNA (2 × 30 mL), and the combined organic layers were washed with brine (10 mL) and then dried over anhydrous Na₂SO₄. The organic portion was concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 20-22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 29% (0.3g, white solid). LCMS: (Method A) 527.1(M + +H), Rt.2.89 min, 91.85% (maximum).

[0359] Intermediate 40 3-Butyl-7-(ethylthio)-8-hydroxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0360] [ka]

[0361] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-2-(4-methoxybenzyl)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 39; 0.4 g, 0.76 mmol) in toluene (5 mL) at 0°C, triphenylamine (0.09 g, 0.38 mmol) and 2,2,2-trifluoroacetic acid (1.73 g, 15.19 mmol) were added. The reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with water (10 mL), and the aqueous layer was extracted with RINKAN (2 × 20 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium 2 SO4, and concentrated under vacuum. The obtained crude substance was purified by Isolera column chromatography (eluent: 25% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 30% (0.2 g, white solid). LCMS: (Method B) 407.1(M + +H), Rt.2.58 min, 47.18% (max).

[0362] Intermediate 41 Ethyl 1-(((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0363] [ka]

[0364] To a stirred solution of 3-butyl-7-(ethylthio)-8-hydroxy-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 40; 0.05 g, 0.12 mmol) in THF (5 mL) at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.03 g, 0.18 mmol) and triphenylphosphine (0.05 g, 0.18 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.04 g, 0.19 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude substance was purified by Isolera column chromatography (eluent: 20-22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 76% (50 mg, white solid). LCMS: (Method A) 532.7(M + ), Rt.3.00 min, 98.06% (max).

[0365] Intermediate 42 7-Bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-(4-methoxybenzyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0366] [ka]

[0367] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 27; 5g, 10.93 mmol) in NMP (50 mL), Cs2CO3 (7.12 g, 21.86 mmol) was added, and the reaction mixture was stirred at 0°C for 30 minutes. Then, 1-(bromomethyl)-4-methoxybenzene (3.30 g, 16.40 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was filtered through a Celite bed, and the Celite bed was washed with siRNA (2 × 20 mL). The filtrate was concentrated under vacuum, and the crude product was purified by Isolera column chromatography (eluent: 15-20% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 73% (6g, off-white solid). LCMS: (Method A) 578.1(M + +H), Rt.3.49 min, 75.44%.

[0368] Intermediate 43 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-2-(4-methoxybenzyl)-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0369] [ka]

[0370] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-(4-methoxybenzyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 42; 1 g, 1.23 mmol) in DMF (20 mL), sodium thiomethoxide (0.43 g, 6.14 mmol) was added at room temperature, and the resulting mixture was stirred at 100 °C for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was quenched with water (50 mL), and the aqueous layer was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium 2SO4, and concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 10-15% ethyl acetate / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 66% (500g, off-white solid). LCMS: (Method B) 529.1(M +_ H), Rt.3.20 minutes, 85.70% (maximum).

[0371] Intermediate 44 3-Butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0372] [ka]

[0373] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-2-(4-methoxybenzyl)-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 43; 0.2 g, 0.37 mmol) in toluene (10 ml), triphenylamine (0.09 g, 0.37 mmol) and 2,2,2-trifluoroacetic acid (0.04 g, 0.37 mmol) were added at 0°C, and the reaction mixture was stirred at room temperature for 4 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with water (10 mL), and the aqueous layer was extracted with ELISA (2 × 20 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium 2 SO4, and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 20-25% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 90% (0.15 g, white solid). LCMS: (Method A) 411.0(M + +H), Rt.2.26 minutes, 93.21% (maximum).

[0374] Intermediate 45 Ethyl 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0375] [ka]

[0376] To a stirred solution of 3-butyl-5-(4-fluorophenyl)-8-hydroxy-7-(methylthio)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 44; 0.05 g, 0.12 mmol) in THF (5 mL) at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.02 g, 0.12 mmol) and triphenylphosphine (0.05 g, 0.18 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.04 g, 0.18 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 1 hour. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 20-22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 51% (0.1 g, white solid). LCMS: (Method B) 536.2(M + ), Rt.2.79 min, 96.56% (max).

[0377] Intermediate 46 3-Butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0378] [ka]

[0379] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-(4-methoxybenzyl)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 42; 0.3 g, 0.52 mmol) in DMF (5 mL), sodium ethanethiolate (0.22 g, 2.60 mmol) was added at room temperature, and the reaction mixture was stirred at 100 °C for 12 hours. After the reaction was completed (monitored by TLC), the reaction mixture was quenched with water (20 mL), and the aqueous layer was extracted with ethyl acetate (2 × 30 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium 2 SO4, and concentrated under vacuum. The resulting crude product was purified by Isolera column chromatography (eluent: 20% ethyl acetate / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 97% (0.23g, white solid). LCMS: (Method A) 425.1(M + +H), Rt.2.97 min, 92.88% (maximum).

[0380] Intermediate 47 Ethyl 1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate

[0381] [ka]

[0382] To a stirred solution of 3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 46; 0.1 g, 0.24 mmol) in THF (5 mL) at 0°C, ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (0.102 g, 0.71 mmol) and triphenylphosphine (0.19 g, 0.71 mmol) were added, and the reaction mixture was stirred for 10 minutes. Then, DBAD (0.16 g, 0.71 mmol) was added at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 22-25% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 49% (70 mg, brown solid). LCMS: (Method A) 551.1(M + +H), Rt.2.93 minutes, 90.19% (maximum).

[0383] Intermediate 48 Ethyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoate

[0384] [ka]

[0385] To a stirred solution of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 8; 0.1 g, 0.25 mmol) in DMF (3 mL) at 0°C, Cs2CO3 (0.12 g, 0.37 mmol) was added, and the reaction mixture was stirred at room temperature for 30 minutes. Then, ethyl 3-bromo-2,2-difluoropropanoate (0.07 g, 0.30 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After TLC revealed that the starting material had not been completely consumed, the reaction mixture was heated at 60°C for 2 hours. The reaction mixture was then diluted with water (5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na2SO4. The organic portion was filtered and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 8-10% HCl / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 33% (0.1 g, brown solid). UPLC: (Method B) 543.2(M + +H), Rt.2.55 min, 43.90% (max).

[0386] Intermediate 49 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxy-2-methylpropanoate

[0387] [ka]

[0388] To a stirred solution of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 8; 0.5 g, 1.22 mmol) in DMF (5 mL), Cs2CO3 (0.78 g, 2.4 mmol) and methyl 2-methyloxirane-2-carboxylate (0.42 g, 3.6 mmol) were added at 0°C. The reaction mixture was stirred at room temperature for 72 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with dilute HCl (1.5 N, 5 mL). The aqueous layer was extracted with ethyl acetate (2 × 20 mL), and the combined organic layers were washed with water (10 mL) and brine (10 mL). The organic portion was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 20% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 27% (0.17 g, brown solid). 1 H NMR (400 MHz, CDCl3): δ 7.36 (s, 1H), 7.29-7.25 (m, 2H), 6.97 (s, 1H), 6.83-6.80 (m, 1H), 6.68-6.65 (m, 2H), 4.37-4.36 (m, 1H), 4.15 (m, 1H), 4.04 (s, 1H), 4.00 (s, 1H), 3.88 (s, 3H), 3.65 (bs, 1H), 3.15 (bs, 1H), 2.59 (s, 3H), 2.33 (s, 3H), 1.66 (m, 2H), 1.6 (m, 6H), 1.3 (m, 1H), 0.98-0.96 (m, 3H). LCMS: (Method K) 523.1 (M + +H), Rt. 2.97 minutes, 94.53% (max).

[0389] Intermediate 50 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxy-2-methylpropanoate

[0390] [ka]

[0391] Starting with enantiomer 2 of 0.15 g of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 9), the title compound was obtained by following the same procedure as described above for intermediate 49. The crude product was purified by Isolera column chromatography (eluent: 10-15% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. The absolute configuration of the compound is unknown. Yield: 47% (90 mg, brown solid). 1 H NMR (400 MHz, CDCl3): δ 7.37 (s, 1H), 7.29 (m, 2H), 6.98 (s, 1H), 6.84 (t, J = 4.4 Hz, 1H), 6.68-6.66 (m, 2H), 4.37-4.36 (m, 1H), 4.13 (m, 1H), 4.04 (m, 2H), 3.88 (s, 3H), 3.30 (bs, 1H), 2.98 (s, 2H), 2.59 (s, 3H), 2.33 (s, 3H), 1.60-1.57 (m, 3H), 1.56-1.49 (m, 4H), 0.98-0.96 (m, 3H). LCMS: (Method K) 522.9 (M + +H), Rt. 2.78 minutes, 92.89% (max).

[0392] Intermediate 51 Methyl(S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxy-2-methylpropanoate and Methyl(R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxy-2-methylpropanoate (individual diastereomers)

[0393] [ka]

[0394] Two diastereoisomers of intermediate 50 (0.3 g, 0.58 mmol) were separated using a chiral SFC instrument (Method N). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to diastereomer 1, and the second eluted fraction corresponded to diastereomer 2. Each of the two fractions was then treated individually for further purification. The resulting residues were diluted with ethyl acetate (30 ml) and washed with dilute HCl (1.5 N, 10 mL) and water (10 mL). The organic portion was then dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum to obtain the purified diastereomer of the title compound. The absolute configurations of the two diastereomers are unknown. Diastereoisomer 1: Yield: 43% (0.13 g, off-white gum-like substance). 1H NMR (400 MHz, DMSO-d6): δ 7.30 (s, 1H), 7.16 (t, J = 8.4 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.0 Hz, 2H), 5.74 (s, 1H), 4.21 (m, 2H), 3.88 (bs, 1H), 3.69 (s, 3H), 3.20 (bs, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.64 (m, 1H), 1.50 (m, 1H), 1.49 (s, 3H), 1.36 (m, 4H), 0.93–0.92 (m, 3H). LCMS: (Method H) 523.0 (M + +H), Rt. 2.50 minutes, 96.90% (maximum). HPLC: (Method E) Rt. 5.62 minutes, 98.27% (maximum). SFC: (Method L) Rt. 3.73 minutes, 98.36% (maximum). Sesame heterosexual body 2: Yield: 41% (0.13g, sesame-like substance). 1 H NMR (400 MHz, DMSO-d6): δ 7.30 (s, 1H), 7.16 (t, J = 8.4 Hz, 2H), 7.04 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.0 Hz, 2H), 5.73 (s, 1H), 4.20 (m, 2H), 4.04 (bs, 2H), 3.90 (bs, 1H), 3.69 (s, 4H), 1.99 (m, 1H), 1.44 (m, 4H), 1.35-1.30 (m, 7H), 0.91 (m, 4H). LCMS: (Method H) 523.0 (M + +H), Rt. 2.50 minutes, 93.08% (maximum). HPLC: (Method E) Rt. 5.63 minutes, 94.12% (maximum). SFC: (Method L) Rt. 4.68 minutes, 98.75% (maximum).

[0395] Intermediate 52 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoate

[0396] [ka]

[0397] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-hydroxy-2-methylpropanoate (intermediate 49; 0.17 g, 0.32 mmol) in DMF (5 mL) at 0°C, sodium hydride (6.5 mg, 0.16 mmol) was added, and the reaction mixture was stirred for 10 minutes. Then, methyl iodide (0.23 g, 1.62 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous sodium 2SO4. The organic portion was filtered and concentrated under vacuum. The resulting crude material was purified by Isolera column chromatography (eluent: 10-12% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 75% (0.13 g, brown solid). LCMS: (Method K) 537.2(M + +H), Rt.2.98 min, 96.48% (max).

[0398] Intermediate 53 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoate

[0399] [ka]

[0400] Starting with 0.08 g of intermediate 50, the title compound was obtained by following the same procedure as described for intermediate 52. After workup of the reaction mixture, the crude product was purified by Isolera column chromatography (eluent: 10-15% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. The absolute configuration of the compound is unknown. Yield: 57% (50 mg, off-white solid). LCMS:(Method K)537.0(M + +H), Rt.3.12 minutes, 93.30% (maximum).

[0401] Intermediate 54 Methyl(S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoate and Methyl(R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoate (individual diastereomers)

[0402] [ka]

[0403] Diastereoisomers 1 and 2 of the title compound were prepared from diastereoisomer 1 (0.13 g) and diastereoisomer 2 (0.13 g), respectively, of intermediate 51, following the same procedure as described for intermediate 52. After workup of the reaction mixture, the crude product was purified by Isolera column chromatography (eluent: 22% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. The absolute configurations of the two diastereomers are unknown. Diastereoisomer 1: Yield: 69% (95 mg, pale yellow solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.32 (s, 1H), 7.16 (t, J = 8.0 Hz, 2H), 7.05 (s, 1H), 6.71 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.36 (m, 2H), 4.04-4.03 (m, 1H), 3.90 (bs, 1H), 3.73 (s, 3H), 3.30 (s, 3H), 2.46 (s, 3H), 2.35 (s, 4H), 1.61 (m, 1H), 1.49 (s, 4H), 1.36 (m, 4H), 0.94-0.92 (m, 3H). LCMS: (Method A) 537.1 (M + +H), Rt. 2.89 minutes, 96.63% (max). Diastereoisomer 2: Yield: 64% (90 mg, pale yellow solid). LC-MS: (Method A) 537.1 (M + +H), Rt.2.89 min, 95.04% (max).

[0404] Intermediate 55 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoate

[0405] [ka]

[0406] To a solution of 3-butyl-8-hydroxy-2-methyl-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 8; 0.5 g, 1.22 mmol) in DMF (10 mL), Cs2CO3 (0.79 g, 2.45 mmol) was added, and the reaction mixture was stirred at room temperature for 15 minutes. Then, methyloxirane-2-carboxylate (0.37 g, 3.68 mmol) was added, and the reaction mixture was stirred at room temperature for 72 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute HCl (1.5 N, 15 mL) and diluted with water (10 mL). The aqueous layer was extracted with RINKAN (2 × 15 mL), and the combined organic layers were washed with water (15 mL) and brine (15 mL). The organic portion was dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The obtained crude material was purified by Isolera column chromatography (eluent: 10% SiO2 / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 29% (0.18 g, colorless gum-like substance). 1 H NMR (400 MHz, DMSO-d6): δ 7.33 (s, 1H), 7.17-7.05 (m, 3H), 6.72-6.56 (m, 2H), 5.91-5.89 (m, 1H), 4.51-4.49 (m, 1H), 4.32-4.27 LCMS: (Method B) 509.0 (M + +H), Rt. 2.57 minutes, 99.63% (max).

[0407] Intermediate 56 Methyl 3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoate and Methyl 3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoate

[0408] [ka]

[0409] Stereoisomers 1 and 2 of the title compound were prepared from enantiomer 1 (0.3 g) and enantiomer 2 (0.3 g) of intermediate 9, respectively, following the same procedure as described for intermediate 55. The absolute configurations of the two stereoisomers are unknown. Stereoisomer 1: Yield: 47.1% (0.18 g, brown solid). 1 H-NMR (400 MHz, CDCl3): δ 7.39 (s, 1H), 7.29-7.20 (m, 2H), 6.98 (s, 1H), 6.83-6.78 (m, 1H), 6.67-6.65 (m, 2H), 4.60-4.59 (m, 1H), 4.44-4.42 (m, 2H), 4.04-4.00 (m, 2H), 3.90-3.85 (m, 3H), 3.26-3.24 (m, 1H), 2.99-2.90 (m, 1H), 2.58 (s, 3H), 2.33 (s, 3H), 1.49-1.24 (m, 6H), 0.98-0.94 (m, 3H). LCMS: (Method A) 509.1 (M + +H) Rt. 2.92 minutes, 98.11% (max). Stereoisomer 2: Yield: 44.8% (0.17 g, off-white solid). 1H-NMR (400 MHz, DMSO-d6): δ 7.39 (s, 1H), 7.29-7.21 (m, 2H), 6.98 (s, 1H), 6.85-6.83 (m, 1H), 6.68-6.67 (m, 2H), 4.60-4.58 (m, 1H), 4.46-4.42 (m, 2H), 4.04-4.00 (m, 2H), 3.90-3.85 (m, 3H), 3.26-3.24 (m, 1H), 2.98-2.91 (m, 1H), 2.58 (s, 3H), 2.33 (s, 3H), 1.49-1.24 (m, 6H), 0.98-0.94 (m, 3H). LCMS: (Method E) 508.9 (M + +H) Rt. 2.72 minutes, 98.85% (max).

[0410] Intermediate 57 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoate

[0411] [ka]

[0412] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-hydroxypropanoate (intermediate 55; 180 mg, 0.35 mmol) in DMF (2 mL) at 0°C, a suspension of sodium hydride (7.06 mg, 0.17 mmol) in DMF (2 mL) at 0°C was added dropwise, and the reaction mixture was stirred at room temperature for 10 minutes. Then, methyl iodide (109 mL, 1.76 mmol) in DMF (1 mL) was added dropwise at 0°C, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was quenched with dilute HCl (1.5 N, 1 mL), diluted with water (5 mL), and the aqueous layer was extracted with SiO2 (2 × 10 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered, concentrated under vacuum, and the resulting crude material was purified by Isolera column chromatography (eluent: 20-30% Â₂-PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 31.4% (55 mg, brown solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.34 (s, 1H), 7.15 (t, J = 7.6 Hz, 2H), 7.13 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.44-4.42 (m, 1H), 4.37-4.35 (m, 2H), 4.00-3.95 (m, 1H), 3.73-3.73 (m, 1H), 3.43 (s, 3H), 3.41 (s, 3H), 3.20-3.19 (m, 1H), 2.37 (s, 3H), 2.28 (s, 3H), 1.36-1.34 (m, 2H), 1.27-1.24 (m, 4H), 0.9 (t, J = 6.8 Hz, 3H). LCMS: (Method E) 522.8 (M + +H), Rt. 2.87 minutes, 95.53% (max).

[0413] Intermediate 58 Methyl 3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoate and Methyl 3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoate

[0414] [ka]

[0415] Stereoisomers 1 and 2 of the title compound were prepared from stereoisomer 1 (0.25 g) and stereoisomer 2 (0.24 g), respectively, of intermediate 56, following the same procedure as described for intermediate 57. The absolute configurations of the two stereoisomers are unknown. Stereoisomer 1: Yield: 54.9% (0.15g, white solid). 1 H-NMR (400 MHz, CDCl3): δ 7.39 (s, 1H), 7.22-7.20 (m, 2H), 6.98 (s, 1H), 6.83-6.78 (m, 1H), 6.67-6.65 (m, 2H), 4.44-4.38 (m, 2H), 427-4.25 (m,1H), 4.09-4.04 (m, 2H), 3.87-3.80 (m, 5H), 3.61 (s, 3H), 3.23 (s, 1H), 2.57 (s, 3H), 2.33 (s, 3H), 1.75-1.70 (m, 1H), 1.58 (s, 3H), 1.50-1.28 (m, 3H). LCMS: (Method B) 523.1(M + +H) Rt.2.71 min, 94.97% (max). Stereoisomer 2: Yield: 38.6% (0.1 g, white solid). LCMS: (Method B) 523.0(M + +H)Rt.2.71 minutes, 95.14% (maximum).

[0416] Intermediate 59 Methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-ethoxypropanoate

[0417] [ka]

[0418] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-hydroxypropanoate (intermediate 55; 140 mg, 0.28 mmol) in DMF (3 mL) at 0°C, sodium hydride (5.5 mg, 0.14 mmol) was added, and the reaction mixture was stirred for 5 minutes. Then, ethyl iodide (0.11 mL, 1.38 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete (monitored by TLC), the reaction mixture was quenched with dilute HCl (1.5 N, 1 mL), and the aqueous layer was extracted with butyl (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude substance was purified by Isolera column chromatography (eluent: 30-45% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 20% (0.03 g, off-white gum-like substance). LCMS: (Method E) 537.0(M + +H) Rt.3.12 minutes, 73.10% (max).

[0419] Intermediate 60 Methyl 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2-hydroxypropanoate

[0420] [ka]

[0421] To a stirred solution of 3-butyl-8-hydroxy-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (0.2 g, 0.51 mmol) in DMF (5 mL) at 0°C, methyloxirane-2-carboxylate (0.16 g, 1.53 mmol) and Cs2CO3 (0.33 g, 1.02 mmol) were added, and the reaction mixture was stirred at room temperature for 16 hours. Since TLC showed incomplete conversion, further methyloxirane-2-carboxylate (0.16 g, 1.53 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. Although TLC showed that not all of the starting material was consumed, the reaction mixture was quenched with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with SiO2 (2 × 15 mL). The combined organic layers were washed with water (5 mL) and brine (10 mL) and dried over anhydrous Na2SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude substance was purified by Isolera column chromatography (eluent: 40% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 67% (0.17 g, brown gum-like substance). 1 H NMR (400 MHz, DMSO-d6): δ 7.42 (s, 1H), 7.28 (t, J = 6.04 Hz, 2H), 7.17 (s, 1H), 6.68 (t, J = 7.32 Hz, 1H), 6.55 (d, J = 8.04 Hz, 2H), 5.91 (m, 1H), 4.52-4.49 (m, 1H), 4.37-4.31 (m, 2H), 4.29-4.26 (m, 1H), 3.72 (s, 3H), 3.69-3.68 (m, 1H), 3.34 -3.32 (m,1H), 3.18-3.01 (m, 1H), 2.34 (s, 3H), 1.39-1.18 (m, 7H), 0.92-0.89 (m, 3H). LCMS: (Method E) 494.1 (M + +H) Rt. 2.44 minutes, 95.67% (max).

[0422] Intermediate 61 3-Butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide

[0423] [ka]

[0424] To a stirred solution of 7-bromo-3-butyl-5-(4-fluorophenyl)-8-methoxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 28; 0.500 g, 1.06 mmol) in NMP (4 mL), sodium ethanethiolate (0.45 g, 5.30 mmol) was added, and the reaction mixture was heated at 100 °C for 16 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was diluted with water (20 mL), and the aqueous layer was extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), and the organic portion was dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 30-50% ethyl acetate / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 86% (0.4g, yellowish solid). LCMS: (Method A) 439.1(M + +H) Rt.2.69 minutes, 54.66% (max).

[0425] Intermediate 62 Methyl 3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoate

[0426] [ka]

[0427] To a stirred solution of 3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-8-hydroxy-2-methyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine 1,1-dioxide (intermediate 61; 100 mg, 0.23 mmol) in DMF (1 mL), Cs2CO3 (153 mg, 0.47 mmol) was added, and the reaction mixture was stirred at room temperature for 10 minutes. Then, methyloxirane-2-carboxylate (68.4 mg, 0.69 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 24 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 2 mL), and the aqueous layer was extracted with RINKAN (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude substance was purified by Isolera column chromatography (eluent: 0-20% Â1 / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 79.6% (55 mg, white solid). LCMS: (Method B) 541.2(M + +H)Rt.2.65 minutes, 79.63% (max).

[0428] (Example 1) 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0429] [ka]

[0430] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate (intermediate 10; 0.15 g, 0.28 mmol) in a mixture of 1,4-dioxane and water (3:2; 5 mL) at 0°C, lithium hydroxide (24 mg, 0.50 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 7% (10 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.46 (s, 1H), 7.28 (s, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.05 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), 4.12 (s, 2H), 4.08-3.92 (m, 1H), 3.92-3.82 (m, 1H), 3.25-3.12 (m, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.70-1.60 (m, 1H), 1.58-1.42 (m, 1H), 1.42-1.32 (m, 4H), 1.28-1.25 (m, 6H), 0.9 (t, J = 7.2 Hz, 3H). LCMS: (Method K) 506.9 (M + +H), Rt. 2.85 min, 95.20% (max). HPLC: (Method E) Rt. 5.85 min, 97.92% (max).

[0431] (Example 2) (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid and (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0432] [ka]

[0433] To a stirred solution of enantiomer 1 (intermediate 11; 80 mg, 0.06 mmol) of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoate in a mixture of 1,4-dioxane and water (3:2; 5 mL) at 0°C, lithium hydroxide (15 mg, 0.11 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by preparative HPLC (Method A) to obtain enantiomer 1 of the title compound. Starting with 0.4 g of enantiomer 2 of intermediate 11, enantiomer 2 of the title compound was obtained by following the same procedure. The resulting crude product was purified by preparative HPLC (Method B) to obtain the title compound. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 75% (15 mg, white solid). 1H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.28 (s, 1H), 7.16 (t, J = 7.6 Hz, 2H), 7.05 (, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.12 (s, 2H), 4.1-3.98 (m, 1H), 3.98-3.8 (m, 1H), 3.3-3.1 (m, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.65-1.64 (m, 1H), 1.51-1.49 (m, 1H), 1.28 (m, 10H), 0.94 - 0.90 (m, 3H). LCMS: (Method K) 507.0 (M + +H), Rt. 3.04 points, 98.00% (maximum). HPLC: (Method E) Rt. 6.02 points, 99.04% (maximum). Chlorine purity: (Method D) Rt. 1.90 points, 100.00% (maximum). Enomax 2: Yield: 13% (50 mg, Enotomo solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.46 (s, 1H), 7.28 (s, 1H), 7.16 (t, J = 7.6 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.12 (s, 2H), 4.1-3.98 (m, 1H), 3.98-3.8 (m, 1H), 3.25-3.1 (bs, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.7-1.45 (m, 2H), 1.4-1.2 (m, 10H), 0.94-0.92 (m, 3H). LCMS: (Method H) 507.0 (M + +H), Rt. 2.82, 96.15% (maximum). HPLC: (Method D) Rt. 5.94, 95.57% (maximum). Chlorine purity: (Method D) Rt. 2.61, 97.52% (maximum).

[0434] (Example 3) 1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0435] [ka]

[0436] To a stirred solution of ethyl 1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 12; 0.12 g, 0.23 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL) at 0°C, lithium hydroxide (10.79 mg, 0.45 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude substance was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 22% (25 mg, white solid). 1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 7.28 (s, 1H), 7.16 (t, J = 8.4 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.27 (dd, J = 3.6, 10.0 Hz, 2H), 4.04-3.99 (m, 1H), 3.90 (bs, 1H), 3.15 (bs, 1H), 2.40 (s, 3H), 2.29 (s, 3H), 1.65-1.62 (m, 1H), 1.51-1.50 (m, 1H), 1.47-1.45 (m, 4H), 1.24-1.23 (m, 2H), 1.15-1.12 (m, 2H), 0.94-0.92 (m, 3H). LCMS: (Method K) 505.3 (M + +H), Rt. 2.76 min, 99.10% (max). HPLC: (Method E) Rt. 5.70 min, 98.59% (max).

[0437] (Example 4) (S)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid and (R)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0438] [ka]

[0439] To a stirred solution of enantiomer 1 (intermediate 13; 0.12 g, 0.23 mmol) of ethyl 1,4-dioxane and water (3:2; 5 mL), lithium hydroxide (10.79 mg, 0.45 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL). The aqueous layer was extracted with ethyl acetate (2 × 10 mL), and the combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude substance was purified by preparative HPLC (Method A) to obtain the title compound. Starting with 0.13 g of enantiomer 2 of intermediate 13, enantiomer 2 of the title compound was obtained by following the same procedure. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 26% (30 mg, white solid). 1 H NMR (400 MHz, DMSO-d6) δ 12.47 (s, 1H), 7.28 (s, 1H), 7.16 (t, J = 8.4 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.0 Hz, 2H), 4.28 - 4.26 (m, 2H), 4.02 (m, 1H), 3.89 (bs, 1H), 3.47 (bs, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.63-1.62 (m, 1H), 1.51-1.50 (m, 1H), 1.36-1.35 (m, 4H), 1.23-1.22 (m, 2H), 1.10-1.09 (m, 2H), 0.94-0.92 (m, 3H). LCMS: (Method K) 505.0 (M ++H), Rt. 3.01 min, 96.72% (maximum). HPLC: (Method E) Rt. 5.61 min, 97.75% (maximum). Chiral purity: (Method H) Rt. 3.19 min, 99.69% (maximum). Enantiomer 2: Yield: 20% (25 mg, white solid). 1 H NMR (400 MHz, DMSO-d6) δ 12.44 (s, 1H), 7.28 (s, 1H), 7.16 (t, J = 7.2 Hz, 2H), 7.05 (s, 1H), 6.71 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.27 (m, 2H), 4.02 (m, 1H), 3.90 (bs, 1H), 3.21 (bs, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.65-1.62 (m, 1H), 1.50-1.49 (m, 1H), 1.37-1.35 (m, 4H), 1.24-1.23 (m, 2H), 1.11-1.10 (m, 2H), 0.94-0.92 (m, 3H). LCMS: (Method K) 505.0 (M + +H), Rt. 3.01 min, 97.62% (maximum). HPLC: (Method E) Rt. 5.61 min, 98.84% (maximum). Chiral purity: (Method H) Rt. 4.18 min, 99.55% (maximum).

[0440] (Example 5) 3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0441] [ka]

[0442] To a stirred solution of methyl 3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2,2-dimethylpropanoate (intermediate 15; 0.16 g, 0.30 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL) at 0°C, lithium hydroxide (0.02 g, 0.60 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude substance was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 38% (60 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.29 (s, 1H), 7.16 (t, J = 7.6 Hz, 2H), 7.08 (s, 1H), 6.71 (t, J = 7.6 Hz, 1H), 6.59 (d, J = 7.6 Hz, 2H), 4.11 (s, 2H), 4.05-3.85 (m, 2H), 3.25-3.15 (m, 1H), 3.02-2.8 (m, 2H), 2.60 (m, 1H), 2.47 (s, 3H), 1.7-1.45 (m, 2H), 1.42-1.3 (m, 5H), 1.28 (m, 1H), 1.27 (s, 6H), 1.21 (t, J = 7.60 Hz, 3H), 0.92 (t, J = 6.8 Hz, 3H). LCMS: (Method B) 521.0 (M + +H), Rt. 2.05 min, 96.18% (max). HPLC: (Method E) Rt. 5.94 min, 97.88% (max).

[0443] (Example 6) (S)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid and (R)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0444] [ka]

[0445] Two enantiomers of racemic 3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid (Example 5; 50 mg, 0.09 mmol) were separated using a chiral SFC instrument (Method F). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 37% (20 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.29 (s, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.08 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.59 (d, J = 8.0 Hz, 2H), 4.11 (s, 2H), 4.05-3.83 (m, 2H), 3.28-3.12 (m, 1H), 2.95-2.82 (m, 2H), 2.47 (s, 3H), 1.68-1.55 (m, 1H), 1.55-1.45 (m, 1H), 1.42-1.32 (m, 4H), 1.32-1.22 (m, 6H), 1.20 (t, J = 7.20 Hz, 3H), 0.95-0.88 (m, 3H). LCMS: (Method K) 521.2 (M+ +H), Rt. 3.13 min, 98.08% (maximum). HPLC: (Method E) Rt. 5.91 min, 91.39% (maximum). Chiral SFC: (Method H) Rt. 1.72 min, 95.81% (maximum). Enantiomer 2: Yield: 23% (15 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.29 (s, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.08 (s, 1H), 6.70 (t, J = 7.6 Hz, 1H), 6.59 (d, J = 8.0 Hz, 2H), 4.11 (s, 2H), 4.08-3.80 (m, 2H), 3.28-3.12 (m, 1H), 2.92-2.82 (m, 2H), 2.47 (s, 3H), 1.68-1.58 (m, 1H), 1.58-1.45 (m, 1H), 1.42-1.32 (m, 4H), 1.32-1.22 (m, 6H), 1.2 (t, J = 7.2 Hz, 3H), 0.95-0.88 (m, 3H). LCMS: (Method D) 521.0 (M + +H), Rt. 3.13 min, 94.38% (maximum). HPLC: (Method E) Rt. 5.93 min, 94.93% (maximum). Chiral SFC: (Method H) Rt. 2.30 min, 95.03% (maximum).

[0446] (Example 7) 1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0447] [ka]

[0448] To a stirred solution of ethyl 1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 16; 0.05 g, 0.091 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL) at 0°C, lithium hydroxide (4.38 mg, 0.18 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude substance was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 30% (15 mg, white solid). 1 H NMR (400 MHz, DMSO-d6) δ 12.46 (s, 1H), 7.28 (s, 1H), 7.15 (t, J = 7.6 Hz, 2H), 7.08 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.29-4.20 (m, 2H), 4.04-4.00 (m, 1H), 3.88 (m, 1H), 3.22 (m, 1H), 2.88 (m, 2H), 2.46 (s, 3H), 1.65-1.60 (m, 1H), 1.54-1.49 (m, 1H), 1.35 (m, 4H), 1.24-1.18 (m, 5H), 1.09 (m, 2H), 0.93 (m, 3H). LCMS: (Method K) 519.2 (M + +H), Rt. 2.83 min, 94.83% (max). HPLC: (Method E) Rt. 5.79 min, 94.74% (max).

[0449] (Example 8) (S)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid and (R)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0450] [ka]

[0451] Two enantiomers of racemic 1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid (Example 7; 60 mg, 0.12 mmol) were separated using a chiral SFC instrument (Method H). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 24% (15 mg, off-white solid). 1H NMR (400 MHz, DMSO-d6): δ 12.43 (s, 1H), 7.28 (s, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.08 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.24 (m, 2H), 4.10-3.95 (m, 1H), 3.95-3.80 (m, 1H), 3.28-3.12 (m, 1H), 2.98-2.84 (m, 2H), 2.46 (s, 3H), 1.70-1.58 (m, 1H), 1.58-1.45 (m, 1H), 1.40–1.32 (m, 4H), 1.28–1.18 (m, 5H), 1.15–1.05 (m, 2H), 0.9 (t, J = 6.8 Hz, 3H). LCMS: (Method A) 519.2 (M + +H), Rt. 3.15 points, 97.05% (maximum). HPLC: (Method E) Rt. 5.94 points, 97.46% (maximum). KuraSFC: (Method K) Rt. 2.87 points, 99.75% (maximum). Enatoplast 2: Yield: 23% (15 mg, Enatoplast solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.43 (s, 1H), 7.28 (s, 1H), 7.15 (t, J = 7.6 Hz, 2H), 7.08 (s, 1H), 6.70 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.35-4.12 (m, 2H), 4.10-3.98 (m, 1H), 3.98-3.80 (m, 1H), 3.28-3.10 (m, 1H), 2.89 (m, 2H), 2.47 (s, 3H), 1.68-1.58 (m, 1H), 1.58-1.45 (m, 1H), 1.45–1.30 (m, 4H), 1.28–1.18 (m, 5H), 1.15–1.05 (m, 2H), 1.00–0.85 (m, 3H). LCMS: (Method A) 519.1 (M ++H), Rt. 2.70 min, 95.84% (maximum). HPLC: (Method E) Rt. 5.79 min, 94.28% (maximum). Chiral SFC: (Method K) Rt. 3.61 min, 99.46% (maximum).

[0452] (Example 9) 3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0453] [ka]

[0454] To a stirred solution of methyl 3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2,2-dimethylpropanoate (intermediate 21; 0.12 g, 0.23 mmol) in a mixture of 1,4-dioxane and water (3:2; 5 mL) at 0°C, lithium hydroxide (10.97 mg, 0.46 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 17% (20 mg, white solid). 1H NMR (400 MHz, DMSO-d6): δ 12.43 (s, 1H), 7.35 (s, 1H), 7.03-6.97 (m, 3H), 6.58-6.54 (m, 2H), 4.25-4.08 (m, 3H), 3.50-3.35 (m, LCMS: (Method A) 510.0 (M + +H), Rt. 3.03 min, 98.51% (max). HPLC: (Method E) Rt. 5.67 min, 99.12% (max).

[0455] (Example 10) 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0456] [ka]

[0457] To a stirred solution of ethyl 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 22; 0.1 g, 0.19 mmol) in a mixture of 1,4-dioxane and water (5:1, 6 mL) at 0°C, lithium hydroxide (8.94 mg, 0.373 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 15% (15 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.43 (s, 1H), 7.35 (s, 1H), 7.03-6.97 (m, 3H), 6.57-6.54 (m, 2H), 4.32-4.12 (m, 3H), 3.50-3.38 (m, LCMS: (Method A) 508.1 (M + +H), Rt. 2.96 min, 94.20% (max). HPLC: (Method E) Rt. 5.53 min, 94.35% (max).

[0458] (Example 11) 1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0459] [ka]

[0460] To a stirred solution of ethyl 1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 30;80 mg, 0.15 mmol) in a mixture of 1,4-dioxane and water (3:2, 5 mL) at 0°C, lithium hydroxide (6.96 mg, 0.29 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude substance was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 29% (22 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.27 (s, 1H), 7.10-6.82 (m, 3H), 6.72-6.48 (m, 2H), 4.25 (m, 2H), 4.05-3.92 (m, 1H), 3.92-3.80 (m, 1H), 3.28-3.10 (m, 1H), 2.45 (s, 3H), 2.34 (s, 3H), 1.68-1.55 (m, 1H), 1.55-1.42 (m, 1H), 1.42-1.28 (m, 4H), 1.28-1.18 (m, 2H), 1.18-1.02 (m, 2H), 1.00-0.82 (m, 3H). LCMS: (Method B) 523.0 (M + +H), Rt. 2.10 min, 98.06% (max). HPLC: (Method E) Rt. 5.75 min, 99.00% (max).

[0461] (Example 12) (S)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid and (R)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0462] [ka]

[0463] Two enantiomers of racemic 1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid (Example 11; 40 mg, 0.077 mmol) were separated using a chiral SFC instrument (Method A). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 25% (10 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.44 (s, 1H), 7.27 (s, 1H), 7.02-7.01 (m, 3H), 6.59 (m, 2H), 4.26 (m, 2H), 4.05-3.98 (m, 1H), 3.92-3.82 (m, 1H), 3.2-3.15 (m, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.68-1.55 (m, 1H), 1.55-1.48 (m, 1H), 1.4-1.3 (m, 4H), 1.25-1.18 (m, 2H), 1.12-1.05 (m, 2H), 0.98-0.88 (m, 3H). LCMS: (Method A) 523.1 (M ++H), Rt. 3.05 min, 97.58% (maximum). HPLC: (Method E) Rt. 5.66 min, 99.56% (maximum). Chiral SFC: (Method U) Rt. 2.37 min, 99.39% (maximum). Enantiomer 2: Yield: 36% (15 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.27 (s, 1H), 7.10-6.90 (m, 3H), 6.65-6.48 (m, 2H), 4.32-4.18 (m, 2H), 4.05-3.95 (m, 1H), 3.90-3.82 (m, 1H), 3.25-3.15 (m, 1H), 2.47 (s, 3H), 2.34 (s, 3H), 1.65-1.55 (m, 1H), 1.55-1.45 (m, 1H), 1.42-1.28 (m, 4H), 1.28-1.20 (m, 2H), 1.15-1.05 (m, 2H), 0.9 (t, J = 6.8 Hz, 3H). LCMS: (Method A) 523.1 (M + +H), Rt. 3.05 min, 96.30% (maximum). HPLC: (Method E) Rt. 5.62 min, 95.65% (maximum). Chiral SFC: (Method U) Rt. 2.93 min, 99.67% (maximum).

[0464] (Example 13) 3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0465] [ka]

[0466] To a stirred solution of methyl 3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoate (intermediate 31; 0.04 g, 0.074 mmol) in a mixture of 1,4-dioxane and water (5:1, 6 mL) at 0°C, lithium hydroxide (3.56 mg, 0.15 mmol) was added, and the reaction mixture was stirred at room temperature for 12 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude substance was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 25% (10 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.46 (s, 1H), 7.27 (s, 1H), 7.13-6.82 (m, 3H), 6.70-6.40 (m, 2H), 4.11 (s, 2H), 4.05-3.95 (m, 1H), 3.95-3.75 (m, 1H), 3.30-3.15 (m, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.72-1.55 (m, 1H), 1.55-1.42 (m, 1H), 1.40-1.30 (m, 4H), 1.30-1.25 (m, 6H), 0.95-0.88 (m, 3H). LCMS: (Method A) 524.8 (M + ), Rt. 2.74 min, 95.76% (max). HPLC: (Method E) Rt. 5.75 min, 96.44% (max).

[0467] (Example 14) (S)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid and (R)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid

[0468] [ka]

[0469] Two enantiomers of racemic 3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid (Example 13; 0.025 g, 0.143 mmol) were separated by chiral SFC (Method G). The substance was concentrated under vacuum at 40°C. The first elution fraction corresponds to enantiomer 1, and the second elution fraction corresponds to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 33.2% (0.025g, off-white solid). 1 H-NMR (400 MHz, DMSO-d6): δ 12.46 (s, 1H), 7.27 (s, 1H), 7.02-7.01 (m, 1H), 6.98-6.96 (m, 2H), 6.59-6.56 (m, 2H), 4.11 (s, 2H), 4.01-3.97 (m, 1H), 3.86 (s, 1H), 3.24-3.21 (m, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.60-1.41 (m, 2H), 1.35-1.34 (m, 4H), 1.27 (s, 6H), 0.93-0.91 (m, 3H). LCMS: (Method A) 525.1 (M ++H), Rt. 3.18 min, 99.48% (max). HPLC: (Method B) Rt. 5.88 min, 99.62% (max). Chiral HPLC: (Method G) Rt. 1.65 min, 100% (max) Enantiomer 2: Yield: 26.6% (0.020 g, off-white solid). 1 H-NMR (400 MHz, DMSO-d6): δ 12.46 (s, 1H), 7.27 (s, 1H), 7.02-7.01 (m, 1H), 6.98-6.96 (m, 2H), 6.59-6.57 (m, 2H), 4.11 (s, 2H), 4.01-3.97 (m, 1H), 3.87 (s, 1H), 3.24-3.23 (m, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.60 (s, 2H), 1.35 (s, 4H), 1.27-1.24 (m, 6H), 0.93-0.91 (m, 3H). LCMS: (Method A) 525.2 (M + +H), Rt. 3.17 min, 98.37% (maximum). HPLC: (Method B) Rt. 5.88 min, 99.71% (maximum). Chiral HPLC (Method G) Rt. 2.22 min, 99.76% (maximum)

[0470] (Example 15) 1-(((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0471] [ka]

[0472] To a stirred solution of ethyl 1-(((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 41; 0.05 g, 0.09 mmol) in a mixture of 1,4-dioxane and water (5:1, 6 mL) at 0°C, lithium hydroxide (4.50 mg, 0.19 mmol) was added, and the reaction mixture was stirred at room temperature for 12 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The resulting crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 20% (10 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.32 (s, 1H), 7.25 (d, J = 9.2 Hz, 1H), 7.14 (t, J = 8.4 Hz, 2H), 7.08 (s, 1H), 6.69 (t, J = 7.2 Hz, 1H), 6.57 (d, J = 8.4 Hz, 2H), 4.45-4.30 (m, 1H), 4.30-4.15 (m, 2H), 3.52-3.42 (m, 1H), 2.95-2.80 (m, 3H), 1.70-1.52 (m, 2H), 1.52-1.38 (m, 4H), 1.35-1.28 (m, 2H), 1.25-1.22 (m, 3H), 1.12-1.08 (m, 2H), 0.9 (t, J = 7.2 Hz, 3H). LCMS: (Method A) 505.1 (M + +H), Rt. 2.52 min, 92.00% (max). HPLC: (Method E) Rt. 5.55 min, 92.07% (max).

[0473] (Example 16) 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0474] [ka]

[0475] Lithium hydroxide (2.68 mg, 0.11 mmol) was added to a stirred solution of ethyl 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 45; 0.03 g, 0.06 mmol) in a mixture of 1,4-dioxane and water (5:1, 6 mL) at 0°C, and the reaction mixture was stirred at room temperature for 12 hours. After the reaction was completed (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 33% (10 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.51 (s, 1H), 7.36 (s, 1H), 7.32 (d, J = 9.6 Hz, 1H), 7.12-6.98 (m, 3H), 6.72-6.55 (m, 2H), 4.42-4.22 LCMS: (Method A) 509.1 (M) + +H), Rt. 2.41 min, 91.15% (max). HPLC: (Method E) Rt. 5.40 min, 93.38% (max).

[0476] (Example 17) (S)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid and (R)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0477] [ka]

[0478] Two enantiomers of racemic 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid (Example 16; 0.1 g, 0.19 mmol) were separated using a chiral SFC instrument (Method M). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 40% (40 mg, off-white solid). 1H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.30 (s, 1H), 7.26 (d, J = 9.2 Hz, 1H), 7.05-6.95 (m, 3H), 6.62-6.48 (m, 2H), 4.38-4.15 (m, 3H), 3.48-3.40 (m, 1H), 2.95-2.78 (m, 1H), 2.33 (s, 3H), 1.65-1.42 (m, 2H), 1.42-1.28 (m, 4H), 1.28-1.20 (m, 2H), 1.15-1.05 (m, 2H), 0.90 (t, J = 7.20 Hz, 3H). LCMS: (Method K) 509.2 (M + +H), Rt. 2.40 minutes, 98.25% (maximum). HPLC: (Method E) Rt. 5.51 minutes, 99.22% (maximum). SFC: (Method G) Rt. 1.41 minutes, 100% (maximum). Enomax 2: Yield: 40% (40 mg, Enotomo solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.30 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.10-7.92 (m, 3H), 6.65-6.48 (m, 2H), 4.38-4.18 (m, 3H), 3.52-3.42 (m, 1H), 2.95-2.78 (m, 1H), 2.33 (s, 3H), 1.65-1.45 (m, 2H), 1.45-1.30 (m, 4H), 1.28-1.20 (m, 2H), 1.15-1.05 (m, 2H), 0.90 (t, J = 6.80 Hz, 3H). LCMS: (Method B) 508.9 (M + +H), Rt. 1.88 points, 96.57% (maximum). HPLC: (Method E) Rt. 5.51 points, 98.55% (maximum). KuraSFC: (Method G) Rt. 2.13 points, 99.05% (maximum).

[0479] (Example 18) 1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0480] [ka]

[0481] Lithium hydroxide (6.09 mg, 0.25 mmol) was added to a stirred solution of ethyl 1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylate (intermediate 47; 0.07 g, 0.13 mmol) in a mixture of 1,4-dioxane and water (5:1, 6 mL) at 0°C, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 3 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 58% (40 mg, white solid). 1H NMR (400 MHz, DMSO-d6): δ 12.45 (s, 1H), 7.31 (s, 1H), 7.26 (d, J = 9.2 Hz, 1H), 7.05 (s, 1H), 6.99 (t, J = 8.8 Hz, 2H), 6.68-6.45 (m, 2H), 4.42-4.22 (m, 2H), 4.22-4.10 (m, 1H), 3.50-3.40 (m, 1H), 2.87 (m, 3H), 1.65-1.52 (m, 1H), 1.48-1.22 (m, 7H), 1.22-1.18 (m, 3H), 1.15-1.05 (m, 2H), 0.90 (t, J = 7.20 Hz, 3H). LCMS: (Method A) 521.3 (M + -H), Rt. 3.02 min, 95.10% (max). HPLC: (Method E) Rt. 5.61 min, 97.11% (max).

[0482] (Example 19) (S)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid and (R)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid

[0483] [ka]

[0484] Two enantiomers of racemic 1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid (Example 18; 30 mg, 0.06 mmol) were separated using a chiral SFC instrument (Method M). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 30% (9 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.43 (s, 1H), 7.31 (s, 1H), 7.26 (d, J = 9.6 Hz, 1H), 7.05 (s, 1H), 6.99 (t, J = 8.8 Hz, 2H), 6.65-6.52 (m, 2H), 4.38-4.12 (m, 3H), 3.42-3.38 (m, 1H), 2.92-2.85 (m, 3H), 1.65-1.52 (m, 2H), 1.45-1.38 (m, 2H), 1.25-1.20 (m, 3H), 1.20-1.18 (m, 3H), 1.12-1.02 (m, 3H), 0.95-0.88 (m, 3H). LCMS: (Method A) 521.2 (M + -H), Rt. 3.01 min, 95.40% (maximum). HPLC: (Method E) Rt. 5.63 min, 99.21% (maximum). Chiral SFC: (Method G) Rt. 2.2 min, 99.74% (maximum). Enantiomer 2: Yield: 23% (7 mg, off-white solid). 1H NMR (400 MHz, DMSO-d6): δ 12.44 (s, 1H), 7.31 (s, 1H), 7.26 (d, J = 9.6 Hz, 1H), 7.05 (s, 1H), 6.99 (t, J = 8.8 Hz, 2H), 6.68-6.50 (m, 2H), 4.35-4.15 (m, 3H), 3.42-3.38 (m, 1H), 2.92-2.85 (m, 3H), 1.65-1.55 (m, 1H), 1.50-1.32 (m, 4H), 1.28-1.15 (m, 6H), 1.12-1.08 (m, 2H), 0.95-0.85 (m, 3H). LCMS: (Method A) 521.1 (M + -H), Rt. 3.00 min, 97.25% (maximum). HPLC: (Method E) Rt. 5.70 min, 97.41% (maximum). Chiral SFC: (Method G) Rt. 3.45 min, 99.49% (maximum).

[0485] (Example 20) 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid

[0486] [ka]

[0487] To a stirred solution of ethyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoate (intermediate 48; 0.1 g, 0.18 mmol) in a mixture of 1,4-dioxane and water (3:1, 4 mL) at 0°C, lithium hydroxide (8.83 mg, 0.37 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum. The obtained crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 14% (14 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.33 (s, 1H), 7.15 (t, J = 8.4 Hz, 2H), 7.06 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.51 (t, J = 14.4 Hz, 2H), 4.08-3.98 (m, 1H), 3.95-3.85 (m, 1H), 3.25-3.15 (m, 1H), 2.46 (s, 3H), 2.36 (s, 3H), 1.68-1.58 (m, 1H), 1.55-1.45 (m, 1H), 1.40-1.28 (m, 4H), 0.95-0.88 (m, 3H). LCMS: (Method K) 515.2 (M + +H), Rt. 2.46 min, 95.16% (max). HPLC: (Method E) Rt. 5.57 min, 96.09% (max).

[0488] (Example 21) (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid and (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid

[0489] [ka]

[0490] Two enantiomers of racemic 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid (Example 20; 40 mg, 0.08 mmol) were separated using a chiral SFC instrument (Method F). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 12% (5 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.34 (s, 1H), 7.15 (t, J = 8.4 Hz, 2H), 7.06 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.52 (t, J = 14.0 Hz, 2H), 4.05-3.95 (m, 1H), 3.95-3.80 (m, 1H), 3.25-3.15 (m, 1H), 2.46 (s, 3H), 2.36 (s, 3H), 1.68-1.58 (m, 1H), 1.55-1.45 (m, 1H), 1.42-1.32 (m, 4H), 0.98-0.88 (m, 3H). LCMS: (Method B) 515.0 (M ++H), Rt. 2.09 min, 94.41% (maximum). HPLC: (Method E) Rt. 5.52 min, 98.13% (maximum). Chiral SFC: (Method H) Rt. 3.26 min, 100% (maximum). Enantiomer 2: Yield: 13% (5 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.34 (s, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.06 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.50 (t, J = 14.4 Hz, 2H), 4.05-3.98 (m, 1H), 3.95-3.82 (m, 1H), 3.25-3.12 (m, 1H), 2.46 (s, 3H), 2.36 (s, 3H), 1.68-1.58 (m, 1H), 1.50-1.45 (m, 1H), 1.42-1.30 (m, 4H), 0.92 (t, J = 6.80 Hz, 3H). LCMS: (Method B) 515.1 (M + +H), Rt. 2.09 min, 93.89% (maximum). HPLC: (Method E) Rt. 5.53 min, 99.76% (maximum). Chiral SFC: (Method H) Rt. 5.93 min, 100% (maximum).

[0491] (Example 22) 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid

[0492] [ka]

[0493] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)-2-methoxy-2-methylpropanoate (intermediate 52; 0.13 g, 0.24 mmol) in a mixture of 1,4-dioxane and water (2:1, 3 mL) at 0°C, lithium hydroxide (0.02 g, 0.48 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL) and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 25% (30 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 13.0 (s, 1H), 7.32 (s, 1H), 7.16 (t, J = 7.6 Hz, 2H), 7.05 (s, 1H), 6.71 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.36 (m, 1H), 4.27 (m, 1H), 4.02 (m, 1H), 3.95-3.85 (m, 1H), 3.31 (s, 3H), 3.25-3.15 (bs, 1H), 2.46 (s, 3H), 2.34 (s, 3H), 1.7-1.3 (m, 9H), 0.94-0.92 (m, 3H). LCMS: (Method K) 522.9 (M + +H), Rt. 2.94 min, 98.59% (max). HPLC: (Method E) Rt. 5.54 min, 98.79% (max).

[0494] (Example 23) 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid

[0495] [ka]

[0496] Starting with 0.05 g of intermediate 53, the title compound was obtained by following the same procedure as described in Example 21. After workup of the reaction mixture, the crude product was purified by Isolera column chromatography (eluent: 10-15% Â / PE; silica gel: 230-400 mesh) to obtain the title compound. The absolute configuration of the compound is unknown. Yield: 50% (25 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 13.0 (s, 1H), 7.33 (s, 1H), 7.16 (t, J = 7.2 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.36 (t, J = 9.6 Hz, 1H), 4.27 (t, J = 8.0 Hz, 1H), 4.02 (m, 1H), 3.89-3.88 (m, 1H), 3.30 (s, 3H), 3.25-3.15 (m, 1H), 2.46 (s, 3H), 2.35 (s, 3H), 1.7-1.6 (m, 1H), 1.6-1.42 (m, 4H), 1.42-1.28 (m, 4H), 1.0-0.85 (m, 3H). LCMS: (Method K) 522.9 (M + +H), Rt. 2.73 min, 99.48% (max). HPLC: (Method E) Rt. 5.51 min, 99.35% (max).

[0497] (Example 24) (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid and (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid (individual diastereomers)

[0498] [ka]

[0499] Diastereoisomers 1 and 2 of the title compound were prepared from diastereoisomer 1 (95 mg) and diastereoisomer 2 (90 mg), respectively, of intermediate 54, following the same procedure as described in Example 21. After workup of the reaction mixture, the crude product was purified by Isolera column chromatography (eluent: 4% MeOH / DCM; silica gel: 230-400 mesh) to obtain the title compound. The absolute configurations of the two diastereomers are unknown. Diastereoisomer 1: Yield: 57% (55 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.33 (s, 1H), 7.16 (t, J = 7.2 Hz, 2H), 7.05 (s, 1H), 6.71 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.42-4.32 (m, 1H), 4.3-4.2 (m, 1H), 4.1-3.8 (m, 2H), 3.31 (s, 3H), 3.25-3.15 (m, 1H), 2.46 (s, 3H), 2.35 (s, 3H), 1.7-1.58 (m, 1H), 1.55 - 1.28 (m, 8H), 0.95-0.88 (m, 3H). LCMS: (Method K) 523.3 (M +(+H), Rt. 2.71 min, 98.96% (maximum). HPLC: (Method E) Rt. 5.45 min, 97.51% (maximum). Chiral purity: (Method H) Rt. 9.02 min, 98.10% (maximum). Diastereoisomer 2: Yield: 49% (45 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 13.08 (s, 1H), 7.33 (s, 1H), 7.16 (t, J = 8.0 Hz, 2H), 7.06 (s, 1H), 6.71 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.4 Hz, 2H), 4.42-4.32 (m, 1H), 4.3-4.18 (m, 1H), 4.1-3.85 (m, 2H), 3.30 (s, 3H), 3.25-3.15 (m, 1H), 2.47 (s, 3H), 2.35 (s, 3H), 1.7-1.45 (m, 5H), 1.45-1.28 (m, 4H), 0.95-0.88 (m, 3H). LCMS: (Method K) 523.3 (M + +H), Rt. 2.71 min, 98.20% (maximum). HPLC: (Method E) Rt. 5.45 min, 98.01% (maximum). Chiral purity: (Method H) Rt. 7.83 min, 98.92% (maximum).

[0500] (Example 25) 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid

[0501] [ka]

[0502] To a stirred solution of 3-butyl-8-hydroxy-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (0.2 g, 0.05 mmol) in THF (5 mL), potassium tert-butoxide (0.063 g, 0.06 mmol) and oxetan-2-one (0.04 g, 0.06 mmol) were added, and the reaction mixture was stirred at 50°C for 3 hours. Since TLC showed incomplete conversion, further oxetan-2-one (0.04 g, 0.06 mmol) was added, and the reaction mixture was stirred at 50°C for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (5 mL, 1.5 N HCl), and the aqueous layer was extracted with ELISA (2 × 15 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered, concentrated under vacuum, and the resulting substance was purified by Isolera column chromatography (eluent: 20% siRNA / PE; silica gel: 230-400 mesh) to obtain the title compound. Yield: 31% (75 mg, white solid). 1 H-NMR (400 MHz, DMSO-d6): δ 7.51 (s, 1H), 7.18 (t, J = 8.00 Hz, 2H), 7.06 (s, 1H), 6.75 (t, J = 7.20 Hz, 1H), 6.67 (d, J = 8.00 Hz, 2H), 4.40 (s, 2H), 4.35-4.31 (m, 1H), 3.44-3.40 (m, 1H), 3.14-3.05 (m, 2H), 2.87-2.85 (m, 2H), 2.45 (s, 1H), 2.33 (s, 3H), 1.47-1.40 (m, 6H), 1.00-0.89 (m, 3H). LCMS: (Method E) 464.1 (M + +H) Rt. 4.81 min, 95.14% (max). HPLC: (Method B) Rt. 5.36 min, 95.27% (max).

[0503] (Example 26) (S)-3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid and (R)-3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid

[0504] [ka]

[0505] Two enantiomers of racemic 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid (Example 25; 68 mg, 0.15 mmol) were separated by chiral SFC (Method D). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponded to enantiomer 1, and the second eluted fraction corresponded to enantiomer 2. The absolute configurations of the two enantiomers are unknown. Enantiomer 1: Yield: 35% (0.024g, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 12.47 (s, 1H), 7.39 (s, 1H), 7.15 (t, J = 7.60 Hz, 2H), 7.06 (s, 1H), 6.68 (t, J = 7.20 Hz, 1H), 6.56 (d, J = 8.00 Hz, 2H), 4.34-4.21 (m, 3H), 3.34 (s, 1H), 3.14 (s, 1H), 3.10-3.04 (m, 1H), 2.72 (s, 2H), 2.34 (s, 4H), 1.40-1.30 (m, 6H), 0.93-0.89 (m, 3H). LCMS: (Method A) 464.1 (M + (+H) Rt. 2.54 min, 94.45% (maximum). HPLC: (Method B) Rt. 5.36 min, 97.37% (maximum). Chiral HPLC: (Method D) Rt. 2.07 min, 100% (maximum). Enantiomer 2: Yield: 12% (0.008g, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.39 (s, 1H), 7.17-7.15 (m, 2H), 7.06 (s, 1H), 6.68 (t, J = 7.20 Hz, 1H), 6.55 (d, J = 8.00 Hz, 2H), 4.34-4.30 (m, 3H), 3.44-3.41 (m, 1H), 3.40-3.33 (m, 1H), 3.29-3.23 (m, 1H), 2.76-2.73 (m, 2H), 2.34 (s, 4H), 1.40-1.30 (m, 6H), 0.93-0.89 (m, 3H). LCMS: (Method A) 464.2 (M + +H) Rt. 2.55 min, 99.61% (maximum). HPLC: (Method B) Rt. 5.35 min, 99.92% (maximum). Chiral HPLC: (Method D) Rt. 3.28 min, 99.26% (maximum).

[0506] (Example 27) 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-ethoxypropanoic acid

[0507] [ka]

[0508] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-ethoxypropanoate (intermediate 59; 30 mg, 0.06 mmol) in 1,4-dioxane (1 mL) at 0°C, lithium hydroxide (4.69 mg, 0.11 mmol) was added, and the reaction mixture was stirred at room temperature for 30 minutes. After the reaction (monitored by TLC) was complete, the reaction mixture was quenched with dilute HCl (1.5 N, 1 mL), and the aqueous layer was extracted with RINKAN (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), and dried over anhydrous Na₂SO₄. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by preparative HPLC (Method A) to obtain the title compound. Yield: 13% (4 mg, off-white solid). 1 H NMR (400 MHz, DMSO-d6): δ 13.21 (s, 1H), 7.38 (s, 1H), 7.15 (t, J = 8.00 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 4.00 Hz, 1H), 6.58 (d, J = 6.80 Hz, 2H), 4.43-4.41 (m, 1H), 4.33-4.25 (m, 2H), 4.03-3.87 (m, 2H), 3.74-3.70 (m, 1H), 3.58-3.54 (m, 1H), 3.23-3.11 (m, 1H), 2.51 (s, 3H), 2.34 (s, 3H), 1.61-1.48 (m, 2H), 1.36-1.30 (m, 4H), 1.17-1.13 (m, 3H), 0.94-0.90 (m, 3H). LCMS: (Method E) 523.0 (M + +H) Rt. 2.89 min, 95.56% (max). HPLC: (Method B) Rt. 5.59 min, 93.21% (max).

[0509] (Example 28) 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2-hydroxypropanoic acid

[0510] [ka]

[0511] To a stirred solution of methyl 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2-hydroxypropanoate (intermediate 60; 0.17 g, 0.34 mmol) in 1,4-dioxane (2 mL) at 0°C, dilute HCl (6 N, 2 mL) was added dropwise, and the reaction mixture was heated at 80°C for 3 hours. After the reaction (monitored by TLC) was complete, the reaction mixture was diluted with water (5 mL), and the aqueous layer was extracted with ELISA (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), and the organic portion was dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude substance was purified by Isolera column chromatography (eluent: 3-10% MeOH in DCM; silica gel: 230-400 mesh) to obtain the title compound. Yield: 30% (50 mg, light brown solid). 1 H NMR (400 MHz, DMSO-d6): δ 7.42 (s, 1H), 7.14 (t, J = 8.00 Hz, 2H), 7.04 (s, 1H), 6.67 (t, J = 7.60 Hz, 1H), 6.55 (d, J = 8.00 Hz, 2H), 4.37-4.32 (m, 1H), 4.27-4.19 (m, 3H), 3.43-3.39 (m, 1H), 3.33-3.20 (m, 1H), 3.08-3.02 (m, 1H), 2.34 (s, 3H), 2.33-2.27 (m, 1H), 1.38-1.35 (m, 4H), 1.33-1.25 (m, 3H), 0.91-0.88 (m, 3H). LCMS: (Method E) 480.1 (M+ +H) Rt. 2.68 min, 98.95% (max). HPLC: (Method B) Rt. 4.91 min, 97.58% (max).

[0512] (Example 29) 3-((3-ethyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid

[0513] [ka]

[0514] To a stirred solution of 3-ethyl-8-hydroxy-7-(methylthio)-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine 1,1-dioxide (0.2 g, 0.55 mmol) in 5 mL of THF at 0°C, KO t Bu (0.07 g, 0.60 mmol) and oxetane-2-one (0.04 g, 0.60 mmol) were added, and the reaction mixture was stirred at 50°C for 3 hours. Since TLC showed incomplete conversion, further oxetane-2-one (0.04 g, 0.06 mmol) was added, and the reaction mixture was stirred at 50°C for 16 hours. After the reaction was complete, the reaction mixture was acidified with dilute HCl (1.5 N, 5 mL), and the aqueous layer was extracted with ethyl acetate (2 × 15 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), and dried over anhydrous sodium 2 SO4. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by Isolera column chromatography (eluent: 45% ethyl acetate: PE; silica gel: 230-400 mesh). The obtained substance was re-purified by preparative HPLC (Method A) to obtain the title compound. Yield: 6.2% (15 mg, light brown solid). 1H NMR (400 MHz, DMSO-d6): δ 7.39 (s, 1H), 7.17-7.13 (m, 2H), 7.06 (s, 1H), 6.68 (t, J = 7.20 Hz, 1H), 6.57 (d, J = 8.00 Hz, 2H), 4.31-4.25 (m, 3H), 3.47-3.43 (m, 1H), 3.43-3.26 (m, 1H), 3.10-3.04 (m, 1H), 2.72-2.68 (m, 2H), 2.34 (s, 3H), 2.24 (s, 1H), 1.48-1.38 (m, 2H), 0.99 (t, J = 7.60 Hz, 3H). LCMS: (Method A) 436.1(M + +H) Rt. 2.10 min, 98.88% (max). HPLC: (Method B) Rt. 4.33 min, 99.77% (max).

[0515] (Example 30) 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid

[0516] [ka]

[0517] To a stirred solution of methyl 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoate (intermediate 57;55 mg, 0.10 mmol) in a mixture of 1,4-dioxane and water (2:1, 3 mL) at 0°C, lithium hydroxide (10 mg, 0.21 mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. After the completion of the reaction (monitored by TLC), the reaction mixture was acidified with dilute HCl (1.5 N, pH approximately 4) and diluted with ice-cold water (2 mL). The aqueous layer was extracted with RINKAN (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL) and dried over anhydrous Na₂SO₄. The organic portion was filtered and concentrated under vacuum to obtain the title compound. Yield: 28% (15 mg, white solid). 1 H NMR (400 MHz, DMSO-d6): δ 13.02 (bs, 1H), 7.34 (s, 1H), 7.15 (t, J = 8.0 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.0 Hz, 2H), 4.43 (t, J = 3.2 Hz, 1H), 4.37-4.31 (m, 1H), 4.19-4.15 (m, 1H), 4.04-4.01 (m, 1H), 4.00-3.90 (m, 1H), 3.43 (s, 3H), 3.20-3.19 (m, 1H), 2.45 (s, 3H), 2.35 (s, 3H), 1.62-1.60 (m, 1H), 1.52-1.50 (m, 1H), 1.36-1.31 (m, 4H), 0.93-0.92 (m, 3H). LCMS: (Method E) 508.9 (M + +H), Rt. 2.87 min, 96.57% (max). HPLC: (Method B) Rt. 5.44 min, 98.31% (max).

[0518] (Example 31) 3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid and 3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid

[0519] [ka]

[0520] Stereoimers 1 and 2 of the title compound were prepared from stereoisomer 1 (0.15 g) and stereoisomer 2 (0.1 g), respectively, of intermediate 58, following the same procedure as described in Example 30. After workup of the reaction mixture, the crude product was purified by Isolera column chromatography (eluent: 0-30% Â / PE; silica gel: 230-400 mesh) to obtain the title compound. The absolute configurations of the two stereoisomers are unknown. Stereoisomer 1: Yield: 71.3% (0.11g, brown solid). 1 H-NMR (400 MHz, DMSO-d6): δ 12.64 (s, 1H), 7.35 (s, 1H), 7.15 (t, J = 8.00 Hz, 2H), 7.06 (s, 1H), 6.70 (t, J = 7.60 Hz, 1H), 6.58 (d, J = 8.40 Hz, 2H), 4.44-4.41 (m, 2H), 4.37-4.34 (m, 1H), 4.19-4.19 (m, 1H), 4.03-4.00 (m, 1H), 3.43 (s, 3H), 3.18-3.17 (m, 1H), 2.46 (s, 3H), 2.35-2.33 (m, 3H), 1.60-1.62 (m, 2H), 1.36-1.31 (m, 4H), 0.94-0.90 (m, 3H). LCMS: (Method E) 509.2 (M ++H) Rt. 2.64 min, 94.06% (max). HPLC: (Method B) Rt. 5.33 min, 94.60% (max). Stereoisomer 2: Yield: 66.7% (0.07 g, white solid). 1 H-NMR (400 MHz, DMSO-d6): δ 13.03 (s, 1H), 7.35 (s, 1H), 7.15 (t, J = 8.00 Hz, 2H), 7.06 (s, 1H), 6.70 (t, J = 7.20 Hz, 1H), 6.58 (d, J = 8.40 Hz, 2H), 4.44-4.39 (m, 2H), 4.33-4.33 (m, 1H), 4.19-4.04 (m, 1H), 4.00-3.90 (m, 1H), 3.38 (s, 3H), 3.19-3.17 (m, 1H), 2.46 (s, 3H), 2.33 (s, 3H), 1.62-1.51 (m, 2H), 1.36-1.31 (m, 4H), 0.94-0.92 (m, 3H). LCMS: (Method A) 509.0(M + +H) Rt. 2.90 min, 99.65% (max). HPLC: (Method B) Rt. 5.29 min, 99.81% (max).

[0521] (Example 32) (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid and (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid (individual diastereomers)

[0522] [ka]

[0523] The two diastereomers of stereoisomer 2 from Example 31 were separated by SFC (Method H). The substance was concentrated under vacuum at 40°C. The first eluted fraction corresponds to diastereomer 1, and the second eluted fraction corresponds to diastereomer 2. The absolute configurations of the two diastereomers are unknown. Diastereomer 1: Yield: 15.37% (0.01 g, white solid). 1 H-NMR (400 MHz, DMSO-d6): δ 7.34 (s, 1H), 7.15 (t, J = 7.20 Hz, 2H), 7.05 (s, 1H), 6.70 (t, J = 6.80 Hz, 1H), 6.58 (d, J = 8.00 Hz, 2H), 4.48-4.42 (m, 1H), 4.22 (m, 1H), 4.03-3.89 (m, 3H), 3.55-3.51 (m, 1H), 3.33 (s, 3H), 2.51 (s, 3H), 2.35 (s, 3H), 1.63-1.60 (m, 2H), 1.36-1.31 (m, 4H), 0.94-0.86 (m, 3H). LCMS: (Method E) 508.9 (M + +H) Rt. 2.91 min, 98.24% (max). HPLC: (Method B) Rt. 5.30 min, 99.93% (max). Chiral HPLC (Method H) Rt. 4.33 min, 100% (max). Diastereomer 2: Yield: 22.96% (0.02 g, white solid). 1H-NMR (400 MHz, DMSO-d6): δ 7.33 (s, 1H), 7.15 (t, J = 7.60 Hz, 2H), 7.05 (s, 1H), 6.69 (t, J = 7.20 Hz, 1H), 6.58 (d, J = 8.40 Hz, 2H), 4.48-4.42 (m, 1H), 4.29-4.21 (m, 1H), 3.99-3.90 (m, 3H), 3.45-3.40 (m, 1H), 3.23 (s, 3H), 2.46 (s, 3H), 2.35 (s, 3H), 1.63-1.51 (m, 2H), 1.50-1.35 (m, 4H), 0.94-0.86 (m, 3H). LCMS: (Method A) 508.9 (M + +H) Rt. 2.91 min, 98.61% (maximum). HPLC: (Method B) Rt. 5.30 min, 99.48% (maximum). Chiral HPLC (Method H) Rt. 5.41 min, 99.23% (maximum).

[0524] (Example 33) 3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoic acid

[0525] [ka]

[0526] To a stirred solution of methyl 3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoate (intermediate 63; 55 mg, 0.10 mmol) in 1,4-dioxane at 0°C, dilute HCl (6N, 3 mL) was added dropwise, and the reaction mixture was heated at 80°C for 16 hours. After the completion of the reaction (monitored by TLC), the reaction mixture was diluted with cold water (5 mL), and the aqueous layer was extracted with RINKAN (2 × 5 mL). The combined organic layers were washed with water (5 mL) and brine (5 mL), and dried over anhydrous Na₂SO₄. The organic portion was filtered, concentrated under vacuum, and the resulting crude product was purified by preparative HPLC (Method C) to obtain the title compound. Yield: 18.11% (0.01g, white solid). 1 H-NMR (400 MHz, DMSO-d6): δ 12.84 (s, 1H), 7.34 (s, 1H), 7.06 (s, 1H), 6.99 (t, J = 8.80 Hz, 2H), 6.60-6.57 (m, 2H), 5.62-5.60 (m,1H), 4.32-4.29 (m, 1H), 4.27-4.25 (m, 2H), 4.01-3.97 (m, 1H), 3.86-3.85 (m, 1H), 3.23-3.22 (m, 1H), 2.91-2.85 (m, 2H), 2.52 (s, 3H), 1.62-1.58 (m, 1H), 1.58-1.50 (m, 1H),1.35-1.34 (m, 4H), 1.24-1.17 (m, 3H), 0.91 (t, J = 6.80 Hz, 3H). LCMS: (Method A) 527.1 (M + +H) Rt. 2.42 min, 93.98% (max). HPLC: (Method B) Rt. 5.31 min, 95.21% (max).

[0527] Biological assays IBAT (h / m) Assay Protocol 10,000 cells (human or mouse IBAT-overexpressing cells) were seeded in 200 μL of MEM-alpha medium (Gibco 12571-063) supplemented with 10% FBS (Gibco 10438026) containing puromycin (Gibco A1113803) (10 μg / mL) in a 96-well plate (Corning CLS3809), and incubated at 37°C in 5% CO2 for 48 hours. After incubation, the medium was decanted from the wells, and the cells were washed twice with 300 μL of basic MEM-alpha medium (without FBS). After each decant of basic MEM-alpha medium, the plate was gently tapped against a paper towel to ensure that the maximum amount of residual medium was removed. Dilutions of the test inhibitor prepared with DMSO (Sigma D2650) (maximum test concentration 10 μM, 3-fold serial dilution, 10 points) were added to an incubation mixture containing 0.25 μM 3H-taurocholic acid (ARC ART-1368) and 5 μM cold taurocholic acid (Sigma T4009) (maintaining a final DMSO concentration of 0.2%). Then, 50 μL of the incubation mixture containing the test inhibitor was added to the wells (double-layered), and the plate was incubated in a CO2 incubator at 37°C for 20 minutes. After incubation, the reaction was stopped by keeping the plate on an ice water mixture for 2-3 minutes, and then the incubation mixture was completely aspirated from the wells. The wells were washed twice with 250 μL of chilled, unlabeled 1 mM taurocholic acid dissolved in 10 mM HEPES (Gibco 15630080) buffered HBSS (Gibco 14175079) (pH 7.4). After each wash, the plate was gently tapped against a paper towel to ensure that blocking buffer was removed to the maximum extent possible. 100 μL of MicroScint-20 (PerkinElmer 6013621) was added to each well, kept at room temperature overnight, and then the plates were read using a PerkinElmer TopCount NXT® Microplate Scintillation and Luminescence Counter under the 3H Test protocol (set to a reading time of 120 seconds per well).

[0528] LBAT (h / m) assay protocol 20,000 cells (human or mouse LBAT overexpressing cells) were seeded in 100 μL of MEM-alpha medium (Gibco 12571-063) supplemented with 10% FBS (Gibco 10438026) containing Geneticin (Gibco 10131-027) (1 mg / mL) in a 96-well plate (Corning CLS3809), and incubated at 37°C in 5% CO2 for 24 hours. After incubation, the medium was decanted from the wells, and the cells were washed twice with 300 μL of basic MEM-alpha medium (without FBS). After each decant of basic MEM-alpha medium, the plate was gently tapped against a paper towel to ensure that the maximum amount of residual medium was removed. For human LBATs, the incubation mixture was prepared by adding a diluted test inhibitor (3-fold serial dilution in DMSO (Sigma D2650), 10 points) to MEM-Alpha (without FBS) containing 0.3 μM 3H-taurocholic acid (ARC ART-1368) and 7.5 μM cold taurocholic acid (Sigma T4009) (maintaining a final DMSO concentration of 0.2%). For mouse LBATs, the incubation mixture was prepared by adding a diluted test inhibitor (3-fold serial dilution in DMSO, 10 points) to MEM-Alpha (without FBS) containing 0.3 μM 3H-taurocholic acid and 25 μM cold taurocholic acid (maintaining a final DMSO concentration of 0.2%). Next, 50 μL of incubation mixture containing the test inhibitor was added to the wells (double-layered), and the plate was incubated in a CO2 incubator at 37°C for 20 minutes. After incubation, the reaction was stopped by keeping the plate on an ice water mixture for 2-3 minutes, and then the incubation mixture was completely aspirated from the wells. The wells were washed twice with 250 μL of chilled, unlabeled 1 mM taurocholic acid dissolved in 10 mM HBSS (Gibco 14175079) (pH 7.4) buffered with HEPES (Gibco 15630080). After each wash, the plate was gently tapped against a paper towel to ensure that the blocking buffer was removed to the maximum extent possible. 100 μL of MicroScint-20 (PerkinElmer 6013621) was added to each well, kept at room temperature overnight, and then the plates were read using a PerkinElmer TopCount NXT® Microplate Scintillation and Luminescence Counter under the 3H Test protocol (normal plate orientation, with a reading time of 120 seconds per well).

[0529] Bidirectional permeability assay (Caco-2 cells) Caco-2 cells (Evotec) were seeded at a density of 70,000 cells / well in Millicell® 24-well cell culture insert plates and maintained in an incubator (37°C, 5% CO2, 95% RH) for 21 days, with the culture medium changed every other day. Stock solutions (10 mM) of the test compounds, atenolol (low permeability marker), propranolol (high permeability marker), and digoxin (substrate for the P-gp transport pathway) were prepared in dimethyl sulfoxide (DMSO). An intermediate stock solution (1 mM) was prepared by diluting 10 μL of 10 mM master stock solution with 90 μL of neat DMSO. A working stock solution (10 μM) was prepared by diluting 50 μL of 1 mM with 4950 μL of FaSSIF buffer. After adding the compounds to FaSSIF, the samples were subjected to sonication for 2 hours and centrifuged at 37°C at 4000 RPM for 30 minutes. 4 mL of the resulting supernatant was used directly in the assay. The final DMSO concentration in the transport experiment was 1%. On the day of the assay, the Caco-2 monolayer was washed twice with transport buffer (HBSS, pH 7.4) and pre-incubated in an incubator for 30 minutes (37°C, 5% CO2, 95% RH). The electrical resistance of the monolayer was measured using the Millicell®-ERS system. 350 ohms / cm² 2 Monolayers with transepithelial electrical resistance (TEER) values ​​exceeding 100% were selected for the assay. The assay was performed in both the absorption direction (A2B) and the secretion direction (B2A). Transport experiments were initiated by adding a transport assay buffer (FaSSIF buffer prepared in HBSS) consisting of the compound to the donor compartment (apical chamber AB; basal outer chamber BA) in a double-well (n=2) system. Drug-free HBSS buffer (pH 7.4) containing 1% bovine serum albumin (BSA) was introduced into the receiver compartment (AB-basal outer; BA-apical). The volumes of the apical and basal outer compartments were 0.4 and 0.8 mL, respectively. After adding the administration solution, the plate was incubated at 37°C for 120 minutes. After 120 minutes, donor and receiver samples were collected and matrix-matched with the buffer on the opposite side (1:1, 30 μL of test sample + 30 μL of blank buffer). The administered sample was matrix-matched with the buffer on the opposite side (1:1, 30 μL of test sample + 30 μL of blank buffer). The sample was treated by adding acetonitrile containing an internal standard (60 μL of test sample + 200 μL of acetonitrile containing internal standard - tolbutamide, 500 ng / mL). The sample was vortexed and centrifuged at 4000 rpm for 10 minutes. The resulting supernatant (100 μL) was diluted with 100 μL of water and transferred to a new 96-well plate. The concentration of compounds in the sample was analyzed using discovery-grade biological analytical methods, where applicable, by liquid chromatography-tandem mass spectrometry (LC-MS / MS). The average apparent permeability (P) of the test compound, atenolol, propranolol, and digoxin. app , ×10 -6 The value (cm / sec) was calculated as follows:

[0530]

number

[0531] (In the formula, dq / dt = transport rate (transport rate of the compound in the receiver compartment), C0 = initial concentration in the donor compartment, A = surface area of ​​the effective filtration membrane).

[0532] HepaRG-based assay protocol Differentiated HepaRG cells are thawed in cryopreserved vials (Biopredic International HPR116080) in HepaRG Thawing / Plating / General Purpose Medium (Biopredic International ADD670C) supplemented with 200 mM Glutamax (Gibco 35050061) according to the protocol provided by Biopredic International. 70,000 cells per well are seeded in 100 μL of HepaRG Thawing / Plating / General Purpose Medium supplemented with 200 mM Glutamax in 96-well plates (Corning CLS3809) and incubated at 37°C in 5% CO2 for 24 hours. After incubation, the seeding medium is replaced with HepaRG Maintenance / Metabolism Medium (Biopredic International ADD620C), and fresh HepaRG Maintenance / Metabolism Medium is replenished every 48 hours for 6 days. After 7 days of incubation following seeding, decant the incubation medium from the wells and wash the cells twice with 250 μL of William's E Basal Media (Gibco 12551032). After each decant with William's E Basal Media, gently tap the plate against a paper towel to ensure that as much residual medium as possible is removed. The incubation mixture is prepared by adding a diluted solution of the test inhibitor (3-fold serial dilution in DMSO (Sigma D2650)) to William's E medium (basic) containing 0.3 μM 3H-taurocholic acid (ARC ART-1368) and 7.5 μM cold taurocholic acid (Sigma T4009) (maintaining a final DMSO concentration of 0.2%). Then, 50 μL of the incubation mixture containing the test inhibitor is added to the wells (double-row), and the plate is incubated in a 5% CO2 incubator at 37°C for 30 minutes. After incubation, the reaction is stopped by keeping the plate on an ice water mixture for 2-3 minutes, and then the incubation mixture is completely aspirated from the wells. Wash the wells twice with 250 μL of chilled, unlabeled 1 mM taurocholic acid dissolved in 10 mM HEPES (Gibco 15630080) buffered HBSS (Gibco 14175079) (pH 7.4). After each wash, gently tap the plate against a paper towel to ensure that the blocking buffer is removed to the maximum extent possible. Add 100 μL of MicroScint-20 (PerkinElmer 6013621) to each well, keep at room temperature overnight, and then read the plate using a PerkinElmer TopCount NXT® Microplate Scintillation and Luminescence Counter under the 3H Test protocol (normal plate orientation, with a reading time of 120 seconds per well).

[0533] Preparation of diluted solutions of the test compound All test compounds were prepared in powder form at room temperature. A 10 mM DMSO stock solution of each test compound was prepared, aliquoted, and stored at -20°C. From the 10 mM DMSO stock solution of each compound, three-fold serial dilutions in DMSO were prepared to obtain dilutions of a total of 10 test compounds. 0.5 μL of this DMSO dilution was added to 250 μL of a basic medium containing 3H-taurocholic acid and cold taurocholic acid, without FBS, to prepare the incubation mixture.

[0534] Bioavailability test Male mice (C57BL / 6 or CD1) or Wistar rats aged 8-9 weeks were used. For each test compound, two groups of three animals were used. One group received a single intravenous dose of 1 mg / kg (vehicle 100% DMSO) via the tail vein, while the other group received a single oral dose of 10 mg / kg via a gastric tube. The group receiving the oral dose was fasted overnight. Blood samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after intravenous administration, and at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after oral administration. Blood samples were taken from the saphenous vein. 0.2% EDTA was used as an anticoagulant. The samples were analyzed using an LC-MS / MS system with discovery-grade biological analytical methods developed to estimate the presence of test compounds in plasma.

[0535] result The biological data for the compounds used in the examples are shown in Table 8 below.

[0536] [Table 8A]

[0537] [Table 8B]

[0538] PD Model: Evaluation of test compounds on total bile acid levels in male C57BL6 mice The effect of bile acid modulators on bile acid levels will be tested using 8-9 week old C57BL / 6N Tac mice. After the quarantine and acclimatization period, the animals will be randomly divided into two experimental groups based on body weight: (i) vehicle control and (ii) test compound y mg / kg orally once daily. The animals will be treated with the test compound for 7 days. On day 5 of the study, the animals will be individually housed in new cages. On day 7, fecal samples will be collected from each cage, followed by blood collection from each animal via the postorbital pathway. The animals will be euthanized, and the liver and terminal ileum will be collected from each animal for further analysis. Body weight and food intake will be measured twice a week. Serum lipid profiles will be analyzed in serum samples from day 7. Total bile acids in serum will be measured in serum samples from day 7. Bile excretion in feces will be measured in fecal samples from day 7. The expression of CYP7A1 and SHP in the liver will be quantified in liver samples taken on day 7. Liver triglycerides and total cholesterol will be analyzed in liver samples taken on day 7.

[0539] Urinary bile acid model: Evaluation of test compounds for urinary bile acid levels in male C57BL / 6N mice The effect of bile acid modulators on bile acid levels will be tested using 8-9 week old C57BL / 6N Tac mice. After the quarantine and acclimatization period, the animals will be randomly divided into two experimental groups based on body weight: (i) vehicle control and (ii) test compound y mg / kg orally once daily. The animals will be treated with the test compound for 7 days. On day 6 of the study, the animals will be transferred to metabolic cages. On day 7, fecal and urine samples will be collected from each metabolic cage, and blood will then be collected from each animal via the post-orbital pathway. The animals will be euthanized, and kidneys will be collected from each animal for further analysis. Body weight will be measured twice a week. Total bile acids in serum will be measured in serum samples on day 7. Bile acid excretion in feces will be measured in fecal samples on day 7. Urine bile acid excretion will be measured in samples on day 7. The expression of ASBT, OSTa, OSTAb, and MRP2 in the kidney will be quantified in the 7-day sample.

Claims

1. Compound of formula (I) 【Chemistry 1】 (In the formula, M is -CH 2 - and -NR 5 - Selected from; R 1 C 1～4 It is alkyl; R 2 is independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1～4 alkyl, C 1～4 haloalkyl, C 1～4 alkoxy, C 1～4 haloalkoxy, cyano, nitro, amino, N-(C 1～4 alkyl)amino, N,N-di(C 1～4 alkyl)amino, C 1～6 alkylcarbonylamino, C 3～6 cycloalkylcarbonylamino, N-(C 1～4 alkyl)aminocarbonyl, N,N-di(C 1～4 alkyl)aminocarbonyl, C 1～4 alkyloxycarbonylamino, C 3～6 cycloalkyloxycarbonylamino, C 1～4 alkylsulfonamide, and C 3～6 cycloalkylsulfonamide; n is an integer between 1, 2, or 3; R 3 These are hydrogen, halogen, cyano, and C 1～4 Alkyl, C 3～6 Cycloalkyl, C 1～4 Alkoxy, C 3～6 Cycloalkyloxy, C 1～4 Alkylthio, C 3～6 Cycloalkylthio, amino, N-(C 1～4 Alkyl)amino, and N,N-di(C 1～4 Selected from the group consisting of alkyl)amino; R 4A and R 4B Each of these is independently hydrogen, halogen, hydroxyl, and C 1～4 Alkyl and C 1～4 Selected from the group consisting of alkoxys; or R 4A and R 4B These, together with the carbon atoms to which they are bonded, form a 3- to 5-membered saturated carbocyclic ring; R 4C and R 4D Each of them independently consists of hydrogen and C 1～4 Selected from the group consisting of alkyl groups; R 5 is hydrogen and C 1～4 (Selected from the group consisting of alkyl groups) Or its salt as a medicine.

2. R 1 C 2～4 The compound according to claim 1, wherein it is alkyl.

3. R 1 The compound according to claim 1, wherein is n-propyl or n-butyl.

4. R 2 The compound according to claim 1, wherein is independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, methoxy, amino, methylamino, and dimethylamino.

5. R 3 The compound according to claim 1, wherein the compound is selected from the group consisting of fluoro, chloro, bromo, methyl, cyclopropyl, methoxy, ethoxy, methylthio, ethylthio, amino, methylamino, and dimethylamino.

6. R 4A and R 4B Each of these independently produces hydrogen, halogen, hydroxyl, and C. 1～4 Alkyl and C 1～4 Selected from the group consisting of alkoxys, or R 4A and R 4B The compound according to claim 1, wherein they combine with the carbon atoms to which they are bonded to form a cyclopropyl ring.

7. R 4C and R 4D The compound according to claim 1, wherein each of them is independently hydrogen or methyl.

8. R 5 The compound according to claim 1, wherein is hydrogen or methyl.

9. 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (S)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (R)-3-((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-7-(ethylthio)-2-methyl-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (S)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; (R)-3-((3-butyl-5-(4-fluorophenyl)-2-methyl-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-dimethylpropanoic acid; 1-(((3-butyl-7-(ethylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-5-(4-fluorophenyl)-7-(methylthio)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (S)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; (R)-1-(((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)methyl)cyclopropane-1-carboxylic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid; (S)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid; (R)-3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2,2-difluoropropanoic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (S)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (S)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (R)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; (R)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxy-2-methylpropanoic acid; 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; (S)-3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; (R)-3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-ethoxypropanoic acid; 3-((3-butyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)-2-hydroxypropanoic acid; 3-((3-ethyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepine-8-yl)oxy)propanoic acid; 3-((3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; 3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; 3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (S)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (R)-3-(((R)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (S)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; (R)-3-(((S)-3-butyl-2-methyl-7-(methylthio)-1,1-dioxide-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-methoxypropanoic acid; and 3-((3-butyl-7-(ethylthio)-5-(4-fluorophenyl)-2-methyl-1,1-dioxide-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine-8-yl)oxy)-2-hydroxypropanoic acid; The compound according to claim 1, selected from the group consisting of and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9 and one or more pharmaceutically acceptable excipients.

11. A pharmaceutical product comprising the compound described in any one of claims 1 to 9.

12. The pharmaceutically acceptable agent according to claim 11 for use in the treatment or prevention of cardiovascular diseases or disorders of fatty acid metabolism or glucose utilization, e.g., hypercholesterolemia; disorders of fatty acid metabolism; type 1 and type 2 diabetes mellitus; complications of diabetes, e.g., cataracts, microvascular diseases, retinopathy, neuropathy, nephropathy, and delayed wound healing, tissue ischemia, diabetic foot lesions, arteriosclerosis, myocardial infarction, acute coronary syndrome, unstable angina, stable angina, stroke, peripheral artery occlusive disease, cardiomyopathy, heart failure, heart rhythm disorders, and vascular restenosis; diabetes-related diseases, e.g., insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, dyslipidemia, hyperlipidemia, e.g., hypertriglyceridemia, metabolic syndrome (X syndrome), atherosclerosis, and hypertension; and increased high-density lipoprotein levels.

13. The pharmaceutically acceptable agent according to claim 11 for use in the treatment or prevention of gastrointestinal disorders or conditions, such as constipation (including chronic constipation, functional constipation, chronic idiopathic constipation (CIC), intermittent / sporadic constipation, constipation secondary to diabetes mellitus, constipation secondary to stroke, constipation secondary to chronic kidney disease, constipation secondary to multiple sclerosis, constipation secondary to Parkinson's disease, constipation secondary to systemic sclerosis, drug-induced constipation, constipation-predominant irritable bowel syndrome (IBS-C), mixed-type irritable bowel syndrome (IBS-M), pediatric functional constipation, and opioid-induced constipation); Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); inflammation of the ileum; and reflux disorders and their complications, such as Barrett's esophagus, bile reflux esophagitis, and bile reflux gastritis.

14. Liver diseases or disorders, e.g., hereditary metabolic disorders of the liver; congenital abnormalities of bile acid synthesis; congenital bile duct anomalies; biliary atresia; biliary atresia after Kasai procedure; biliary atresia after liver transplantation; neonatal hepatitis; neonatal cholestasis; hereditary forms of cholestasis; cerebral tendon xanthomatous disease; secondary defects in BA synthesis; Zellweger syndrome; liver diseases associated with cystic fibrosis; α1 antitrypsin deficiency; Alagille syndrome (ALGS); Beiler syndrome; primary defects in bile acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC), e.g., PFIC-1, PFIC-2, PFIC-3, and unspecified PFIC, post-bile diversion PFIC, and post-liver transplant PFIC; benign recurrent intrahepatic cholestasis (BRIC), e.g., BRIC 1. BRIC2, and unspecified BRIC, post-bile diversion BRIC, and post-liver transplant BRIC; autoimmune hepatitis; primary biliary cirrhosis (PBC); hepatic fibrosis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); portal hypertension; cholestasis; cholestasis in Down syndrome; drug-induced cholestasis; intrahepatic cholestasis in pregnancy (jaundice during pregnancy); intrahepatic cholestasis; extrahepatic cholestasis; cholestasis associated with parenteral nutrition (PNAC); cholestasis associated with hypophospholipids; lymphedema-associated cholestasis syndrome 1 (LCS1); primary sclerosing cholangitis (PSC); cholangitis associated with immunoglobulin G4; primary biliary cholangitis; cholelithiasis (gallstones); biliary tract stones (biliary lithiasis) Lithiasis; common bile duct stones; gallstone pancreatitis; caloric disease; malignant neoplasm of the bile duct; malignant neoplasm causing obstruction of the bile duct; bile duct stenosis; AIDS cholangiopathies; ischemic cholangiopathies; pruritus due to cholestasis or jaundice; pancreatitis; chronic autoimmune liver disease leading to progressive cholestasis; fatty liver degeneration; alcoholic hepatitis; acute fatty liver; fatty liver during pregnancy; drug-induced hepatitis; iron overload; congenital bile acid metabolism disorder type 1 (BAS disorder type 1); drug-induced liver injury (DILI); hepatic fibrosis; congenital hepatic fibrosis; cirrhosis; Langerhans cell histiocytosis (LCH); neonatal ichthyosis sclerosing cholangitis (NISCH); myeloid protoporphyria (EPP); idiopathic adult bile duct depression (IAD); idiopathic neonatal hepatitis (INH); asymptomatic intrahepatic bile duct depression (NS) PILBD; Autosomal recessive inherited intrahepatic cholestasis (North American Indian childhood cirrhosis) (NAIC);For use in the treatment or prevention of cholestasis caused by hepatic sarcoidosis; amyloidosis; necrotizing enterocolitis; toxicity caused by serum bile acids, e.g., dyscardia (e.g., atrial fibrillation) in the context of an abnormal serum bile acid profile, cardiomyopathy associated with cirrhosis ("cholecardia"), and skeletal muscle wasting associated with cholestatic liver disease; polycystic hepatic disease; viral hepatitis (including hepatitis A, B, C, D, and E); hepatocellular carcinoma (hepatocellular tumor); cholangiocarcinoma; gastrointestinal cancers related to bile acids; and tumors and neoplasms of the liver, biliary tract, and pancreas; or for use in the augmentation of corticosteroid therapy in liver disease, according to claim 11.

15. The pharmacopoeci of claim 11 for use in the treatment or prevention of pruritus in renal failure; or for use in the protection of kidney injury associated with hepatic or metabolic disease.

Images